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Abstract

TBX3 is a transcriptional regulator involved in embryonic development and in
tumorigenesis of several cancer types. There are two isoforms of TBX3 (TBX3iso1 and
TBX3iso2) with different DNA binding domains. The large-scale functional roles of TBX3iso1
and TBX3iso2 were characterized in a breast cancer context. Both TBX3 isoforms induced
invasiveness and an epithelial-to-mesenchymal (EMT) phenotype. Coupling data from
genome-wide ChIP-array and RNA-Seq studies provided a novel list of genes regulated by
each isoform. Both TBX3 isoforms regulate expression of several EMT-related genes,
including SLUG and TWIST1. Importantly, TBX3 is a direct regulator of SLUG, and SLUG
expression is required for TBX3-induced migration and invasion.
Assessing TBX3 expression in early stage breast cancers by immunohistochemistry
(IHC) revealed high expression in low-grade lesions. Within a second non-high-grade cohort,
there was an association between TBX3 expression in the pre-invasive ductal carcinoma in
situ (DCIS) and size of the invasive focus. Additionally, there was a positive correlation
between TBX3/SLUG, and TBX3/TWIST1 expression by IHC in the invasive carcinoma.
Pathway analysis of transcriptomics data revealed altered expression of several proteases
and their inhibitors, consistent with the ability of tumor cells to degrade basement membrane.
These findings strongly suggest the involvement of TBX3 in the promotion of invasiveness
and progression of early stage pre-invasive DCIS to invasive carcinoma through the lowgrade molecular pathway.
Interestingly, only TBX3iso1 overexpressing cells exhibited increased tumorigenic
potential in mouse xenograft experiments. Transcriptomics data and functional studies
revealed that TBX3iso1 overexpression promotes angiogenesis and secretion of cancerassociated cytokines (including osteopontin) which is able to induce tubule formation by
endothelial cells in vitro. Tumorigenic TBX3iso1 overexpressing cells also had elevated
hyaluronan synthase 2 (HAS2) levels and high levels of hyaluronan retention. These factors
may contribute to the survival of cells and promote angiogenesis, allowing the formation of
primary tumors in vivo.

In conclusion, I have found evidence for a role of TBX3iso1 and TBX3iso2 in direct
modulation of EMT and invasiveness, and a role for TBX3iso1 in inducing angiogenesis.
Together these, along with previous work showing anti-senescence and pro-proliferative
activities of TBX3, suggest multiple potential activities for promotion of malignancy of breast
cancer.
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1

1.1 Breast Cancer
Recent statistics from the Canadian Cancer Society has revealed that 1 in 2
Canadians will develop cancer in their lifetime, and 1 in 4 Canadians will die of cancer
(Canadian Cancer Society, 2017). Leading the list of cancer prevalence for Canadian women
is breast cancer, with 1 in 8 women expected to develop breast cancer in their lifetime
(Canadian Cancer Society, 2017). This accounted for 10,100 diagnoses of breast cancer in
2017, of which 1,900 succumbed to the disease (Canadian Cancer Society, 2017). While
breast cancer incidence rates rose in the 1990s (likely due to increased opportunistic
mammography screenings), mortality rates have been declining at a rate of approximately
2.3% per year between 1992 and 2012 (Canadian Cancer Society, 2017). This decline is
likely due to a combination of screening mammograms and more effective adjuvant systemic
therapies (Canadian Cancer Society, 2017). Similar reductions in mortality rates have been
observed in the United States, United Kingdom, and Australia (Bray et al., 2004).
The current public health strategy for breast cancer is one of early detection; at this
early stage, treatment generally has a high success rate compared to metastatic diagnosis.
In addition to surgical management, treatment for patients with early-stage breast cancer can
include systemic therapy, such as chemotherapy (i.e. taxanes, anthracyclines) and/or
hormone therapy (i.e. tamoxifen, aromatase inhibitors), which are tailored to the
characteristics of the tumour (Esteva and Hortobagyi, 2004). Once the cancer has spread to
distant organs, however, survival is greatly reduced.
Molecular profiling of breast cancers has revealed the presence of distinct breast
cancer subtypes with different clinical outcomes, including luminal A, luminal B, basal-like
and human epidermal growth factor receptor 2 (HER2)-enriched (Perou et al., 2000). In
general, age-standardized survival rates for breast cancers are 97% (1-year), 91% (3-year),
86% (5-year) and 82% (10-year) for the specified number of years post-diagnosis (Canadian
Cancer Society, 2017), although basal-like and HER2-enriched breast cancers are
associated with lower survival rates (Sørlie et al., 2001). Additional prognostic factors that
may help predict patient outcome include tumor size, lymph node status, and nuclear and
histologic grade of the tumor (Esteva and Hortobagyi, 2004).
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Histopathology of breast cancer progression

Figure 1.1.1 – Histology of normal breast epithelium.
Obtained from breast histology slides in The Human Protein Atlas, available at
www.proteinatlas.org/learn/dictionary/normal/breast
Normal breast histology (depicted in Figure 1.1.1) must be appreciated in order to
diagnose pathological conditions. Histologically, the breast is made up of several ductallobular structures. The lactiferous duct is located beneath the nipple, and branches out into
several progressively smaller ductal structures, eventually terminating at the terminal
ductules and lobules (Mills, 2007). The epithelium within these ductal-lobular structures
consists of two distinct cell layers. The inner (luminal) layer is composed of cuboidal to
columnar epithelial cells, with an outer (basal) layer composed of flattened myoepithelial cells
(Mills, 2007). The terminal ducts and their corresponding lobules are collectively referred to
as the terminal duct lobular unit (TDLU), and represents the structural and functional unit of
the breast (Mills, 2007). A layer of type IV collagen and laminin surrounds the ductal-lobular
structures, separating them from the surrounding stroma (Mills, 2007). The stroma
immediately adjacent to the mammary glands is composed of loose fibrovascular tissue, with
dense interlobular stroma composed of collagen, fibroblasts, and adipose tissue surrounding
the aforementioned structures (Mills, 2007).
Most breast pathologies, including atypical ductal hyperplasia (ADH), ductal
carcinoma in situ (DCIS), and invasive breast carcinoma, originate in the TDLUs (Mills, 2007).
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The two most common histological subtypes of invasive breast cancer include infiltrating
ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC). While both arise from the
TDLUs, they present quite different histologically (Wellings and Jensen, 1973, Wellings et
al., 1975). A majority of breast cancers have the morphology of ductal epithelial cells (DCIS,
IDC), representing approximately 80% of diagnoses (Kumar et al., 2013). Lobular
morphologies, including atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS),
and invasive lobular carcinoma (ILC), are less common than their ductal counterparts (Kumar
et al., 2013). The more common pathways, related to IDC, are discussed below.
The IDC breast cancer progression model is often simplified into a series of phenotypic
histological stages, beginning with benign epithelial cells and sometimes transitioning to
columnar cell lesions including flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH),
ductal carcinoma in situ (DCIS), and ultimately invasive and metastatic breast carcinoma
(Burstein et al., 2004, Bombonati and Sgroi, 2011). FEA, ADH and DCIS are considered to
be non-obligate precursors for the development of invasive breast cancer, meaning that not
all cases exhibiting the aforementioned precursor lesions will progress to invasive carcinoma
(Bombonati and Sgroi, 2011). Epidemiological, histological, immunohistochemical, loss of
heterozygosity (LOH), comparative genomic hybridization (CGH), and later high-throughput
mutational studies have shed light on the intricacies of this process, and highlighted the
presence of divergent low-grade and high-grade pathways (Thorat et al., 2007, Formenti et
al., 2011, Bombonati and Sgroi, 2011, Sagara et al., 2015).
Low-grade (LG) breast lesions usually contain near-diploid chromosomal content, with
frequent loss of 16q and gain of 1q (Bombonati and Sgroi, 2011). High-grade (HG) breast
lesions are typically aneuploid and associated with a collection of more complex mutational
alterations including recurrent loss of 8p, 11q, 13q, 1p and 18q, and recurrent gain of 8q,
17q, 20q and 16p (Buerger et al., 1999, Roylance et al., 1999, Bombonati and Sgroi, 2011).
Intermediate grade (IG) breast lesions possess a combination of LG and HG genetic
alterations (Buerger et al., 2001). When loss of 16q is observed in HG lesions, the remaining
underlying genetic alterations are distinct; while LG lesions demonstrate physical loss of 16q,
HG lesions are missing small regions of 16q and undergo mitotic recombination, leading to
shuffling of these genetic components (Cleton-Jansen et al., 2004, Abdel-Fatah et al., 2008).
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These findings suggest that high-grade breast cancers (basal-like and HER2-enriched) do
not arise from low-grade breast cancers (Bombonati and Sgroi, 2011).
Immunohistochemical studies of FEA, ADH and LG DCIS has revealed high
expression levels of estrogen receptor (ER) and progesterone receptor (PR), along with lack
of HER2 expression (Buerger et al., 2001). Additionally, these precursor lesions frequently
express high levels of the proliferation marker Ki67, luminal cytokeratins CK8/18/19, B-cell
lymphoma 2 (Bcl2), cyclin D1, and are negative for basal cytokeratins CK5/6 (Schnitt, 2003,
Abdel-Fatah et al., 2008, Ahmad, 2013). Genetic analysis of FEA, ADH and LG DCIS has
revealed comparable loss of 16q, which is an early hallmark genetic change in LG lesions;
the degree of genomic instability, however, increases with further progression (O'Connell et
al., 1998, Moinfar et al., 2000, Simpson et al., 2005, Larson et al., 2006, Gao et al., 2009).
Genes which may function as tumor suppressors that are subsequently lost with 16q
deletions have been assessed, and include E-cadherin (CDH1) and CCCTC-binding factor
(CTCF), with reduced expression reported in LG lesions, as assayed by PCR and
immunohistochemistry (Bürger et al., 2013). The detailed breast cancer progression
pathways of the LG and HG molecular pathways is depicted in Figure 1.1.2.

Figure 1.1.2 – Detailed breast cancer progression pathway of LG and HG breast cancers.

Adapted from Bombonati & Sgroi, 2011.
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Columnar cell lesions (CCLs)

Figure 1.1.3 – Columnar cell lesions (CCLs) of the breast.
Columnar cell change (CCC), columnar cell hyperplasia (CCH), and flat epithelial atypia
(FEA) of the breast (left to right).
Columnar cell lesions (CCLs) are among the most common abnormalities observed
in breast biopsies (Turashvili et al., 2008). CCLs are generally divided into columnar cell
change (CCC) and columnar cell hyperplasia (CCH), consisting of one or several layers of
pseudostratified ductal epithelial cells, respectively, which have taken on a columnar
phenotype (depicted in Figure 1.1.3) (Dabbs et al., 2006). CCLs present with frequent
exaggerated apical blebs or snouts, often resulting in intraluminal secretions that can calcify,
and are thus often detected as abnormalities on mammographic screening (Lerwill, 2008).
CCC and CCH with the aforementioned histological patterns can be further subdivided,
depending on the presence or absence of atypia (Turashvili et al., 2008, Go et al., 2012).
Genetic analysis of CCLs without atypia has revealed infrequent mutations relative to
the background of normal ductal epithelial cells (Dabbs et al., 2006), although more recently,
phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) mutations have been
documented in CCLs with or without atypia (Troxell et al., 2012). The atypical CCL variant
FEA is often considered to be the earliest neoplastic lesion within the breast (Dabbs et al.,
2006, Turashvili et al., 2008). FEA lesions show slightly enlarged columnar epithelial cells,
frequently consisting of several layers, and low-grade cytologic atypia (Turashvili et al.,
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2008). Interestingly, CCLs with HG atypia tend to progress to comedo DCIS (associated with
necrosis and higher rates of invasive recurrence), whereas FEA with LG cytologic atypia is
thought to progress to LG DCIS (Azzopardi et al., 1979), further providing evidence for the
divergent LG and HG progression pathways. Additionally, CCLs were reported to coexist in
76% of LG and 10% of HG breast cancers (Abdel-Fatah et al., 2008). Coexisting CCLs, ADH
and DCIS lesions often exhibit near identical cytological morphologies, with the differences
typically being size and architecture-related (Go et al., 2012).
Little is known regarding the clinical significance of the presence of CCLs and FEA in
a biopsy. The risk of invasive recurrence for patients with FEA is unclear – some studies
suggest that the associated risk is slightly increased relative to that of the general population,
up to a risk similar to ADH (4-5 fold) (Schnitt, 2003, Kunju and Kleer, 2007, Martel et al.,
2007, Lerwill, 2008, Ahmad, 2013). Longitudinal studies examining rates of invasive
recurrence revealed that 7.4% of patients with CCLs without atypia, and 18.3% of patients
with CCLs with atypia (diagnosed as FEA) developed invasive breast cancer over a period
of 5 years (Guerra-Wallace et al., 2004). Upon analysis of 1,000 FEA lesions, it was reported
that 7% and 26% of cases had coexisting invasive carcinoma and lobular neoplasia,
respectively (Bratthauer and Tavassoli, 2004). The presence of FEA in a biopsy should
therefore prompt for potential identification of coexisting precursor lesions and invasive
carcinoma (Lerwill, 2008). Although these studies demonstrate that the risk of progression to
invasive carcinoma after FEA diagnosis by biopsy is higher than the general population, the
relative risk of invasive recurrence is quite low. Clinical management of patients with FEA on
biopsy usually consists of close follow-up with repeat mammograms to detect cases of occult
carcinoma within the vicinity that were missed by biopsy (Turashvili et al., 2008), or surgical
excision if there is any residual abnormality (i.e. indeterminate calcifications) (Calhoun et al.,
2015). Larger studies with extended follow-up times are required for critical evaluation of
long-term risk of progression to invasive cancer for these patients, as well as time course for
progression (Lerwill, 2008). A more thorough understanding of clinicopathologic
characteristics would allow for optimal management of patients with CCL lesions, including
the FEA variant.
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Atypical ductal hyperplasia (ADH)

Figure 1.1.4 – Atypical ductal hyperplasia (ADH) of the breast.
Normal breast ductal epithelial cells are lined by two layers of cells consisting of a
luminal and myoepithelial cell layer (Kumar et al., 2013). The presence of hyperplasia
signifies an excess of two layers of epithelial cells, and can range from mild to florid ductal
epithelial hyperplasia without atypia, to atypical ductal hyperplasia (ADH) (Kumar et al.,
2013). The pattern observed in ADH is consistent with the presence of two different cell
populations: a low-grade neoplastic cell population and a benign ductal epithelial cell
population, observed within the same duct cross-section (Kumar et al., 2013). The nonneoplastic cell population contains cells showing random placement and streaming patterns,
with nuclei of varying shape and size (Pinder and Ellis, 2003). Conversely, the atypical (LG
neoplastic) cells contain enlarged, hyperchromatic nuclei, with uniformity in shape and size
and even cell placement, suggestive of a clonal population (Pinder and Ellis, 2003).
The atypical cells are often arranged in various architectural patterns, including solid,
cribriform, papillary or micropapillary (Kader et al., 2018). Cribriform pattern ADH is shown in
Figure 1.1.4.
ADH is frequently described as having some but not all features of DCIS (Fitzgibbons
et al., 1998). ADH and DCIS are distinguished from each other by the degree of atypia and
the extent of atypical epithelial proliferation (Tavassoli and Norris, 1990, Page and Rogers,
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1992, Ahmad, 2013). Additionally, ADH is usually small and focal, measuring less than 2
mm; if larger and more extensive, a diagnosis of DCIS is typically made (Pinder and Ellis,
2003). LOH and CGH-based studies of ADH have revealed frequent loss of the 16q
chromosomal region (Lakhani et al., 1995, O'Connell et al., 1998, Amari et al., 1999).
Additionally, microsatellite analysis has revealed that 60% of IDC and DCIS showed
concurrent ADH that was clonal in origin (Larson et al., 2006), with copy number alterations
and documented at early stages of ADH (Crissman et al., 1990, Eriksson et al., 1992,
Stomper et al., 1992, Ruiz et al., 1999, Niu et al., 2013, Kader et al., 2018).
Marked transcriptional changes have been identified at the ADH stage relative to
adjacent benign ductal epithelium (Ma et al., 2003), including up-regulation of several
oncogenes such as FOXA1 and GATA3 (Brunner et al., 2014). Several studies have
therefore proposed that alteration in expression of genes at the early stages of progression,
including ADH and DCIS, may be critical for progression to invasive breast cancer, as
expression of several transcripts is maintained throughout progression (van de Vijver et al.,
2002, Paik et al., 2004). In fact, transcriptional studies have shown that ADH and LG DCIS
possess near-identical gene expression profiles (Bombonati and Sgroi, 2011).
Epidemiological studies estimate that an ADH diagnosis is associated with a 4-5 fold
increased risk of developing invasive breast cancer relative to the general population (Page
et al., 1985, Page and Dupont, 1993, Fitzgibbons et al., 1998). If an immediate family member
has previously been diagnosed with breast cancer, the risk of upgrade from an ADH
diagnosis becomes about 10-fold (Page et al., 1985, Tavassoli and Norris, 1990, Page and
Dupont, 1992, Pinder and Ellis, 2003). A recent study showed that approximately 20%
(142/698) of women with ADH lesions had an upgrade in diagnosis (typically to DCIS) without
surgical intervention (Hartmann et al., 2015). Clinical management of patients with ADH upon
needle core biopsy thus includes surgical excision to rule out concomitant malignancy
(Morrow et al., 2015, Rageth et al., 2016).
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Ductal carcinoma in situ (DCIS)

Figure 1.1.5 – Ductal carcinoma in situ (DCIS) of the breast.
Low-grade DCIS, intermediate-grade DCIS, and high-grade DCIS (left to right); all neoplastic
cells of the DCIS are confined to the duct and possess an intact basement membrane.

1.1.4.1

Histopathology of DCIS

The presence of pure ductal carcinoma in situ (DCIS) is observed in approximately
15-20% of breast biopsies, compared to 5% before the introduction of mammography
screening (van Dongen et al., 1989, Lagios, 1990, Faverly et al., 1994). DCIS is referred to
as “Stage 0” breast cancer, with the cancer cells located within the confines of the basement
membrane. Relative to ADH, DCIS contains further expansion of tumor volume through the
ductal system, along with elevated histological and biological diversity (Allred et al., 2008).
Clinically significant parameters which are reported for DCIS include nuclear grade, size,
architecture, positive margins, and presence or absence of comedo necrosis (presence of
necrosis is an independent prognostic indicator for invasive recurrence) (Lester et al., 2009).
The expanded volume of cells within DCIS can exhibit a wide spectrum of histological
patterns (Allred et al., 2001). LG DCIS is composed of small uniform cells, with nuclei subtly
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larger than those of adjacent normal epithelial cells (Figure 1.1.5, left panel) (Pinder and
Ellis, 2003). HG DCIS is associated with an increase in the nuclei to cytoplasm ratio, coarse
chromatin, prominent nucleoli, loss of polarization, frequent mitoses, and pleomorphism from
cell to cell (Figure 1.1.5, right panel) (Lester et al., 2009). The architecture is variable (i.e.
solid, cribriform, micropapillary, and/or papillary), although solid is frequently observed, often
with central zone necrosis which may undergo calcification (Pinder and Ellis, 2003). The
diagnosis of IG DCIS is quite subjective, and is made if nuclear pleomorphism exhibits an
intermediate between LG and HG DCIS with some degree of polarization (Pinder and Ellis,
2003). On this note, a recent study using integrative bioinformatic analysis of the Cancer
Genome Atlas (TCGA) breast cancer cohort reported that patients with IG IDC could be reclassified into LG-like and HG-like IDC based on a 22 gene tumor aggressiveness classifier
(Aswad et al., 2015), suggesting that this subgroup consists of both LG and HG lesions
(Bombonati and Sgroi, 2011).
The distinguishing factor between DCIS and IDC is the dissolution of the myoepithelial
cell layer in IDC, with neoplastic cells invading beyond the basement membrane and into the
adjacent stroma. Previous studies have shown that myoepithelial cells possess tumorsuppressor functions through their secretion of protease inhibitors and continuous synthesis
and maintenance of the basement membrane (Barsky and Karlin, 2005, Polyak and Hu,
2005, Hu et al., 2008). During progression of DCIS to IDC, the myoepithelial cell layer
gradually disappears, and their associated tumor suppressive function is thus lost (Hu et al.,
2008). This can be tracked immunohistochemically using molecular markers such as smooth
muscle myosin heavy chain (cytoplasmic) and/or p63 (nuclear), which are characteristically
expressed by myoepithelial cells. Staining for these markers is lost with dissolution of the
myoepithelial layer. This event results in loss of organization and polarity of breast epithelial
cells, paving the way for tumor progression to invasion (Hu et al., 2008).
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1.1.4.2

Clinical Management of DCIS

It is estimated that 25-50% of DCIS (depending on the DCIS characteristics) will
progress to invasive carcinoma during the lifetime of the patient, generating potentially lifethreatening disease (Page and Dupont, 1993, Fitzgibbons et al., 1998, Sanders et al., 2005,
Ahmad, 2013, Sagara et al., 2015). Local recurrence rates for patients with DCIS are 5-25%
with lumpectomy (Fisher et al., 1993, Warneke et al., 1995, Ernster et al., 1996, Fowble et
al., 1997, Habel et al., 1998, Boyages et al., 1999, Hetelekidis et al., 1999), and 1-2% for
mastectomy in the absence of radiation therapy (Silverstein et al., 1995a, Warneke et al.,
1995, Boyages et al., 1999). This risk of non-invasive or invasive recurrence further depends
on characteristics of the DCIS, including the nuclear grade, extent and presence or absence
of necrosis.
The natural history of DCIS is for the most part unknown since routine treatment
includes surgical excision (Bartlett et al., 2014). Prior to the 1980s, most patients with DCIS
underwent a mastectomy (Waldman et al., 2000). Such radical surgical practices have been
replaced by breast-conserving surgery (lumpectomy), often combined with radiation therapy,
regardless of grade (Waldman et al., 2000, Mokbel and Cutuli, 2006). The higher rates of
local recurrence for DCIS patients treated with lumpectomy suggest that the recurrent DCIS
arises from residual tumor cells missed by surgery (Waldman et al., 2000). Work by Waldman
et al. reported that recurrent DCIS lesions exhibited the same histologic architecture as the
initial DCIS, and CGH analysis revealed that the initial and recurrent DCIS were clonally
related (Waldman et al., 2000).
In a retrospective longitudinal cohort study examining 57,222 patients with
documented DCIS and surgery status, Sagara et al. reported a significant survival benefit
when comparing the surgery vs. non-surgery arm of patients with IG and HG DCIS (Sagara
et al., 2015). In contrast, there was no survival benefit for patients with LG DCIS that
underwent surgical excision (Sagara et al., 2015). In the only existing study assessing the
natural history of LG DCIS, however, Sanders et al. identified 28 women in which DCIS was
not initially diagnosed upon biopsy, but was detected upon examination of archival samples
(Sanders et al., 2005). In their median follow-up time of 31 years, 11/29 (39.3%) women
developed IDC, and 5/28 (17.9%) died of metastatic breast cancer (Sanders et al., 2005).
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They noted that the risk of invasive recurrence is greatest within the first fifteen years after
diagnosis (Sanders et al., 2005). Omission of surgical excision for patients with LG DCIS
therefore leaves a percentage of women at risk for recurrence.
Randomized control trials have concluded that the addition of radiation therapy to
lumpectomy reduces recurrence rates for early breast cancers by approximately 50%, similar
to that of mastectomy (Fisher et al., 1998, Bijker et al., 2001, Fisher et al., 2001, Fisher et
al., 2002, Bijker et al., 2006, Holmberg et al., 2008, Correa et al., 2010, Cuzick et al., 2011,
Wapnir et al., 2011). Clinical records, however, show that only half of women treated by
lumpectomy receive radiation therapy (Baxter et al., 2004, Jackson et al., 2008, Hughes et
al., 2009). Several studies have also reported that approximately 30% of patients do not
receive any significant benefit from radiation therapy (Lagios et al., 1989, Schwartz et al.,
1992, Zafrani et al., 1994, Silverstein et al., 1995b, Silverstein et al., 1996).
DCIS represents a heterogeneous spectrum of lesions with several treatment
approaches. Some DCIS may require local surgical excision, while others require radiation
therapy or mastectomy. While the benefit of lumpectomy and radiation therapy results in
great survival benefits to early breast cancer patients as a whole, we are unable to identify
which patients are over-treated and do not benefit from these interventions (Bartlett et al.,
2014). Paradoxically, we are uncertain of which DCIS lesions have an intrinsically higher
propensity to progress to invasive cancer, such that some patients may be under-treated
(Bartlett et al., 2014). Most patients therefore receive identical treatment, even though the
risk, particularly of over-diagnosis and treatment, is well-recognized (Miller et al., 2014). The
exception to this is patients with small, localized, non-high grade DCIS, for whom surgery
without radiation is sometimes considered (Hetelekidis et al., 1999, Wong et al., 2014). Due
to this important clinical problem, the 2009 National Institutes of Health State-of-the-Science
Conference recommended that a focus on development and validation of risk stratification
models and/or biomarkers is vital in order to optimize treatment strategies based on the
underlying biology of each patient’s DCIS (Allegra et al., 2010).
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Biomarkers for progression to invasive carcinoma
Breast cancers are now being diagnosed earlier, but this lead-time has not resulted in
significant reductions in diagnosis of invasive carcinoma after DCIS (Kerlikowske, 2010,
Miller et al., 2014). While up to 50% of DCIS lesions are expected to progress to IDC in the
lifetime of the patient (Sagara et al., 2015), there is a high degree of variability in terms of
latency (Muggerud et al., 2010). Indeed, some patients with DCIS progress to invasion
quickly, while others remains relatively unchanged over 20 years (Porter et al., 2003, Schuetz
et al., 2006). Previous studies have reported that traditional clinical and pathologic criteria
are not sufficient to consistently and accurately define DCIS risk groups (Porter et al., 2003,
Solin et al., 2013, Rakovitch et al., 2015). Conventional markers which are routinely assessed
by immunohistochemistry in invasive breast cancers (ER, PR) are also of limited value in
DCIS (Bartlett et al., 2014). The lack of reliable markers for risk stratification of patients
diagnosed with DCIS results in identical treatment for almost all patients (Bartlett et al., 2014).
There is therefore a pressing need for the development of novel diagnostic approaches for
risk stratifications of patients with DCIS in order to optimize treatment strategies.
The majority of examined IDCs possess non-invasive DCIS components; histological
analysis of both lesion types in these instances has revealed near identical histological and
biological features (Allred et al., 2008). A more thorough understanding of molecular
alterations within precursor lesions has been made possible through the use of tissue
microdissection technologies and high throughput genomic analyses. Diversity has been
shown to emerge at the DCIS stage, with very similar histology and transcriptional profiles in
the IDC portions within the same patient (Perou et al., 2000, Ma et al., 2003, Porter et al.,
2003, Schuetz et al., 2006, Allred et al., 2008). Analysis of pure DCIS, IDC, and mixed DCIS
and IDC has revealed that by conducting hierarchical clustering based on the most variably
expressed genes, DCIS cluster by “intrinsic subtype” and not by diagnosis (DCIS vs. IDC)
(Muggerud et al., 2010). This suggests that genes that confer the ability to invade are active
in some pre-invasive lesions (Muggerud et al., 2010). Additionally, they showed that not all
HG DCIS exhibit the potential for invasion (Muggerud et al., 2010). Importantly, several
studies have demonstrated that most gene expression changes characteristic of invasive
breast cancers, including genes which confer invasive growth, are already present at the preinvasive stage (ADH, DCIS, and persist in IDC) (Ma et al., 2003, Porter et al., 2003, Abba et
13

14

al., 2015). These findings are consistent with early LOH and CGH-based studies showing
that similar genetic abnormalities associated with DCIS and IDC are already present at the
ADH stage (Zhuang et al., 1995, Deng et al., 1996, O'Connell et al., 1998, Allred et al., 2001).
Van’t Veer et al. established a poor-prognosis signature associated with a 28-fold
increased risk for the development of metastasis over a 5-year period (van 't Veer et al.,
2002). Based on their 70-gene approach, they concluded that even small primary tumors
displaying a poor prognosis signature are already programmed for a metastatic phenotype
(van 't Veer et al., 2002). Taken together, these studies suggest that since DCIS and IDC
possess very similar transcriptional profiles, and a poor prognosis signature can be
established from the primary IDC, the same may hold true for DCIS.
The assessment of biomarkers for DCIS is still in its infancy. As highlighted by Bartlett
et al., 60 DCIS biomarker studies were published during the 2004-2014 period, with 90% of
the published studies regarded as statistically under-powered (Bartlett et al., 2014).
Additionally, several of these studies remain un-validated (Bartlett et al., 2014).
One DCIS biomarker that has been validated by several groups, however, is HER2
expression (as assessed by immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH)). High HER2 expression in DCIS is associated with non-invasive
recurrence (Provenzano et al., 2003, Kepple et al., 2006, Nofech-Mozes et al., 2008, Holmes
et al., 2011, Ringberg et al., 2001, Han et al., 2012). Additionally, joint assessment of HER2
and Ki67 expression in DCIS was associated with a 3.22-fold increased risk of non-invasive
recurrence (Rakovitch et al., 2012). Kerlikowske et al. reported that patients with DCIS which
are ER- and HER2+ with high expression of Ki67 possess the greatest risk (Kerlikowske et
al., 2010). The conclusions regarding HER2 expression and invasive recurrence postlumpectomy are variable. This discrepancy was discussed by Kerlikowske et al. and
Rakovitch et al., where they suggested this outcome was dependent on subtype (Kerlikowske
et al., 2010, Rakovitch et al., 2012, Bartlett et al., 2014).
Biomarkers which have been assessed by immunohistochemistry include HER2, ER,
PR, Ki67, cyclooxygenase 2 (COX2), p16 and p53 (Kerlikowske et al., 2010, Rakovitch et al.,
2012, Bartlett et al., 2014). Noteworthy examples include studies examining the coexpression of p16, COX2 and Ki67. High expression of p16 and COX2 in the absence of the
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proliferation marker Ki67 is indicative of a normal stress response, and protective against
progression of DCIS (Gauthier et al., 2007). High p16, and COX2 with elevated Ki67
expression, however, is associated with a 2-fold higher rate of invasive recurrence (Gauthier
et al., 2007, Kerlikowske et al., 2010).
The usage of one biomarker for risk stratification will likely result in limited predictive
power, so multiple markers are likely needed (van 't Veer et al., 2002). Multi-parameter gene
expression approaches for risk stratification of patients with DCIS has also been reported in
the literature. Oncotype Dx, a qRT-PCR based assay consisting of a panel of 16 breastcancer related genes and 5 housekeeping genes, possesses significant prognostic value in
predicting recurrence of patients with early-stage, node-negative invasive breast cancers
treated with adjuvant tamoxifen (Paik et al., 2004). The Oncotype Dx assay was adapted for
assessment of DCIS recurrence risk after treatment by surgical excision without radiation
therapy, and referred to as the DCIS Score (Solin et al., 2013). The DCIS Score is calculated
through assessment of a 12-gene panel (including the previously-used 5 housekeeping
genes), with an emphasis on genes involved in proliferation (Solin et al., 2013). The DCIS
score of low, intermediate, and high-risk was associated with a 10.6% (3.7%), 26.7%
(12.3%), and 25.9% (19.2%) risk of non-invasive (and invasive) recurrence over 10-years in
the absence of radiation therapy (Solin et al., 2013). Interestingly, the DCIS Score was not
associated with existing clinical or pathologic factors (Solin et al., 2013). These findings have
been validated in an independent cohort of 718 patients, with 12.7% (low-risk), 33.0%
(intermediate-risk), 27.8% (high-risk) local recurrence rates for the specified risk group over
a 10-year follow-up period (Rakovitch et al., 2015). These findings may therefore be used to
provide predictive information in order to determine which patients may be spared radiation
therapy due to their low intrinsic risk of developing invasive breast cancer.
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Experimental Models of Breast Cancer Progression
The development of breast cancer is a multi-step process, and our understanding of
the underlying molecular events has been hindered due to a lack of suitable models of
progression (Liu et al., 1994). Previous studies have demonstrated that mouse-derived premalignant lesions are histologically different from those of humans, particularly in transgenic
mouse models where the cellular origin of hyperplastic lesions is more often associated with
the promoter rather than the transgenes used (Cardiff et al., 2000). The standard method
used to determine malignant potential of cells within precursor lesions is transplantation
(Cardiff et al., 2000). As described by Cardiff et al., this is similar to “Koch’s Postulates” of
tumor biology, including “identification [of cells representing the precursor stage], isolation,
transplantation and characterization” (Cardiff et al., 2000). Most human cells lines
representing pre-malignant stages do not form any discernible histologic lesions in nude
mice, and the majority of existing cell lines used for xenograft assays are of metastatic origin
(Band et al., 1990, Miller, 2000). Importantly, only the 21T, HMT-3522, and MCF10AT breast
epithelial cell line series have been reported to recapitulate the various histological
characteristics of human breast carcinoma within a xenograft model (Santner et al., 2001,
Rizki et al., 2008, Souter et al., 2010).
The 21T series cell lines were isolated from a single patient with invasive ductal
carcinoma through selective trypsinization and expanding of polygonal tumor-like cells from
spindle-shaped epithelial cells and fibroblasts (Band et al., 1989, Band et al., 1990). The
21PT and 21NT cells were isolated from the primary tumor, and 21MT-1 cells were isolated
from a pleural effusion (Band and Sager, 1989, Band et al., 1989, Souter et al., 2010).
Importantly, the isolated cell lines represent distinct stages of progression: 21PT cells mimic
ADH (non-tumorigenic), 21NT cells mimic DCIS (tumorigenic, non-metastatic), and 21MT-1
mimic IDC (tumorigenic, metastatic) when injected into the mammary fat pad of nude mice
(Band et al., 1990, Souter et al., 2010). Karyotyping of the 21T series cell lines has previously
been conducted by our laboratory (Xu et al., 2008), indicating that all three cell lines have
common chromosomal aberrations, potentially reflecting a common origin within the same
tumor (Xu et al., 2008). Additionally, these cells are weakly ER and PR positive, HER2
amplified, and possess a mutated form of p53 (Band et al., 1990, Liu et al., 1994, Biswas et
al., 1998, Biswas et al., 2001).
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The HMT-3522 human breast epithelial cell lines were derived from a reduction
mammoplasty, with the S1 cells isolated from a sample with fibrocystic breast disease
(Madsen et al., 1992, Rizki et al., 2008). The S2, S3(A-B) and T4-2 cell lines were established
through sub-culturing of cells (in 2D or 3D Matrigel), isolation of colonies with distinct
phenotypes characteristic of aggressiveness, along with inoculation of cells into mice and
passaging of xenograft cells for T4-2 cells (Madsen et al., 1992, Rizki et al., 2008). The cells
represent a model of spontaneous transition and exhibit differential growth patterns and
phenotypes in 3D Matrigel, along with varying tumorigenicity in nude mouse xenograft assays
(Rizki et al., 2008). The S3 cell lines represent the pre-invasive stage of the human breast
cancer progression series, but give rise to a metaplastic phenotype (Rizki et al., 2008).
Human metaplastic breast cancers are rare, but also extremely aggressive, sharing similar
clinical behavior and markers with basal-like breast carcinomas (Kenny et al., 2007, Rizki et
al., 2008).
There are several variants of the MCF10A cell line, all previously isolated from a
sample consisting of fibrocystic breast disease, most notably the pre-malignant MCF10AT
and malignant MCF10CA variants both of which are Ras transformed (Miller, 2000, Miller et
al., 2000). In mouse xenograft assays, MCF10AT cells initially form simple ducts and lead to
a wide spectrum of pre-malignant lesions, including ADH and DCIS, with approximately 25%
of mice developing invasive carcinoma (Miller, 2000). Lesions formed by MCF10AT cells are
highly heterogeneous, giving rise to several different and distinct histological subtypes as
well as differential immunoreactivity (Strickland et al., 2000, Santner et al., 2001).
Additionally, these cells are able to give rise to a myoepithelial cell layer (Tait et al., 1996),
indicating the presence of precursor stem cells and likely explaining the unstable and
heterogeneous phenotype (Miller, 2000). The MCF10DCIS.com cell variants were isolated
from a xenograft lesion formed by MCF10AT cells (Miller et al., 2000). The MCF10DCIS.com
cells are highly proliferative and form comedo DCIS (high nuclear grade with zonal necrosis)
in vivo (Miller, 2000). These cells have high rates of spontaneous progression to invasive
carcinoma, although the DCIS component is retained (Miller et al., 2000). The MCF10CA cell
line was isolated through serial transplantation of spontaneous tumors formed by MCF10AT
cells, and is malignant and highly metastatic (Miller, 2000, Santner et al., 2001). The
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tumorigenic MCF10AT cell line variants are ER and PR positive, and possess wildtype p53
(Shekhar et al., 1998, Miller, 2000, Hevir et al., 2011).
A major advantage of utilizing a series of cell lines derived from a single patient to
study progression is the minimal genetic variability. This allows for the mining of biologically
relevant driver mutations and gene expression changes directly related to a subset of genetic
alterations, independent of individual variability. Genetic manipulation of cell lines
representing various stages of progression can be used to examine the relative functional
impacts of genes on transitions between distinct stages (ADH, DCIS, IDC) (Souter et al.,
2010). This can often be done through the use of in vitro techniques, which can be modified
for high-throughput screens for identification of genes important in functional and phenotypic
transitions, or for identification of therapeutically effective chemical agents in preclinical
screens (Miller, 2000). Souter et al. described a 3D in vitro Matrigel culture in which cells
were seeded on Matrigel and the resultant colonies were phenotypically assessed (Souter et
al., 2010). Through the use of this 3D culture system, the 21PT, 21NT and 21MT-1 cells were
shown to exhibit differential phenotypes and display features of distinct stages of the breast
cancer progression pathway (Souter et al., 2010). Less aggressive cell lines (including the
21PT cells) typically show more polarized cells and higher rates of lumen formation, along
with more spherical colonies and a lower frequency of single, dispersed cells (Souter et al.,
2010) (depicted in Figure 1.1.6).
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Figure 1.1.6 – Characteristic growth patterns of 21T cell lines in 2D, 3D, and in mouse
xenografts.
H&E images were obtained from Souter et al., 2010.
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1.2 TBX3
TBX3 is a member of the highly conserved family of T-box transcription factors. The
18 T-box genes within mammals are believed to have evolved from tandem duplication of a
primordial gene, followed by cluster dispersion (Agulnik et al., 1996, DeBenedittis and Jiao,
2011). Several of the T-box genes are expressed throughout development, with tight
temporal and spatial regulation (DeBenedittis and Jiao, 2011). The identification of T-box
family members generally occurred through experiments designed to identify genes involved
in embryonic development, with lack of expression resulting in developmental defects (Bollag
et al., 1994, Bamshad et al., 1999).
The first T-box transcription factor identified was the Brachyury (TBXT) gene
(Gruneberg, 1958). In mice, homozygous mutations in Brachyury are embryonic lethal due
to insufficient formation of mesodermal cells in the developing embryo, while heterozygous
mutations result in a variable short tail phenotype (Gluecksohn-Schoenheimer, 1938,
Gruneberg, 1958, Yanagisawa et al., 1981, Stott et al., 1993). Several decades later, TBX3
was discovered by Bollag et al., who postulated its role in development after observing highly
specific patterns of expression in the developing mouse embryo (Bollag et al., 1994). It was
later discovered that TBX3 plays an important role in limb, heart, and mammary gland
development (Wilson and Conlon, 2002). In mice, homozygous TBX3 mutations are
embryonic lethal, and most embryos die by E12.5 due to yolk sac defects (Davenport et al.,
2003). Limb defects, along with lack of mammary glands was also documented (Davenport
et al., 2003), similar to the conditions observed in human patients. In humans, mutations or
haploinsufficiency of TBX3 results in Ulnar-Mammary Syndrome (UMS, OMIM 181450). UMS
is fully penetrant although it presents with highly variable clinical characteristics, mainly
consisting of mammary gland hypoplasia, apocrine gland, dental, and genital defects
(Bamshad et al., 1997, Bamshad et al., 1999, Davenport et al., 2003). These observed
phenotypes are consistent with the broad expression profile of TBX3 (Figure 1.2.2).
Complete loss of TBX3 expression is predicted to be fatal, as patients lacking both copies of
TBX3 have not been identified (Rowley et al., 2004).
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Figure 1.2.1 – Full-length TBX3 protein structure. Adapted from Willmer et al., 2017.
The full-length TBX3 protein is 743 residues in length, containing the T-box domain
(residues 105-305), nuclear localization sequence (NLS; residues 312-317), activation
domain (residues 443-520) and repression domains (residues 123-200, 587-643) (Smith,
1999, Carlson et al., 2001, Papaioannou, 2001, Willmer et al., 2017) (Figure 1.2.1). Two
TBX3 isoforms exist through alternative splicing: TBX3iso1 and TBX3iso2 (which contains
the 2a exon). TBX3 isoforms are described in Section 2.3.1.
All T-box transcription factors possess the highly conserved DNA binding domain
known as the T-box domain which shares no sequence similarity to other known DNA binding
motifs (Wilson and Conlon, 2002). Most of the described T-box domains are approximately
180 amino acids in length (Coll et al., 2002). T-box transcription factors bind to DNA
sequences containing the T-box element (TBE) (Wilson and Conlon, 2002). To date, all Tbox transcription factors examined are able to bind to the TBE consisting of bases
TCACACCT (Wilson and Conlon, 2002). Coll et al. have proposed a less stringent consensus
sequence (5’-xTxxCACxx’-3’; x signifies a less conserved base) for identification of new Tbox binding sites (Coll et al., 2002).
T-box proteins function as transcriptional activators or repressors depending on the
promoter context (Wilson and Conlon, 2002, Lu et al., 2010). TBX2 is the most closely related
T-box gene to TBX3, sharing ~95% sequence homology in the T-box domain and ~70%
homology in the repression domain (Bamshad et al., 1999). Interestingly, TBX2 and TBX3
are the only T-box transcription factors that function as transcriptional repressors (Carlson et
al., 2001, Lu et al., 2010). Sequence analysis of the repression domain of TBX2 and TBX3
revealed no conserved sequence or motifs shared with other known repression domains (Lu
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et al., 2010). While TBX2 and TBX3 exhibit overlapping and complementary expression
patterns in the developing mouse embryo, they were found to have non-redundant roles in
developmental processes (Rowley et al., 2004).
TBX3 possesses both activation and repression domains. Most of the existing cancerrelated literature focuses on transcriptional repression of target genes by TBX3, while
transcriptional activation of target genes has been further characterized in heart development
(Boogerd et al., 2011, Lu et al., 2011). The effect of TBX3 on transcription likely depends on
interacting partners and target genes (Willmer et al., 2017). Several domains which facilitate
protein-protein interaction likely reside outside of the T-box domain, since this area has
undergone rapid diversification between T-box genes (Bamshad et al., 1999, Coll et al.,
2002). The effect of TBX3 on transcription of downstream target genes as they relate to the
process of tumorigenesis is discussed in the next section.

Figure 1.2.2 – TBX3 mRNA expression by tissue type.
Graphical representation of TBX3 mRNA expression across tissue types was obtained from
Jensen TISSUES database (tissues.jensenlab.org), depicting Genotype Tissue Expression
(GTEx) dataset (histogram plot on upper right). TBX3 mRNA expression in normal tissue is also
shown from the Human Protein Atlas (HPA) dataset.
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Mechanisms of transcriptional regulation by TBX3
TBX3 is able to bind several target genes through recognition of the conserved TBE
sequence by the DNA binding domain (Wilson and Conlon, 2002). X-ray crystallography
studies of TBX3 and Brachyury indicate that there are only two specific contacts within the
DNA binding domain per TBE (Müller and Herrmann, 1997, Coll et al., 2002). The binding of
TBX3 to the phosphatase and tensin homolog (PTEN) promoter, however, occurs in the
absence of a TBE sequence (Burgucu et al., 2012), thereby suggesting that the binding of
TBX3 to target sites is likely dependent on: i) DNA specificity and binding to a conserved
TBE, ii) interaction with specific DNA binding proteins, iii) interaction with chromatin
determinants (Lingbeek et al., 2002, Rodriguez et al., 2008). TBX3 is able to interact with
chromatin, and directly binds to histone H2A (Kumar P et al., 2014b), histone deacetylases
(HDACs), and DNA methyltransferases (DNMTs) (Yarosh et al., 2008, Dan et al., 2013),
leading to transcriptional up-regulation or down-regulation of target genes. Additionally,
TBX2, TBX4, TBX5 and TBX6 are able to bind to histone H3 N-terminal tails (Demay et al.,
2007), the primary location of histone post-translational modifications (Mersfelder and
Parthun, 2006).
Acetylation of histones is associated with active chromatin (Lewin et al., 2011).
Histone deacetylases (HDACs) are involved in the removal of acetyl groups from histones,
which results in tighter histone-DNA interactions and reduced levels of transcription (Yarosh
et al., 2008). As HDACs do not contain a DNA binding domain, they are recruited by DNAbinding transcription factors (Cress and Seto, 2000). TBX3 is able to recruit and directly
interact with histone deacetylases (HDACs) in order to epigenetically silence gene promoters
(Willmer et al., 2017). This includes direct interaction with HDAC1, HDAC2, HDAC3, and
HDAC5 to transcriptionally repress p14ARF in MCF7 cells (Yarosh et al., 2008). HDACs are
often overexpressed in breast cancers (Zhang et al., 2005, Glozak and Seto, 2007), and it is
suggested that each HDAC plays a specific role in the process of breast tumorigenesis (Puri
et al., 2001, Dokmanovic and Marks, 2005, Glozak et al., 2005). The association between
TBX3 and HDACs may therefore play an important role in breast cancer progression (Yarosh
et al., 2008). Additionally, in a recent study in hepatocellular carcinoma (HCC), TBX3 was
found to directly interact with HDAC5, resulting in down-regulation of E-cadherin;
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administration of HDAC inhibitor was able to block TBX3-induced repression of E-cadherin
and TBX3-induced migration in HCC cell lines (Dong et al., 2018).
DNA methylation is associated with transcriptionally inactive DNA (Lewin et al., 2011).
ChIP-Seq analysis revealed that TBX3 binds upstream of the DNA methyltransferases
DNMT3A and DNMT3B genes, leading to their transcriptional repression (Han et al., 2010).
TBX3 overexpression results in a reduction in the global DNA methylation levels, likely
through down-regulation of DNMT3B (involved in DNA methylation) and up-regulation of
TET2 (involved in DNA de-methylation) (Dan et al., 2013).
Not only is TBX3 able to modify epigenetic profile of target genes, the physical
interaction of TBX3 with several RNA-binding proteins and splice factors has revealed that
TBX3 is also able to bind to TBEs within mRNA transcripts and directly regulate splicing
(Kumar P et al., 2014b). These studies show that not only does TBX3 regulate gene
expression through activation/repression of genes through various means including
alterations of histone modifications, but is also able to modulate splicing of target mRNA
sequences. In fact, there is an over-representation of TBEs in sequences flanking alternative
exons (Kumar P et al., 2014b). Alternative splicing is an important post-transcriptional
mechanism of gene regulation, and changes in alternative splicing profiles has been
observed in several cancers (Venables, 2004, Pajares et al., 2007, Venables et al., 2008,
Shapiro et al., 2011, Oltean and Bates, 2014). The study by Kumar et al. sheds light on other
potential mechanisms in which TBX3 overexpression in several cancer types may lead to
tumorigenesis (Kumar P et al., 2014b).
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TBX3 in Cancer
TBX3 levels are up-regulated in several cancers, including breast (Fan et al., 2004,
Lomnytska et al., 2006, Yarosh et al., 2008, Souter et al., 2010), melanoma (Rodriguez et
al., 2008), pancreatic (Hansel et al., 2004, Cavard et al., 2009, Begum and Papaioannou,
2011), cervical (Lyng et al., 2006), ovarian (Lomnytska et al., 2006), gastric (Miao et al.,
2016), and prostate cancers (Gudmundsson et al., 2010, Witte, 2010). TBX3 expression
levels in normal tissues, tumor tissues, and plasma samples have been assessed in several
studies described below, using methods ranging from IHC, microarray analysis, qRT-PCR,
western blot, and 2D gel electrophoresis coupled to mass spectrometry.
TBX3 PROTEIN IN CANCERS – Assessment of TBX3 expression in pancreatic cancer by
IHC revealed that elevated TBX3 expression within tumor samples was an independent
prognostic factor for reduced overall survival (Wang et al., 2015). In gastric cancers, elevated
TBX3 expression by IHC was significantly associated with advanced TNM (tumor, node,
metastasis) stage and higher incidence of relapse (Miao et al., 2016). In colorectal cancer,
elevated TBX3 expression by IHC was an independent predictor of poor outcome, and was
correlated with tumor size, differentiation, TNM stage and lymph node metastasis (Shan et
al., 2015).
Lomnytska et al. assessed differential protein expression within plasma samples of
breast and ovarian cancer patients through the use of 2D gel electrophoresis coupled to
matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOFMS) (Lomnytska et al., 2006). This study revealed significantly higher levels of TBX3 in
plasma of both early stage and advanced stage breast cancer and ovarian cancer patients
relative to healthy control patients (Lomnytska et al., 2006).
Examination of TBX3 expression by western blot in a diverse subset of cell lines
representing normal human fibroblasts, transformed fibroblasts, and several soft tissue and
bone sarcoma cell lines reported high levels of TBX3 in transformed fibroblasts and sarcoma
cell lines relative to normal human fibroblast controls (Willmer et al., 2016a). Willmer et al.
suggested clinical assessment of TBX3 expression to differentiate benign soft tissue masses
from sarcomas (Willmer et al., 2016a).
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TBX3 mRNA IN CANCERS – TBX3 is overexpressed in a variety of different cancer types
(Figure 1.2.3). Microarray analysis revealed that elevated TBX3 mRNA expression was
associated with advanced tumor stage, chemo-resistance and an unfavorable prognosis in
patients with hepatoblastoma (Renard et al., 2007). Assessment of TBX3 expression by qRTPCR and western blot in non-small cell lung cancer (NSCLC) patient samples revealed that
overexpression of TBX3 was associated with tumor size, TNM stage, differentiation, and
recurrence, and was an independent prognostic marker for overall survival (Wu et al., 2017).
Additionally, up-regulation of TBX3 has been documented with chronic exposure to
carcinogens, including a positive correlation with tobacco smoking status (Wu et al., 2017)
and exposure to the environmental toxin DE-71 and liver tumorigenesis (Shimbo et al., 2017).

Figure 1.2.3 – TBX3 mRNA expression by cancer type.
Graphic obtained from CCLE (Cancer Cell Line Encyclopedia).
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The single published transgenic TBX3-inducible mouse model used a doxycyclineinducible TBX3iso2 expression system under the control of the mouse mammary tumor virus
(MMTV) promoter (Liu et al., 2011). Their results showed that overexpression of TBX3iso2
in murine mammary glands resulted in mild focal hyperplasia and importantly no tumor
formation (Liu et al., 2011). The effect of inducible overexpression of TBX3iso1 was not
examined. Few xenograft studies have been conducted overexpressing either TBX3iso1 or
TBX3iso2 (or knockdown of total TBX3 levels) in various cell line backgrounds in order to
assess resultant tumorigenicity. TBX3iso1 was overexpressed in SWI1353 chondrosarcoma
cells and exhibited enhanced tumor growth (Willmer et al., 2016a). Injection of TBX3overexpressing non-tumorigenic WM1650 melanoma cells into the flank of nude mice
resulted in 6/6 of mice forming tumors compared to 0/6 in the parental control cells (Peres
and Prince, 2013). Overexpression of TBX3 in pancreatic cancer cell lines resulted in
significantly larger tumors than controls (Perkhofer et al., 2016). The latter two examples did
not state which TBX3 isoform was overexpressed. The shRNA-mediated knockdown of TBX3
in tumorigenic ME1402 melanoma cells abolished their ability to form tumors when injected
into the flank of nude mice (Peres et al., 2010).
The use of TBX3 as a potential biomarker in various cancer subtypes has been
examined through the use of several methodologies, as has its role in chemically-induced
carcinogenesis. In all documented cancer cases aside from fibrosarcoma, overexpression of
TBX3 has led to increased migration and invasion (Rodriguez et al., 2008, Peres et al., 2010,
Krstic et al., 2016, Willmer et al., 2016a). Although the contribution of TBX3 in tumorigenesis
is not fully understood, accumulating evidence suggests that several pathways may be
involved (summarized in Figure 1.2.4). More research is needed for further identification of
upstream activators of TBX3 signaling, its target genes, along with co-factors required for its
proper functioning (Willmer et al., 2017). Some of the cancer-associated pathways in which
TBX3 is involved are described in the next sections.
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Figure 1.2.4 – Cancer-related TBX3 signaling pathways.
Green lines represent direct transcriptional interactions, while red lines represent direct
post-translational interactions.
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TBX3 and Cellular Senescence – p14ARF / p53 / p21CIP1 Pathway
The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene encodes the p16INK4A and
p14ARF proteins in humans, with differential promoters and partially overlapping reading
frames (Ruas and Peters, 1998). Both proteins act as tumor suppressors and are important
regulators of cellular senescence (Ruas and Peters, 1998). While p14ARF is primarily involved
in stabilization of p53, p16INK4A inhibits the enzymatic activity of cyclin-dependent kinases 4
and 6 (CDK4/6) (Rayess et al., 2012). CDK4/6 binds cyclin D, which then phosphorylates the
Retinoblastoma (Rb) protein, resulting in dissociation of Rb and the E2F transcription factor,
thereby promoting the G1 to S phase transition (Rayess et al., 2012).
Cellular senescence is a protective mechanism of irreversible growth-arrest resulting
in permanent exit from the cell cycle. Senescence can be induced by cellular stresses
(accelerated senescence) or telomere shortening (replicative senescence) (Lu et al., 2010).
One of the most well described pathways of accelerated senescence is through activation of
p14ARF, whereby p14ARF binds to and sequesters mouse double minute 2 (MDM2), preventing
MDM2 from targeting p53 for destruction (Tao and Levine, 1999). High expression of p14ARF
thus stabilizes p53, leading to expression of p53 target genes (Lu et al., 2010). Early studies
reported that TBX3 overexpression leads to impaired functioning of the p53-pathway,
suppression of apoptosis and facilitation of cell transformation (Carlson et al., 2002). TBX3
was later identified in a senescence screen and described as a potent inhibitor of senescence
through inhibition of p14ARF (and p19ARF mouse ortholog), explaining the previously reported
effect on p53 (Brummelkamp et al., 2002). After this initial identification of the powerful antisenescence effect of TBX3, both TBX3 and TBX2 have been shown to bind to a variant TBE
in the human p14ARF promoter matching 13 of 20 nucleotides within the consensus TBE
(Lingbeek et al., 2002). Specifically, TBX3 is able to interact with HDACs 1, 2, 3 and 5, leading
to local changes in histone acetylation and subsequent down-regulation of p14ARF expression
in breast cancer cell lines (Yarosh et al., 2008).
Overexpression of several oncogenes and activation of mitogenic signaling pathways
induces p14ARF expression, and subsequent p53-dependent cell cycle arrest (Rowley et al.,
2004). Overexpression of MYC or oncogenic H-RasVal17 with TBX3 (but not by themselves),
however, protects cells from apoptosis through inhibition of p14ARF (Carlson et al., 2002). On
a similar note, knockdown of TBX3 was shown to sensitize cells to doxorubicin in rat bladder
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carcinoma and human colorectal cancer, later attributed to activation of the p14 ARF / p53
pathway (Renard et al., 2007, Zhang et al., 2011a).
The cyclin-dependent kinase inhibitor p21CIP1 is essential for p53-induced cellular
senescence (Waldman et al., 1995). TBX3 was shown to directly bind to the p21CIP1 promoter
and repress gene transcription in a dose-dependent manner in melanoma cell lines
(Hoogaars et al., 2008, Willmer et al., 2016b). This was shown by electromobility shift assays
(EMSA), luciferase assays, and ChIP qRT-PCR validation (Hoogaars et al., 2008, Willmer et
al., 2016b). Repression of both p14ARF and p21CIP1 by TBX3 produces a powerful synergistic
effect, leading to a strong inhibition of senescence (Lu et al., 2010).
Lastly, TBX3 is also able to bypass senescence through down-regulation of p16INK4A
through formation of a co-repressor complex, leading to destabilization of p16INK4A and
inhibition of the Rb pathway (Kumar P et al., 2014a).

TBX3 and the TGF-ß Pathway
The transforming growth factor beta (TGF-ß) signaling pathway is involved in
development, along with the processes of homeostasis, proliferation and differentiation in
adult tissues (Massagué, 2012). TGF-ß proteins bind their cognate receptors, and the signal
is mediated through the canonical suppressor of mothers against decapentaplegic (SMAD)
proteins that control the expression of hundreds of genes (Massagué, 2012). The TGF-ß
signaling pathway is constitutively activated in several breast cancers, leading to a promotion
of migration but inhibition of proliferation of cancer cells (Tian et al., 2003, Moses and
Barcellos-Hoff, 2011). Treatment of epithelial cell lines with TGF-ß results in up-regulation of
TBX3 (Kang et al., 2003). Later it was discovered that TGF-ß1 is able to up-regulate TBX3
through cooperative binding of Smad3/4 and JunB in the TBX3 promoter, with subsequent
TBX3-dependent repression of the pro-proliferative family member TBX2 in melanoma cell
lines (Li et al., 2013, Li et al., 2014). While overexpression of TBX3 results in an increased
proliferation rate in several cell lines, TBX3 has an anti-proliferative effect in melanoma cell
lines while still maintaining its pro-tumorigenic properties (Peres et al., 2010). TBX3 was
therefore proposed to mediate the anti-proliferative, pro-migratory effect associated with
TGF-ß signaling in melanoma cells (Li et al., 2013, Li et al., 2014).
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TBX3 and the FGF Pathway
The fibroblast growth factor (FGF) signaling pathway is comprised of a group of
developmentally-important secreted signaling proteins. Binding of FGF ligands to their
signaling receptors (FGFRs) results in activation of their intracellular tyrosine kinase domain,
which can activate several intracellular signaling pathways involved in maintenance, repair,
regeneration and metabolism of adult tissues (Ornitz and Itoh, 2015).
During development in the mouse, TBX3 is initially expressed in the mammary lineage
prior to mammary bud formation at E10.25, which is followed by the first signs of the
mammary gland at E10.5 to E11, and expression of several Wnts and FGF ligands (Eblaghie
et al., 2004). Eblaghie et al. soaked beads in various FGF proteins, and implanted them into
the flank of mice in order to assess expression of downstream genes of interest (Eblaghie et
al., 2004). They reported that FGF8 induces expression of TBX3 in an FGFR1-dependent
manner (Eblaghie et al., 2004). These early studies showed that TBX3 and FGF ligands are
able to interact and influence expression of one another within a developmental context
(Eblaghie et al., 2004). Several other studies have reported autoregulation of expression
between T-box and FGF family members (Isaacs et al., 1994, Schulte-Merker and Smith,
1995, Casey et al., 1998, Eblaghie et al., 2004).
In a breast cancer context, Fillmore et al. reported that estrogen leads to an expansion
of breast cancer stem cells (CSCs) through the FGF and TBX3-mediated signaling pathways
(Fillmore et al., 2010). The binding of estrogen to the estrogen receptor results in
transcriptional up-regulation of FGF proteins (Fillmore et al., 2010). Specifically, FGF9 binds
to FGFR3, which induces TBX3 expression (Fillmore et al., 2010). Elevated TBX3 expression
is important for further production of FGF proteins and signal propagation, eventually
resulting in an increase in an expansion of the breast CSC population (Fillmore et al., 2010).
It was therefore shown that due to this TBX3-mediated expansion of CSCs in MCF7 cells
treated with estrogen, TBX3 overexpression resulted in a 100-fold increase in tumor initiation
rates in ovariectomized NOD/SCID mice (Fillmore et al., 2010).
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TBX3 and the Wnt / ß-Catenin Pathway
The Wingless (Wnt) signaling pathway is involved in cellular proliferation and
differentiation, and plays a crucial role in development and tissue homeostasis (Giles et al.,
2003). Several Wnt proteins are overexpressed in breast cancer cell lines, leading to
activation of the canonical Wnt/ß-catenin signaling pathway (Howard and Ashworth, 2006).
ß-catenin directly binds to the TBX3 promoter through a T-cell specific (TCF)-binding site,
leading to increased proliferation and survival of liver cancer cells (Renard et al., 2007).
TBX3 and Wnt signaling have been extensively studied in the processes of
development. Within the developing mammary gland, TBX3 is required for the induction of
Wnt signaling, as homozygous TBX3 mutant transgenic mice showed an inability to initiate
mammary gland development and lack expression of the earliest markers of this
developmental process (Lef1 and Wnt10b) (Davenport et al., 2003, Rowley et al., 2004).
Additionally, induction of TBX3 expression in the developing mammary gland requires Wnt
signaling (Eblaghie et al., 2004, Douglas and Papaioannou, 2013), suggesting the presence
of a feedback loop (Davenport et al., 2003, Eblaghie et al., 2004, Cho et al., 2012). TBX3
overexpression in mammary epithelial cells was additionally reported to coordinate
expansion of progenitor cells through induction of Wnt signaling (Arendt et al., 2014).

TBX3 and the PTEN / PI3K / AKT Pathway
The phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) signaling pathway
has been described as an upstream mediator of TBX3 expression in mouse embryonic stem
cells (Niwa et al., 2009), melanoma, and head and neck squamous cell carcinoma (HNSCC)
(Burgucu et al., 2012, Boyd et al., 2013, Peres et al., 2015). The PI3K/AKT pathway promotes
proliferation and cell survival in response to binding of growth factors, cytokines and/or
hormone ligands to receptor tyrosine kinases (RTKs) (Cantley and Neel, 1999).
AKT3, the predominant AKT isoform expressed in melanomas, was shown to
phosphorylate TBX3 at residue Ser-720 in vitro, leading to increased protein stability and
nuclear localization (Peres et al., 2015). This phosphorylation event resulted in enhanced
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repression of E-cadherin by TBX3, and increased migration and invasion of melanoma cell
lines (Peres et al., 2015).
There is also evidence that TBX3 may function upstream of the PI3K/AKT pathway
through repression of the tumor suppressor PTEN. PTEN is the main negative regulator of
PI3K, thus functioning as a tumor suppressor through its PI3K-dependent inhibition of AKT
(Cantley and Neel, 1999). There is an inverse correlation between TBX3 and PTEN
expression in HNSCC (Burgucu et al., 2012). TBX3 is able to repress both basal and induced
expression of PTEN in HNSCC cell lines, through binding a non-canonical TBX3 binding site
in the PTEN promoter (Burgucu et al., 2012). TBX3 was not able to repress PTEN in muscle
cells, however, suggesting context-dependent repressive functions (Zhu et al., 2016).

Regulation of TBX3 by miRNAs
MicroRNAs (miRNAs) are non-coding RNAs which are able to modulate gene
expression by binding to complementary nucleotides in the 3’ untranslated region (UTR) of
target genes (Bartel, 2004). The 3’ UTR of TBX3 extends 1,587 bp beyond the termination
codon (Bamshad et al., 1999). Binding sites for several microRNAs have been found in the
3’ UTR of TBX3, including miR-25, miR-32, miR-92, miR-93 (validated), miR-137 (validated),
miR-206 (validated), miR-363, and miR-367 (Zhang et al., 2011b, Humtsoe et al., 2012, Jiang
et al., 2013, Cioffi et al., 2015, Amir et al., 2016).
Most of the in vitro studies assessing miRNA regulation of TBX3 have been conducted
with miR-137 (Jiang et al., 2013, Peres et al., 2017). The miR-137 is an important regulator
of differentiation in embryonic stem cells (Szulwach et al., 2010, Sun et al., 2011, Jiang et
al., 2013), and inhibits anchorage-independent growth and migration of malignant melanoma
cells (Peres et al., 2017). Expression of miR-137 is down-regulated in several cancers, with
epigenetic silencing of miR-137 representing an early event in colorectal cancer (Silber et al.,
2008, Balaguer et al., 2010, Chen et al., 2010, Jiang et al., 2013, Peres et al., 2017).
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1.3 Alternative Splicing in normal and neoplastic cells
Gene expression changes, on their own, cannot fully account for changes in gene
functions and cellular phenotype (Venables, 2004). It is estimated that over 90% of human
genes are alternatively spliced, adding an enhanced layer of complexity and diversification
to genes encoded in the genome (Matlin et al., 2005, DeBenedittis and Jiao, 2011). Cancer
cells are able to exploit the process of alternative splicing to produce isoform switches,
resulting in enhanced survival, proliferation and invasiveness (Oltean and Bates, 2014, Shen
et al., 2016).
Genes are transcribed into pre-mRNA, containing long intervening segments called
introns, and protein-coding segments called exons. Alternative splicing refers to the “cutting”
of intron-exon boundaries in pre-mRNA and joining the exons together in highly specific
arrangements, producing structurally and functionally distinct mRNA and protein variants
(Blencowe, 2006). The majority of alternative splicing events occur simultaneously with
transcription, with the emergence of pre-mRNA from RNA polymerase II (Bentley, 2005,
Blencowe, 2006). Additionally, modifiers of chromatin structure, including histone
modifications and nucleosome positioning, affect transcription kinetics and thus alternative
splicing decisions (Kornblihtt et al., 2013). This global post-transcriptional mechanism thus
allows for cell-specific, stage-specific and stimuli-specific responses (Pajares et al., 2007).
After transcription and pre-RNA processing is completed, mature mRNA is exported
from the nucleus to the cytoplasm where it is translated into protein. As a precautionary
quality control mechanism, the nonsense-mediated mRNA decay (NMD) pathway leads to
cytoplasmic degradation of inappropriately expressed transcripts (Pajares et al., 2007).
Sometimes an aberrant transcript is not detected by the NMD pathway and is translated into
protein; this is observed in several diseases including cancers (Pajares et al., 2007).
Each hallmark of cancer has been associated with changes in alternative splicing
(Oltean and Bates, 2014). Mutations in cis-regulatory elements (i.e. splicing enhancers and
silencers), near intron-exon junctions (i.e. creating or disrupting splice sites), or trans-acting
splicing factors (i.e. involved in assembly of spliceosome) can lead to aberrant splicing
(Pajares et al., 2007). Additionally, changes in concentration, localization, activity, and/or
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composition of trans-acting splice factors (even in the absence of mutations) has also been
documented to alter splicing patterns (Pajares et al., 2007). The documented splicing
machinery changes during oncogenesis result in cancer-specific patterns of alternative
splicing, leading to the emergence of previously non-existent transcripts and/or aberrant
isoform ratios expressed within tumors relative to normal tissues (Pino et al., 2003, Venables,
2004, Ladomery et al., 2007, Pajares et al., 2007).
There are numerous examples of alternatively spliced transcripts having diverse and
antagonistic functions (Pajares et al., 2007). A prominent example includes alternative
splicing of vascular endothelial growth factor (VEGF); most splice variants are actively proangiogenic (Ladomery et al., 2007). Interestingly, the VEGFb splice variant is actively antiangiogenic, and contains only 6 different amino acids relative to its most similar isoform
(Ladomery et al., 2007). A splicing switch from the anti-angiogenic to pro-angiogenic variant
is observed both in cancer progression, as well as in diseases such as proliferative diabetic
retinopathy (Blencowe, 2006, Ladomery et al., 2007, Pajares et al., 2007). As such,
differential expression of VEGF isoforms is associated with significant differences in survival
for patients with node-positive breast cancer (Konecny et al., 2004).
Recent studies have shown that alternative-splicing based analyses consistently
outperform gene expression-based survival predictors (Shen et al., 2016, Klinck et al., 2008).
Shen et al. have reported distinct cancer-associated alternative splicing patterns across 6
different cancer types in the TCGA datasets (Shen et al., 2016). Various strategies are
currently being employed in an attempt to exploit alternative splicing in diagnosis, prognosis
and treatment of cancer (Yamaguchi et al., 1998, Venables, 2004). The large number of
genes encoded in the human genome, along with the many subtypes of cancer in which
alternative splicing changes have been documented suggests that the current knowledge is
only the beginning in our understanding of the cause and effect of alternative splicing events
in cancer, as well as how this knowledge may be used clinically.
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Alternative Splicing of T-box genes
Most of the T-box family members encode a single transcript and few examples of
alternative splicing have been documented (Wilson and Conlon, 2002, DeBenedittis and
Jiao, 2011). While TBX3, TBX5 and TBX21 undergo alternative splicing, only TBX3 and
TBX21 contain an insertion in their T-box domain (DeBenedittis and Jiao, 2011). Alternative
splicing of TBX3 leads to two distinct transcripts; TBX3iso2 contains an additional 20 amino
acid sequence in the DNA binding region attributed to the 2a exon, while TBX3iso1 does not
(Bamshad et al., 1999). Alternative splicing of TBX21 leads to a three amino acid insertion in
the DNA binding domain corresponding to the exon 2a insertion site in TBX3 (DeBenedittis
and Jiao, 2011). While alternative splicing of TBX3 in particular is highly conserved within
mammals (Hoogaars et al., 2008), the functional significance of the 2a exon remains unclear.
These alternative splicing events may therefore provide a potentially critical differential role
for TBX3 isoforms in development and tumorigenesis (DeBenedittis and Jiao, 2011).
Previous studies have reported that isoforms of T-box proteins can differ in subcellular
localization, expression, protein-protein interaction, and functionality (Wilson and Conlon,
2002, DeBenedittis and Jiao, 2011). For example, alternative splicing of TBX5 leads to two
protein products, TBX5a and TBX5b (DeBenedittis and Jiao, 2011). While only TBX5a can
bind to the natriuretic peptide A (Nppa) promoter, both TBX5a and TBX5b can interact with
GATA4 (Georges et al., 2008, DeBenedittis and Jiao, 2011). Additionally, TBX5a and TBX5b
have differential cellular localization, with TBX5a being strictly nuclear localized while TBX5b
is localized within the cytoplasm and nucleus (Georges et al., 2008). These studies indicate
that relative levels, along with transcriptional targets and protein-protein interactions of each
isoform must be examined in order to understand the resultant functions of alternatively
spliced transcripts.
The TBX3 isoform ratios were found to be tissue and species specific (Stennard et al.,
1999, Fan et al., 2004). Differing levels of TBX3 isoforms have also been reported in several
breast cancer cell lines (Bamshad et al., 1999, Fan et al., 2004). Additionally, the ratio of
TBX3iso2 to TBX3iso1 increased during osteogenic differentiation in human adipose stromal
cells (Lee et al., 2007), thereby suggesting that isoform ratios are important in differentiation.
Based on preliminary studies assessing functional differences between TBX3 isoforms, along
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with details regarding differential properties of alternatively spliced T-box transcription
factors, DeBenedittis et al. proposed that assessment of TBX3 isoform expression levels is
of importance for future studies (DeBenedittis and Jiao, 2011).
Residues Ser224 and Met225 within the DNA binding domain of human TBX3iso1
have been shown to interact with target DNA sequences with the TBE through polar and
hydrophobic interactions, respectively (see Figure 1.3.1) (Coll et al., 2002). The transcribed
2a exon within TBX3iso2 is located at residues 220-240; this alternative splicing event shifts
the residues that interact with target DNA, while the effect on transcriptional regulation
remains unclear.
Conflicting results have been published regarding functionality of the TBX3 isoforms.
Fan et al. reported that TBX3iso2 did not bind to a sequence containing a previouslyidentified TBE in their in vitro oligonucleotide binding assays (Fan et al., 2004), proposing
that the 20-amino acid addition in the DNA binding domain of TBX3iso2 alters the protein’s
binding to target sequences (Fan et al., 2004). Other studies have assessed TBX3iso1 and
TBX3iso2 in various assays and found both isoforms to have similar functions in vitro,
reporting that both TBX3 isoforms were able to bind to the TBE in the Nppa and p21 CIP1
promoters (Hoogaars et al., 2008). Hoogaars et al. proposed that since the 20-amino acid
insertion does not make contact with DNA, it may not alter binding (Hoogaars et al., 2008).
The function of T-box proteins is regulated by protein-protein interactions with other
transcription factors (Lu et al., 2010), several of which are mediated through the T-box
domain. Some groups have therefore speculated that there may be differential proteinprotein interactions between TBX3 isoforms. Through glutathione S-transferase (GST) pull
down assays to examine TBX3iso1 and TBX3iso2 interacting proteins, it was revealed that
both TBX3 isoforms physically interact with a known T-box interacting protein, NK2
homeobox 5 (Nkx2-5), via the T-box binding domain (Hoogaars et al., 2008). Additionally,
while both TBX3 isoforms were able to inhibit transcription of Nanog in luciferase assays,
only TBX3iso2 was able to directly bind to Nanog in co-immunoprecipitation experiments
(Zhao et al., 2014). More work is therefore needed in order to evaluate which proteins TBX3
physically interacts with, and whether differences exist between isoforms.
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Figure 1.3.1 – TBX3 Protein Sequence Secondary Structure.
Protein structure of TBX3iso1 (with absence of 2a exon at residue 220-240) is shown above.
Image was obtained from Protein Data Bank (PDB), available at https://www.rcsb.org.
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1.4 Epithelial-Mesenchymal Transition (EMT)
Over 90% of cancer-related deaths are due to the process of metastasis (Luzzi et al.,
1998, Kumar et al., 2013). Incredible phenotypic plasticity is required for malignant cells of
epithelial origin to leave the primary tumor, intravasate into the blood or lymphatic vessels,
and then extravasate at a distant secondary site and establish growth (Oltean and Bates,
2014). The acquisition of an epithelial-mesenchymal transition (EMT) phenotype plays an
important role in systemic dissemination of cancer cells through the process of metastasis
(Chaffer and Weinberg, 2011). In breast cancer specifically, the phenomenon of EMT has
been associated with highly aggressive tumors and therapeutic resistance (Blick et al., 2008,
Sarrió et al., 2008, Creighton et al., 2009, Polyak and Weinberg, 2009).
EMT is the process whereby epithelial cells lose apical-basal polarity, tight cell-to-cell
contacts, and undergo remodelling of the actin cytoskeleton, with the acquisition of a more
migratory mesenchymal phenotype. The process of EMT is critical in normal processes such
as embryogenesis and wound healing, and is reactivated in invasive and metastatic tumors
(Polyak and Weinberg, 2009, Thiery et al., 2009). The most studied transcription factors in
the promotion of EMT include TWIST1, SNAIL (SNAI1), and SLUG (SNAI2) (Shapiro et al.,
2011). SNAIL, SLUG and TWIST1 are frequently overexpressed in IDC and have been
associated with histological grade, lymph node metastasis, and reduced survival (Blanco et
al., 2002, Elloul et al., 2005, Martin et al., 2005, Mironchik et al., 2005, Côme et al., 2006,
Palena et al., 2014, Alix-Panabières et al., 2017).
Several studies have shown that expression of EMT markers is associated with poor
clinical outcome in several epithelial cancers, including breast cancer (Abba et al., 2004,
Thompson et al., 2005, Sabbah et al., 2008, Shapiro et al., 2011, Sørlie et al., 2001). The
induction of EMT is associated with alterations in canonical EMT markers, including upregulation of the mesenchymal proteins vimentin (VIM) and N-cadherin (CDH2), as well as
down-regulation of the epithelial protein E-cadherin (CDH1). Both E-cadherin and N-cadherin
are members of the cadherin superfamily of cell adhesion molecules involved in homophilic
cell-to-cell interactions. E-cadherin is an integral epithelial membrane protein that mediates
cell-to-cell adhesion and is widely regarded as a major suppressor of motility and
invasiveness of cancer cells (Le Bras et al., 2012). Several EMT transcription factors (SNAIL,
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SLUG, ZEB1, ZEB2, Brachyury) are able to directly down-regulate E-cadherin expression
(De Craene and Berx, 2013). Combined repression of other junctional proteins, along with
E-cadherin, facilitates the de-differentiation program and induction of EMT (De Craene et al.,
2005, Vandewalle et al., 2005, Moreno-Bueno et al., 2006, De Craene and Berx, 2013). The
switch from E-cadherin to N-cadherin expression is associated with malignant progression
and poor clinical outcome in several cancer types (Gravdal et al., 2007, Polyak and
Weinberg, 2009). Up-regulation of N-cadherin enhances interaction between cancer cells
and endothelial/stromal cells, thereby providing a mechanism for endothelial transmigration
(Tran et al., 1999, Hazan et al., 2000).
EMT is also associated with suppression of apoptosis, cellular senescence, and
chemo-resistance (Polyak and Weinberg, 2009, De Craene and Berx, 2013, Nieto et al.,
2016). Additionally, several correlations have been documented relating expression of EMT
markers and a stem-like phenotype, and response to breast cancer therapy (Mani et al.,
2008, Morel et al., 2008, Aktas et al., 2009, Creighton et al., 2009). This is likely due to an
enrichment of CSCs after standard breast cancer treatments including letrozole or docetaxel
(Mani et al., 2008, Creighton et al., 2009).
Direct in vivo evidence for EMT has been challenging due to its dynamic and transient
nature, as well as the reverse process, mesenchymal-epithelial transition (MET). The
process of MET is believed to play a fundamental role once cells have extravasated from the
vasculature into distant organs, allowing for clonal outgrowth (Alix-Panabières et al., 2017).
While the process of EMT has been documented in mouse models (Oltean et al., 2008),
many invasive tumors and metastatic lesions exhibit epithelial morphology and are positive
for epithelial markers (Christiansen and Rajasekaran, 2006). This is likely attributed to partial
induction of EMT, a restriction of the occurrence of this process to a small number of cells,
and the reverse process of MET (Shapiro et al., 2011). The assessment of EMT markers
would therefore only measure levels at one point in time, and has mostly been reported at
the invasive front of primary tumors of epithelial origin (Scheel et al., 2007, Brabletz, 2012,
Puisieux et al., 2014). Interestingly, studies assessing the importance of MET in metastatic
colonization have reported that tumor cells that have undergone partial EMT possess the
most malignant features (Nieto et al., 2016, Alix-Panabières et al., 2017).
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TBX3 and EMT
An EMT phenotype is characterized by a cadherin switch, with reduced expression of
the epithelial marker E-cadherin, and increased expression of the mesenchymal marker
N-cadherin (Polyak and Weinberg, 2009). Importantly, TBX3 is able to directly repress
E-cadherin expression levels, which has been documented in HCC and melanoma cell lines
(Rodriguez et al., 2008, Dong et al., 2018).
High throughput analyses have linked elevated TBX3 expression with an EMT
phenotype (Humtsoe et al., 2012). In this study, Humtsoe et al. conducted microarray
analysis to examine gene expression differences between a panel of squamous cell
carcinoma (SCC) cell lines displaying either a non-EMT or an EMT-like phenotype (Humtsoe
et al., 2012). They revealed strong up-regulation of TBX3 in EMT-like SCC cells, as well as
in a model of Snail-induced EMT (Humtsoe et al., 2012). Additionally, they reported a close
association between high TBX3 and N-cadherin expression, and low E-cadherin expression
across twelve SCC cell lines (Humtsoe et al., 2012), which has been recapitulated in
colorectal cancer samples (Shan et al., 2015), and gastric cancer cell lines (Miao et al., 2016).
Elevated TBX3 expression is also associated with increased vimentin expression (Krstic et
al., 2016, Miao et al., 2016). Lastly, TBX3 was shown to drive a pro-EMT phenotype in BRAF mutant melanomas (Boyd et al., 2013). These examples show that there is an
abundance of preliminary studies showing a link between TBX3 and an EMT profile, although
the molecular mechanisms remain elusive.
Other T-box transcription factors, including Brachyury and TBX2, are also able to
induce EMT (Fernando et al., 2010, Wang et al., 2012). Brachyury directly represses
E-cadherin by binding to a TBE in the transcription start site (De Craene and Berx, 2013,
Fernando et al., 2010). This binding site in the E-cadherin transcription start site reported for
Brachyury (Fernando et al., 2010) overlaps with the identified binding site for TBX3
(Rodriguez et al., 2008).
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SLUG
SLUG (encoded by the SNAI2 gene) is a member of the SNAIL family of zinc-finger
transcriptional repressors which mediate sequence-specific interactions with DNA (Phillips
and Kuperwasser, 2014). SLUG contains a conserved SNAG domain in the N-terminus
region, which is required for protein-protein interactions, transcriptional repression, and
nuclear localization (Shirley et al., 2010, Chiang and Ayyanathan, 2013, Phillips and
Kuperwasser, 2014). The zinc finger domain is located in the C-terminus of the protein, which
facilitates binding to E-box motifs (Nieto, 2002, Phillips and Kuperwasser, 2014).
The role of SLUG is well characterized in both embryonic development and
tumorigenesis, with most of the literature focusing on its promotion of EMT (Barrallo-Gimeno
and Nieto, 2005, Phillips and Kuperwasser, 2014). Physiologically, SLUG has been
described as an important regulator of mammary epithelial cell differentiation, where it
maintains cells in a basal-like state and repress luminal lineage differentiation (Proia et al.,
2011, Phillips et al., 2014, Phillips and Kuperwasser, 2014). Additionally, SLUG plays a
critical role in multiple stages of cancer development (Phillips and Kuperwasser, 2014), and
has been described as an important early initiator of EMT (Slabáková et al., 2011).
Within breast cancers, elevated SLUG expression is often associated with basal-like
tumors and mutations in the breast cancer associated 1 (BRCA1) gene (Foulkes et al., 2004,
Arnes et al., 2005, Proia et al., 2011). While ER is able to directly repress transcription of
SLUG (Ye et al., 2008, Ye et al., 2010), elevated estrogen levels are also able to induce
SLUG expression through ERα; the effects mediated by ER on SLUG expression are
therefore context-dependent. Elevated expression of SLUG, however, is associated with
poor prognosis in both ER positive (Chimge et al., 2011), and ER negative breast cancers
(Storci et al., 2008, Liu et al., 2013), as well as lymph node metastasis and therapy resistance
(Côme et al., 2006, Alves et al., 2018). Interestingly, elevated SLUG expression in IDC has
been associated with the presence of tubule structures, which is one of three criteria for the
Scarff-Bloom-Richardson (SBR) grading system (Côme et al., 2006). This study by Côme et
al., along with other experimental studies of partial induction of EMT (Dang et al., 2015),
suggest the involvement of SLUG in collective cell migration.
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1.5 Angiogenesis
Solid cancers must form a blood supply through the process of angiogenesis if they
are to grow beyond 1-2 mm in size (Knowles and Selby, 2005). This value represents the
distance that oxygen, nutrients, and wastes can diffuse freely between a tumor and adjacent
blood vessels (Kumar et al., 2013). Angiogenesis is a hallmark of cancer, and the newlyformed blood vessels allow increased delivery of oxygen and nutrients, further providing a
growth advantage for the tumor (Hanahan and Weinberg, 2000). Angiogenesis occurs
through the formation of new micro-vessels from pre-existing vessels. This process also
allows for systemic spread of cancer cells in the process of metastasis. Early studies
assessing tumor angiogenesis in breast cancers showed that higher micro-vessel density
corresponded to increased rates of distant metastasis (Weidner et al., 1991).
The process of angiogenesis is triggered by tissue hypoxia and/or injury. Angiogenic
factors are then released in the microenvironment, which diffuse in the extracellular millieu
and are then able to activate endothelial cells (Nishida et al., 2006). Endothelial cells then
migrate to the hypoxic area, proliferate, and form vessel structures (Nishida et al., 2006). The
process may continue to be influenced through the balance of pro- and anti-angiogenic
signaling molecules present within the microenvironment, which dictate the degree of
angiogenesis (Knowles and Selby, 2005).
The use of anti-angiogenic therapies for cancer treatment was first proposed by
Folkman in 1971 (Folkman, 1971), and this initial proposal has paved the way to a large body
of work investigating the role of angiogenesis in tumor growth, along with the effect of its
inhibition (Knowles and Selby, 2005). The emerging conclusion from several studies was that
anti-angiogenics would be given as an adjuvant therapy in combination with cytotoxic drugs
(Knowles and Selby, 2005). To date, the best characterized pro-angiogenic factor has been
VEGF. Other notable pro-angiogenic regulators include FGF, the transforming growth factor
(TGF) superfamily, hypoxia inducible factor alpha (HIF1α) and osteopontin (OPN; described
in Section 1.5.1).
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Osteopontin and Angiogenesis
OPN is a secreted phosphoprotein that is involved in both cell attachment to the
extracellular matrix (ECM) through interaction with integrins and CD44, and induction of cell
signaling pathways (Rittling and Chambers, 2004). Following binding and receptor activation,
a series of signaling pathways are initiated, ultimately resulting in gene expression changes
which modulate tumor cell behaviour. Elevated OPN expression has been associated with
all six initially-described hallmarks of cancer in several different cancer subtypes (Cook et al.,
2005). For breast cancer specifically, elevated OPN expression is associated with early
metastasis and poor outcome (Bellahcène and Castronovo, 1995, Rudland et al., 2002,
Bramwell et al., 2006, El-Tanani et al., 2006, Tuck et al., 1998, Singhal et al., 1997).
OPN modulates cell migration, invasion, and survival; this is mainly accomplished
through interaction with integrins through its arginine-glycine-aspartate (RGD) integrin
binding domain (Denhardt and Chambers, 1994, Tuck et al., 1999, Sodek et al., 2000, Lin
and Yang-Yen, 2001, Geissinger et al., 2002). Integrins are transmembrane molecules
comprised of a heterodimeric α and ß subunits that function by mediating adhesion between
cells and interactions with the ECM (Knowles and Selby, 2005). OPN binds to the integrin
heterodimers αvß1, αvß3, αvß5, α4ß1, α5ß1, α8ß1, and α9ß1 (Wai and Kuo, 2004, El-Tanani et
al., 2006). Several of the aforementioned integrins are associated with metastasis and poor
outcome, with much of the literature focusing on αvß3 (El-Tanani et al., 2006). In breast
cancers, up-regulation of αvß3 is correlated with extent of disease and presence of bone
metastasis (Liapis et al., 1996, Gasparini et al., 1998). OPN binds to the transmembrane
protein CD44 in an RGD-independent manner (Sodek et al., 2000), resulting in up-regulation
of CD44 and increased migration of breast cancer cell lines (Khan et al., 2005). A schematic
of OPN protein structure and interactions is shown in Figure 1.5.1.
Several studies have also reported crucial roles for tumor-derived OPN on
angiogenesis (Pröls et al., 1998, Shijubo et al., 1999, Takano et al., 2000, Asou et al., 2001,
Takahashi et al., 2002, Hirama et al., 2003, Leali et al., 2003, Cook et al., 2005, Chakraborty
et al., 2006, Chakraborty et al., 2008). While integrins are minimally expressed on the surface
of endothelial cells, their expression is significantly up-regulated during angiogenesis
(Knowles and Selby, 2005). Binding of OPN within the tumor microenvironment to integrin
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receptors (and/or CD44) on endothelial cells promotes angiogenesis through stimulation of
endothelial cell migration, survival and lumen formation (Brooks et al., 1994, Senger et al.,
1996, Arap et al., 1998, Scatena et al., 1998, Bayless et al., 2000). OPN-induction of VEGF
has also been reported (Chakraborty et al., 2008), as well as the reciprocal instance of VEGFinduced OPN expression (Senger et al., 1996). Moreover, OPN, in cooperation with VEGF,
has been shown to mediate αv integrin endothelial cell migration (Senger et al., 1996).
Microarray analysis of transcripts altered upon constitutive OPN overexpression in
breast cancer cells detected up-regulation of several genes, including hyaluronan synthase
2 (HAS2) and increased production of hyaluronan (HA), which also mediates the process of
angiogenesis (discussed in the Section 1.5.2) (Cook et al., 2005).

Figure 1.5.1 – OPN protein structure and interactions.
OPN contains many protein domains which facilitate interactions with receptor proteins,
including the integrin binding domains (amino acid sequence for the domains is shown),
along with the heparin binding domains which facilitates binding to CD44. OPN can be
cleaved by two classes of proteases, including thrombin and MMPs, with the cleavage
exposing new active domains. Adapted from (Musso et al., 2013).
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Hyaluronan and Angiogenesis
The ECM plays a critical role in tumor development, providing cells with a scaffold
which can be used for attachment, migration, and growth. An important ECM component that
is up-regulated by OPN is HA, via up-regulation of HAS2 (Cook et al., 2006). HA is an
unbranched polysaccharide consisting of repeating disaccharide subunits and constitutes a
major portion of the ECM, particularly in tissues undergoing high rates of proliferation (West
and Kumar, 1989). HA regulates the processes of adhesion, migration, proliferation, and
differentiation (Itano et al., 1999, Tammi et al., 2002, Toole, 2004, Cook et al., 2006). HA is
also able to up-regulate expression of OPN (Kim et al., 2005). Interestingly, both HA and
OPN mediate several overlapping functions, and are frequently co-expressed across cancer
subtypes (Kim et al., 2005, Lee et al., 2007).
HA is produced at the intracellular face of the plasma membrane by hyaluronan
synthase enzymes (HAS1-3) (Weigel and DeAngelis, 2007). The HAS enzymes are distinct
in their stability, elongation rate, and size of HA synthesized, along with distinct expression
patterns (Itano et al., 1999). Once synthesized by HAS enzymes, HA is then extruded from
the cell and either released into the microenvironment, or retained in pericellular coats
through interaction with cell surface receptors (Tammi et al., 1998, Evanko et al., 2007,
Weigel and DeAngelis, 2007). High levels of synthesis and retention of HA in pericellular
coats has an important role in malignant progression (Cook et al., 2006) and is an indicator
of poor prognosis in epithelial cancers (Auvinen et al., 2000, Misra et al., 2006, Tammi et al.,
2008, Auvinen et al., 2014). HAS2 is the highest expressed among the HAS enzymes in
breast cancer tissues and cell lines (Udabage et al., 2005b, Auvinen et al., 2014). Elevated
HAS2 expression in breast cancer is associated with invasiveness (Udabage et al., 2005b,
Udabage et al., 2005a), induction of EMT (Zoltan-Jones et al., 2003, Porsch et al., 2013),
induction of angiogenesis (Koyama et al., 2007), and promotion of metastasis through
increased interaction with stromal cells (Cook et al., 2006, Okuda et al., 2012).
The effect of HA on angiogenesis is dependent on its molecular weight, which imparts
unique biochemical properties; high molecular weight HA suppresses angiogenesis, while
low molecular weight HA (4-20 disaccharides) stimulates endothelial cell migration,
proliferation and angiogenesis (West et al., 1985, West and Kumar, 1989). The effect of HA
within a tumor is thought to be dynamic; the leading edge of a tumor possesses large
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amounts of high molecular weight HA, which aids in invasion via hydration of tissues and
expansion of areas through which cancer cells can migrate (Iozzo and Müller-Glauser, 1985,
Knudson et al., 1989, Rooney et al., 1995). As the tumor cells invade adjacent tissues, new
HA is synthesized, while the remaining HA is degraded by hyaluronidase (HAse) enzymes,
creating pro-angiogenic low molecular weight fragments (Rooney et al., 1995).
CD44 is a transmembrane glycoprotein and the principal receptor for HA (Toole, 2009,
Auvinen et al., 2013). CD44 is also able to bind several other ligands including OPN,
collagens, and MMPs (Goodison et al., 1999, Senbanjo and Chellaiah, 2017). CD44 is
ubiquitously expressed in adult and fetal tissues, with elevated expression levels in several
cancers (Basakran, 2015). In breast cancer, elevated expression of standard CD44 as well
as its splice variants is associated with disease progression and metastasis (McFarlane et
al., 2015). Interaction between HA and CD44 results in activation of several signaling
pathways (Misra et al., 2006, Toole, 2009). Additionally, HA is able to regulate the activity of
several RTKs (most notably HER2) through stabilization of oncogenic CD44/RTK cell surface
complexes (Bourguignon et al., 2001, Turley et al., 2002, Ghatak et al., 2005, Misra et al.,
2005, Bourguignon et al., 2006, Misra et al., 2006, Slomiany et al., 2009).
The tumor stroma of breast cancer patients is associated with high HA expression
near carcinoma cells, which is associated with several clinicopathological features including
tumor size, lymph node positivity, and poor differentiation (Auvinen et al., 2013). CD44 is
expressed on endothelial cells (Liesveld et al., 1994, Xu et al., 1994), and binding of HA to
CD44 on endothelial cells promotes their migration (Trochon et al., 1996, Griffioen et al.,
1997, Savani et al., 2001). This provides a mechanism for HA- as well as OPN-induced
angiogenesis, as OPN is able to promote elevated HA levels and itself bind CD44 on
endothelial cells (Trochon et al., 1996, Griffioen et al., 1997, Savani et al., 2001, Kim et al.,
2005, Cook et al., 2006, Lee et al., 2007).
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1.6 Summary of Objectives
I hypothesized that the transcriptional regulatory proteins TBX3iso1 and TBX3iso2
have distinct roles in breast cancer progression. This activity is mediated by their
downstream transcriptional targets.
To address my hypothesis, I had four main aims which are described over three chapters of
my thesis:

Aim 1: Examination of functional and phenotypic changes associated with modulation
of TBX3 levels at various stages of breast cancer progression (Chapter 2).
While TBX3 is overexpressed in several cancer types, the full scope of TBX3-associated
functional changes in breast cancer was unclear due to the focus on melanoma cell lines
within several prominent studies. Initial studies were therefore important in order to
characterize the functional and phenotypic changes associated with modulation of TBX3
levels at various stages of breast cancer progression, in an isoform-specific context. The
majority of my work has focused on non-invasive DCIS-like 21NT cells and invasive IDClike 21MT-1 cells, in which increased TBX3 expression was identified in the DCIS to IDC
transition (Souter et al., 2010). These findings have been corroborated through functional
overexpression studies in 21PT, MCF7, T-47D, SKBR3, and MDA-MB-468 cells. Several
prominent TBX3iso1 and TBX3iso2-dependent changes were observed, including
alterations in growth, survival, invasiveness, and prominently, the acquisition of an EMT
phenotype.

Aims 2 & 3: Elucidation of the molecular mechanism of TBX3-induced EMT, and
assessment of identified downstream targets (SLUG, TWIST1) in clinical samples of
DCIS and early invasive breast cancer (Chapter 3).
As a follow-up to Aim 1, the molecular mechanism of TBX3-induced EMT was investigated
in Aim 2. High throughput studies, including ChIP-array and RNA-Seq, were conducted in
order to gain a thorough understanding of both direct and indirect transcriptional changes
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mediated by TBX3 isoform overexpression, with a focus on genes similarly altered with
both TBX3 isoforms. SLUG was identified as a direct target up-regulated by both TBX3iso1
and TBX3iso2, and an important downstream mediator of TBX3-induced migration and
invasion. Another important regulator of EMT indirectly up-regulated by both TBX3
isoforms was TWIST1. For Aim 3, the expression of TBX3 by IHC was assessed in two
independent cohorts consisting of early stage breast cancers. Within the second cohort,
expression of downstream targets identified in the high-throughput screens (SLUG and
TWIST1) was also assessed by IHC. My findings from Aims 2 and 3 are reported together
in Chapter 3, with a working schematic on the mechanism whereby TBX3 promotes
progression by inducing EMT in low-grade, pre-invasive lesions, which is representative
of luminal A breast cancers.

Aim 4: Examination of the effects of TBX3 isoforms in vivo in nude mice (Chapter 4).
As overexpression of TBX3 was previously identified in the DCIS to IDC transition, the
effect of altered TBX3 expression on in vivo tumorigenesis was assessed in nude mice via
mammary fat pad xenograft assays. Surprisingly, TBX3iso1 and TBX3iso2 differentially
altered tumorigenicity, with overexpression of TBX3iso1 (but not TBX3iso2) in 21NT cells
associated with high rates of invasive carcinoma. The mechanism of TBX3iso1-induced
tumorigenicity was assessed through further mining and enrichment analysis of RNA-Seq
data obtained in Aim 2. Interestingly, TBX3iso1 overexpression was associated with a proangiogenic gene signature, with elevated expression of OPN and HAS2, increased
hyaluronan retention, and thus increased rates of angiogenesis through in vitro assays.
These changes likely explain the differential tumorigenicity between TBX3 isoforms in vivo.
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Examination of functional and phenotypic changes associated
with modulation of TBX3 levels at various stages of breast
cancer progression

SUMMARY OF FINDINGS
TBX3 is abundant in the invasive 21MT-1 cell line, while being minimally expressed in the
non-invasive 21NT and 21PT cell lines. Overexpression of either TBX3iso1 or TBX3iso2 in
21NT cells resulted in increased cell survival/colony forming ability, growth vs. apoptosis and
invasion in Matrigel. In contrast, short hairpin RNA-mediated knockdown of TBX3 in the
21MT-1 cells resulted in smaller colonies, with a more regular, less dispersed (less infiltrative)
morphology. Array profiling of the 21NT TBX3iso1 and TBX3iso2 transfectants showed that
there are common alterations in expression of several genes involved in signal transduction,
cell cycle control/cell survival, epithelial-mesenchymal transition (EMT) and invasiveness.
Overall, these results indicate that TBX3 expression can promote progression in a model of
early breast cancer by altering cell properties involved in cell survival/colony formation and
invasiveness, as well as key regulatory and EMT/invasiveness-related gene expressions.

Chapter 2 in this dissertation has been published (Krstic et al. 2016, BMC Cancer).
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2.1 Introduction
Arguably the most critical stage of early breast cancer progression is the transition
from DCIS to invasive mammary carcinoma (IMC). Although a number of molecular changes
have been identified that accompany invasive breast cancer (Page et al., 1985, Page and
Dupont, 1993, Lakhani et al., 1995, Allred et al., 2001, Arpino et al., 2005, Allred et al., 2008),
those which may directly control the transition from DCIS to IMC remain elusive.
Using microarray analysis, we previously identified TBX3 as a potential regulator of
progression from DCIS to IMC, using the 21T cell lines which represent distinct stages of
breast cancer progression (Souter et al., 2010). Specifically, we found that invasive and
metastatic 21MT-1 cells expressed higher levels of TBX3 than non-invasive DCIS-like 21NT
cells and non-invasive ADH-like 21PT cells (Souter et al., 2010). TBX3 is a member of the
T-box family of transcription factors that play an important role in development of many
animal species. In mouse embryo development, a model has emerged in which TBX3
expression is both induced and maintained in early mammary gland initiation by Wnt and
fibroblast growth factor (FGF) (Eblaghie et al., 2004). In humans, Ulnar-mammary syndrome,
a congenital autosomal dominant disorder, is caused by mutations that result in
haploinsufficiency of TBX3 and is characterized by upper-limb anomalies and mammary
gland hypoplasia (Bamshad et al., 1999).
TBX3 has been linked to tumorigenesis and is involved in cell cycle control and
inhibition of cell senescence, through both p53-dependent and independent pathways
(Brummelkamp et al., 2002, Carlson et al., 2002). The p53-dependent pathway signals
through p14ARF, a tumor suppressor and cell cycle control protein that is a product of the
cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, along with p16INK4A. TBX3 directly
represses transcription of p14ARF (Brummelkamp et al., 2002, Rowley et al., 2004). Downregulation or inhibition of p14ARF leads to increased proliferation and immortalization, as well
as failure of apoptosis (Rowley et al., 2004). Aside from its role in the cell cycle, TBX3 is a
known repressor of E-cadherin expression in melanoma, leading to enhanced invasiveness
(Rodriguez et al., 2008, Boyd et al., 2013). TBX3 expression has also been found to be
associated with cell survival in hepatocellular carcinoma, where it is induced by Wnt/βcatenin signalling (Renard et al., 2007).
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Two different isoforms of TBX3 have been identified, TBX3iso1 and TBX3iso2. The
TBX3iso2 variant has an extra 20 amino acids, encoded by exon 2a, inserted into the T-box
domain (Bamshad et al., 1999). As the 2a insertion is within the T-box domain, which is
required for DNA-binding and protein-protein interactions, it was initially proposed that this
variant may have altered DNA-binding properties, and that it may in fact interfere with the
senescence-inhibiting properties (Fan et al., 2004). However, it has been found that
TBX3iso2 can indeed bind to TBEs and act as an anti-senescence factor (Hoogaars et al.,
2008).
Here we examined whether either or both isoforms of TBX3 can influence breast
cancer progression, in particular the transition from non-invasive to invasive disease. We
show that both isoforms of TBX3 have a similar functional effect in promoting breast cancer
progression to a more malignant phenotype, and identify TBX3-induced changes in
expression of genes involved in signal transduction, cell cycle control, cell survival and
epithelial-mesenchymal transition (EMT)/invasiveness that may play a role in this
progression.
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2.2 Methods
Cell lines and culture conditions
The 21T parental cell lines (21PT, 21NT, and 21MT-1) were a kind gift from Dr. Vimla Band
(Dana Farber Cancer Institute, Boston, MA) (Band et al., 1990) and were cultured in alpha
modification of Eagle’s medium supplemented with 2.8μM hydrocortisone, 12.5ng/ml
epidermal growth factor, 2mM L-glutamine, 1μg/ml insulin, 10mM HEPES, 1mM sodium
pyruvate, 0.1mM non-essential amino acids and 50μg/ml gentamycin reagent (called αHE –
all supplements from Wisent Bioproducts). For regular culture conditions, the αHE media was
further supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich) and named
αHE10F. Stably transfected cells were cultured in αHE10F containing either 500μg/ml G418
(Wisent Bioproducts) or 0.8μg/ml puromycin (Sigma-Aldrich).

Generation of TBX3 expression vectors
Expression vectors were constructed for each TBX3 isoform (TBX3iso1and TBX3iso2). To
obtain TBX3iso2, PCR amplification of the whole transcript was performed from a pOTB7
expression vector containing TBX3iso2 [Genbank:BC025258] (Open Biosystems Thermo
Scientific) as the cDNA template using Phusion High-Fidelity DNA Taq polymerase (New
England BioLabs). Primers used to amplify TBX3iso2 were: forward: 5’-GCC ACC ATG AGC
CTC TCC ATG AGA-3’ and reverse: 5’-TTC GGG ACC GCC TGC GGG ACC TGT CCG GC3’. To produce TBX3iso1, two PCR product fragments, representing the transcript before
(fragment 1) and after (fragment 2) the 60bp TBX3iso2 addition, were PCR amplified. Primers
used for fragment 1 of TBX3iso1 were: forward: 5’-GCC ACC ATG AGC CTC TCC ATG
AGA-3’ and reverse: 5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GAC-3’. Primers
used for fragment 2 of TBX3iso1 were: forward: 5’-TGG ATT TAC TAT ATT GAA CTC CAT
GCA CAA AT-3’ and reverse: 5’-TTC GGG ACC GCC TGC GGG ACC TGT CCG GC-3’. All
primers used for generation of the TBX3 expression vectors were purchased from SigmaAldrich. Products were separated on 1% agarose gel and bands representing TBX3iso2 at
~2000kb were extracted and pooled. For TBX3iso1, a band at ~660kb for fragment 1 and a
band at ~1380kb for fragment 2 were gel extracted and pooled. When designing the PCR
primers for the two fragments of TBX3iso1, the reverse primer of the upstream amplicon
(fragment 1) and the forward primer for the downstream amplicon (fragment 2) had a 20bp
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overlap to ensure that the ends of these amplicons would anneal in a subsequent PCR
reaction to melt the fragments together. This annealed TBX3iso1 PCR product was purified
and amplified again. After running this PCR product on a 1% agarose gel and extracting at
~2000bp, both TBX3iso1 and TBX3iso2 PCR products were incubated with T4
polynucleotide kinase (New England BioLabs), and purified. Both products were inserted
separately into pZsGreen1-N1 plasmids (Clonetech Laboratories), such that the ZsGreen
was fused to the C-terminus of TBX3. To prepare the pZsGreen1-N1 plasmid, it was digested
with Afe1 (New England BioLabs) and incubated with calf intestinal alkaline phosphatase
(New England BioLabs) to dephosphorylate the cut ends. The digested plasmid was
electrophoresed and gel extracted. The plasmid and TBX3 PCR products were incubated
overnight with ATP and T4 DNA Ligase (New England BioLabs) at 16°C to complete ligation.
Competent bacteria (DH5α) were transformed with the ligated plasmid and kanamycin
resistant clones were expanded to isolate DNA. Clones were digested with the following
enzyme pairs to check for proper size and orientation: AgeI/KpnI, MfeI/XhoI, and NheI/HndIII.
Suitable clones were sequenced (DNA Sequencing Facility at Robarts Research Institute,
London, ON).
The use of untagged TBX3 was required so the TBX3 expression vectors underwent
site directed mutagenesis in order to introduce a stop codon at the end of full length TBX3iso1
and TBX3iso2 using QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies)
according to the manufacturer’s protocol. Clones were sent to the DNA Sequencing Facility
at Robarts Research Institute for sequencing. Clones with the proper sequence were used
for stable transfections.

Transfections
Purified TBX3iso1 and TBX3iso2 plasmid DNA was transfected using PolyJet DNA In Vitro
Transfection Reagent (SignaGen Laboratories) following the manufacturer’s protocol. Empty
vector (EV) plasmids were transfected as a control. Stable transfectants were selected in
αHE10F containing 500μg/ml G418 (Wisent Bioproducts). Approximately two weeks posttransfection, resistant clones were pooled, expanded, and frozen for later use.
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Generation of lentiviral particles and transduction
Generation of short hairpin (sh) RNA containing lentivirus particles and knockdown of target
genes were described previously (Moffat et al., 2006, MacMillan et al., 2014). The shRNA
target sequence for TBX3 was GCA TAC CAG AAT GAT AAG ATA which targeted the coding
sequence of both TBX3iso1 and TBX3iso2. The shRNA target sequence for Luciferase (offtarget knockdown control) was ACG CTG AGT ACT TCG AAA TGT. The TBX3 shRNA
lentivirus particles generated were used to knockdown TBX3 in the 21MT-1 cell line and
Luciferase shRNA was used a negative control. One week post-transduction, stable clones
were selected in αHE10F containing 0.8μg/ml puromycin (Sigma-Aldrich) and resistant
clones were pooled, expanded, and frozen for later use.

Isolation of RNA and quantitative real-time polymerase chain reaction (qRT-PCR)
Cells were harvested with trypsin and RNA was isolated using the RNeasy Mini Kit (Qiagen).
Samples were treated with 30U DNase I (Qiagen), and 500ng of RNA was converted into
cDNA with the Superscript III First-Strand Synthesis System (Invitrogen) using Oligo(dT) 1218 primers (Invitrogen). qRT-PCR was performed using RT2 SYBR Green ROX qPCR
Mastermix (Qiagen) on an Mx3000P QPCR system. Primers used for total TBX3 were:
forward: 5’-CGC TGT GAC TGC ATA CCA GA-3’ and reverse: 5’-GTG TCC CGG AAA CCT
TTT GC-3’. Primers used for TBX3iso1 were: forward: 5’-AGT GGA TGT CCA AAG TCG
TCA C-3’ and reverse: 5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GTC TG-3’.
Primers used for TBX3iso2 were: forward: 5’-AGT GGA TGT CCA AAG TCG TCA C-3’ and
reverse: 5’-CAC TTG GGA AGG CCA AAG TAA ATC CAT G-3’. Primers used for GAPDH
were: forward: 5’-AGG CTG GGG CTC ATT TGC AG-3’ and reverse: 5-‘CCA TCC ACA GTC
TTC TGG GTG-3’. All primers were purchased from Sigma-Aldrich. Output values were
reported relative to GAPDH as fold expression normalized to control cell lines.

Preparation of 21T cell lysates
Radioimmunoprecipitation (RIPA) buffer (10nM Tris-HCl pH 7.5, 1mM EDTA, 0.5mM EGTA,
150nM NaCl, 1% Triton-X 100, 0.5% DOC, and 1% SDS) containing one protease inhibitor
tablet per 10mL (Complete, Mini, EDTA-free Protease Inhibitor Cocktail, Roche) was used to
lyse cells grown as subconfluent monolayers in 10cm dishes. The cells were removed with a
cell scraper, collected in a clean microcentrifuge tube, and placed on a rotator for 20 minutes
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at 4°C. Tubes were spun at 13,000 RPM for 10 minutes at 4°C and the resulting supernatant
was collected.

Electrophoresis and Western blotting
Proteins were electrophoresed on 10% polyacrylamide gels and subsequently analyzed after
transfer by Western blot with anti-TBX3 antibody (Abcam, ab58264; 1:2,000), anti-Vimentin
(Dako, clone 3B4; 1/1,000), anti-Twist (Abcam, ab50887; 1:1,000), anti-Src (Cell Signaling,
2108; 1:1,000), and anti-β-actin antibody (Abcam, ab49900; 1:150,000). After incubation with
the appropriate horseradish peroxidase-conjugated secondary antibody (anti-mouse,
Amersham GE Healthcare; anti-rabbit, Sigma) diluted 1:10,000, protein bands were detected
using ECL Plus Western Blotting Detection Reagents (Amersham GE Healthcare) and then
exposed to film in a dark room. Densitometric quantification was performed using ImageJ
(Open source software, National Institutes of Health, USA).

Immunohistochemistry of 21T cell pellets
Trypsinized cells were washed twice in phosphate buffered saline (PBS), and pelleted in
15mL conical tubes. Pellets were re-suspended in 10% neutral buffered formalin (NBF) and
stored at 4°C overnight. Formalin was removed, and pellets re-suspended in 1mL of 1%
agarose cooled to 35°C. The hardened pellets were wrapped in lens paper, cassetted, and
processed to paraffin. For histology, 4μm sections were deparaffinized, pre-treated with
10mM citrate buffer pH 6 and blocked for endogenous peroxidises in 3% H2O2/methanol.
Sections were immunostained with rabbit anti-TBX3 antibody (Abcam, ab99302) diluted
1:300 at 4°C overnight. Signal detection was accomplished using ThermoScientific
UltraVision LP Detection System (TL-060-HD).

Three-dimensional Matrigel culture and immunofluorescence
Three-dimensional Matrigel culture was described previously (Debnath et al., 2003, Lee et
al., 2007a, MacMillan et al., 2014). Following a 9 day growth period, images were taken at
both 4X and 10X objective using an inverted microscope. ImageJ (Open source software)
was used to determine colony formation rates by quantifying the percentage of the population
that formed colonies greater than 50μm in diameter. ImageJ was also used to determine the
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proportion of circular colonies; a binary quantification method was utilized, with a circular
colony having a circularity index above 0.75.
For immunofluorescence of Matrigel cultures, after 9 days of growth, the Matrigel
plugs were fixed (10% NBF) and permeabilized (0.5% Triton X-100 in PBS). After blocking
with normal goat serum (Invitrogen), rabbit anti-Ki67 (Abcam, ab833) and anti-cleaved
caspase 3 (Cell Signaling, 9661) antibodies were incubated at 1:150 dilution in 10% normal
goat serum overnight at 4ºC. Cells were incubated with Alexa Fluor 488 Goat Anti-Rabbit
secondary antibody (Invitrogen, A11034) and counterstained with Hoechst 33342 (Invitrogen,
H1399) and Alexa Fluor 546 Phalloidin (Invitrogen, A22238). Coverslips were mounted over
the stained Matrigel plugs with ProLong Gold Antifade Reagent (Invitrogen). Imaging was
done using an Olympus Confocal Imaging System (FluoView FV1000 coupled to the IX81
Motorized Inverted System Microscope). Nuclei per colony were manually counted after
acquiring 3D colony images.

Transwell migration and invasion assays
To assess the migratory potential of 21NT cells overexpressing TBX3 isoforms, transwell
inserts with 8.0μm pores (Corning, 3422; 24-well plate) were coated with a thin layer of gelatin
(6μg) to serve as a substrate for migration without obstructing movement through the pores.
A 100μL cell suspension (5x105 cells/mL in αHE with 0.1% bovine serum albumin (BSA))
was added to the upper chambers and 0.75mL αHE10F media was added to the bottom
wells. After incubation at 37°C and 5% CO2 for 22 hours, migrated cells were fixed with 1%
glutaraldehyde for 20 minutes and stained with full-strength Hematoxylin for 15 minutes.
Cells that remained on top of the membrane were removed using a cotton swab. Images of
5 non-overlapping fields of view were acquired using Image-Pro Analysis Software (Media
Cybernetics) coupled to an inverted microscope at 10X objective. Cells were counted from
the acquired images using ImageJ (Open source software). Similarly, to assess the invasive
potential, transwell inserts with 8.0μm pores precoated with Matrigel (Corning, 354480) were
used and incubation lasted 22 hours. Means derived from 4 replicates were used during
analysis.
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RT2 PCR arrays
RNA was isolated from TBX3iso1 and TBX3iso2 transfectants, as well as vector controls,
using the RNeasy Mini Kit (Qiagen). 1μg RNA was converted into cDNA using the RT2 First
Strand Kit (Qiagen). RT2 SYBR Green Mastermix was combined with the cDNA and dH 2O
as per the manufacturer’s protocol. Expression of 84 key genes commonly dysregulated in
breast cancer were assessed using Human Breast Cancer RT2 PCR arrays (Qiagen, PAHS131ZA-2). Data analysis was conducted by SA Biosciences PCR Array Data Analysis Web
portal using the ΔΔCt method normalized to acidic ribosomal phosphoprotein P0 (RPLP0)
expression. Heat map showing absolute expression of mRNA was generated using the SA
Biosciences RT2 profiler PCR Array Data Analysis Web Portal.

Statistical analysis
Statistical analyses were done using GraphPad Prism 5.0 software (La Jolla, CA). Colony
morphology experiments, stain quantification, migration and invasion assays, and mRNA and
protein levels were analyzed using one-way ANOVAs followed by Tukey’s post hoc test (for
comparison between more than two groups) or Student’s t-test (for comparison between two
groups). Proportions were analyzed via Fisher’s exact test. For all analyses, p<0.05 was
considered statistically significant.
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2.3

Results
TBX3iso1 and TBX3iso2 are differentially expressed in the 21T cell
lines.

We have previously reported that TBX3 is expressed in the 21T cell lines, with low levels in
the ADH-like 21PT and DCIS-like 21NT cells, and increased expression in the IMC-like
21MT-1 cells (Souter et al., 2010). This finding is consistent with previous reports that TBX3
is up-regulated in invasive stages of cancer. Expression of TBX3 was examined in the
parental 21T cell lines at the mRNA and protein level. Total TBX3 expression was higher in
invasive 21MT-1 cells relative to the non-invasive (21PT and 21NT) cell lines (Figure 2.3.1
A,D,E). Similarly, both TBX3iso1 and TBX3iso2 were up-regulated in 21MT-1 relative to
21PT and 21NT cells (Figure 2.3.1 B,C). In contrast, no difference in either total TBX3
expression, or expression of either isoform, was observed between the ADH-like 21PT cells
and DCIS-like 21NT cells (Figure 2.3.1 A-E).
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Figure 2.3.1 – TBX3iso1 and TBX3iso2 are differentially expressed in the 21T cell lines.
(A-C) Primers specific for either total TBX3, TBX3iso1, or TBX3iso2 were used to assess
relative abundance of each transcript in 21T parental cell lines by qRT-PCR. (D-E) Total
TBX3 protein is differentially expressed in the parental 21T cell lines. An antibody recognizing
both isoforms of TBX3 was used to assess the relative abundance of TBX3 within the 21T
cell lines. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test
and p<0.05 was considered statistically significant; ** p<0.01. Error bars indicate standard
deviation. Results are representative of at least 3 independent experiments.
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TBX3 expression is increased in DCIS-like 21NT cells after stable
transfection.
In order to assess the effect of TBX3 on breast cancer progression, TBX3iso1 or TBX3iso2
were overexpressed in the DCIS-like 21NT cell line and results were compared to an empty
vector (EV) control containing the same antibiotic resistant gene (neomycin). The relative
mRNA expression level of total TBX3, TBX3iso1 and TBX3iso2 was assessed by qRT-PCR
in the stably transfected cells. Total TBX3 mRNA was significantly up-regulated in both
TBX3iso1 and TBX3iso2 transfectants (Figure 2.3.2 A), and the overexpression of TBX3 was
isoform specific (Figure 2.3.2 B,C). Likewise, western blot analysis shows an increase in total
TBX3 protein levels in the TBX3 transfectant cells compared to the empty vector control
(Figure

2.3.2

D,E).

Cell

pellets

of

TBX3

transfectants

were

assessed

by

immunohistochemistry (Figure 2.3.2 F,G). TBX3 protein was localized to the nucleus, and
nuclear expression was significantly higher in TBX3 transfectants. Nuclear localization, as
observed by immunohistochemistry, is consistent with the known function of TBX3 as a
transcriptional regulator.
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Figure 2.3.2 – TBX3 expression is increased in 21NT cell transfectants.
21NT cell lines were stably transfected with either a TBX3iso1 or TBX3iso2 containing
plasmid, or an empty vector control. (A-C) Assessment of relative transcript levels of total
TBX3, TBX3iso1, and TBX3iso2 by qRT-PCR in stably transfected 21NT cells. (D-E)
Assessment of total TBX3 protein levels by western blot in stably transfected 21NT cells. (FG) Assessment of percentage of nuclei staining positive for TBX3 by IHC in stably transfected
21NT cell pellets. Cell pellets were stained using an anti-human TBX3 antibody and counter
stained with Harris’s Hematoxylin (Hx). Means were analyzed using one-way ANOVA
followed by Tukey’s post hoc test and p<0.05 was considered statistically significant; *
p<0.05, ** p<0.01, ***p<0.001. Error bars indicate standard deviation. Results are
representative of at least 3 independent experiments.
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TBX3 overexpression promotes progression of 21NT (DCIS) cells.
To assess the role of TBX3 in the progression of DCIS to a more malignant phenotype, the
3D morphology of the 21NT transfectants was assessed using a 3D Matrigel assay (Figure
2.3.3 A-B). TBX3 isoform overexpression resulted in an increase in colony formation rates
(Figure 2.3.3 C). As an index of the infiltrative vs. non-infiltrative nature of the colonies
forming, we used a circularity index to determine the proportion of colonies that were circular
(non-infiltrative) vs. non-circular (infiltrative). TBX3 isoform overexpression resulted in
significantly less rounded, more infiltrative colonies (Figure 2.3.3 D). Immunofluorescence
staining of colonies after 9 days of growth in Matrigel revealed significantly more nuclei per
colony with TBX3 isoform overexpression (Figure 2.3.3 E). Additionally, immunofluorescence
assessment of Ki67 and cleaved caspase 3 showed a significant increase in Ki67 (Figure
2.3.3 F) and decrease in cleaved caspase 3 (Figure 2.3.3 G) expression in TBX3 isoform
transfectants. This resulted in an increase in the proliferation to apoptosis (Ki67 / cleaved
caspase 3) ratio for both TBX3 isoform transfectants (Figure 2.3.3 H).
To further assess the migratory and invasive ability of TBX3-transfected 21NT cells,
transwell assays were used. Cells were placed in the upper chamber of transwells (8.0μm
pores coated with either a thin layer of gelatin for migration assays, or Matrigel for invasion
assays) and allowed to migrate/invade through the pores towards a chemoattractant in the
lower chamber. TBX3 isoform overexpression increased the ability of the cells to both migrate
over gelatin (Figure 2.3.4 A-B) and invade through Matrigel (Figure 2.3.4 4C-D).
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Figure 2.3.3 – TBX3 overexpression in DCIS-like 21NT cells results in a more
aggressive phenotype in 3D Matrigel.
TBX3 transfectants were seeded in 3D Matrigel at 3,000 cells per well and incubated at 37ºC
and 5% CO2 for 9 days. (A) Immunofluorescence images depicting colony size of 21NT
transfectants. Cells were grown in Matrigel for 9 days, then stained with Hoechst and
Phalloidin and imaged using 60X objective. Scale bars represent 20μm. (B) Brightfield and
phase contrast images showing growth of colonies after 9 days in 3D Matrigel. Brightfield
images were taken using 4X objective, with the scale bar representing 100μm. Phase
contrast images (inset) were taken using 40X objective, with the scale bar representing
20μm. (C) TBX3 overexpression increases colony formation rates. A colony was considered
to be successfully formed when larger than 50μm in diameter. Analysis was conducted using
ImageJ. (D) TBX3 overexpression decreased the proportion of round colonies. Analysis was
conducted using ImageJ. A binary quantification method was utilized; a circularity index
above 0.75 was considered circular. (E) TBX3 overexpression increases the number of nuclei
per cell colony. (F) TBX3 overexpression resulted in an increase in the percentage of Ki-67
positive cells within colonies. (G) TBX3 overexpression resulted in a decrease in the
percentage

of

cleaved

caspase

3

positive

cells

within

colonies.

(H)

The

proliferation/apoptosis ratio, defined as the percentage of positive Ki67 cells divided by the
percentage of positive cleaved caspase 3 cells, increased with overexpression of both TBX3
isoforms. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test.
The proportion of circular colonies was analyzed using Fisher’s exact test. A value of p<0.05
was considered statistically significant; *p<0.05, **p<0.01, ***p<0.001. Error bars indicate
Standard Deviation. Results are representative of at least 3 independent experiments.

93

94

Figure 2.3.4 – TBX3 overexpression increases migration and invasion of 21NT cells.
(A-B) TBX3 overexpression increases migration using a transwell migration assay. 21NT cell
transfectants were placed in the upper chamber of a transwell migration system with media
containing 1% BSA and allowed to migrate towards αHE10F chemoattractant in the bottom
chamber for 22 hours at 37ºC. Stable transfectants of both TBX3 isoforms showed an
increase in migration using the transwell system. Scale bars represent 100μm. Results are
quantified in panel b. (C-D) TBX3 overexpression increases invasion using a transwell
invasion system. 21NT cell transfectants were placed in the upper chamber of a transwell
invasion system with media containing 1% BSA and allowed to invade towards αHE10F
chemoattractant in the bottom chamber for 22 hours at 37ºC. Stable transfectants of both
TBX3 isoforms showed an increase in invasion using the transwell system. Scale bars
represent 100μm. Results are quantified in panel D. Means were analyzed using one-way
ANOVA followed by Tukey’s post hoc test. A value of p<0.05 was considered statistically
significant; *p<0.05, **p<0.01, ***p<0.001. Error bars indicate Standard Deviation. Results
are representative of 4 independent experiments.
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TBX3 knockdown reduces some characteristics of an aggressive
phenotype in 21MT-1 (IMC) cells.
To examine whether reduction of TBX3 expression has an effect at a later stage of
progression, TBX3 was knocked down in the invasive 21MT-1 cell line, using shRNA
targeting both isoforms. TBX3 expression in the knockdown with the greatest reduction in
both TBX3iso1 and TBX3iso2 mRNA expression is shown, with shLUC representing the offtarget luciferase control (Figure 2.3.5 A-C). Quantitative RT-PCR analysis showed a five-fold
reduction in total TBX3, TBX3iso1, and TBX3iso2 mRNA expression (Figure 2.3.5 A-C).
There was also a corresponding reduction in total TBX3 at the protein level (Figure 2.3.5
D,E). While the TBX3 knockdown cells were still able to form colonies at a rate comparable
with the shLUC control cells in the 9-day Matrigel assay (Figure 2.3.5 F,G), TBX3 knockdown
resulted in an increased proportion of round/circular colonies (i.e. less dispersed/infiltrative;
Figure 2.3.5 H) and fewer nuclei per colony (Figure 2.3.5 I), suggesting a reduction in
invasiveness and impaired growth in 3D.
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Figure 2.3.5 – TBX3 knockdown results in a less aggressive phenotype of IMC-like
21MT-1 cells in 3D Matrigel.
(A) Total TBX3 mRNA is decreased in 21MT-1 shTBX3 cells after TBX3 knockdown. (B)
TBX3iso1 mRNA is decreased in 21MT-1 shTBX3 after TBX3 knockdown. (C) TBX3iso2
mRNA is decreased in 21MT-1 after TBX3 knockdown. (D) Western blot showing total TBX3
protein is decreased in 21MT-1 shTBX3 cells after TBX3 knockdown. (E) Densitometry
quantification of western blot shows a significant decrease in total TBX3 protein expression
in the 21MT-1 shTBX3 cells. (F) Brightfield images showing colonies after 9 days in 3D
Matrigel. Images were taken at 4X objective. Scale bars represent 100μm. (G-I) Cells were
seeded in Matrigel and grown for 9 days. All of the cell lines were able to form colonies (G),
but shTBX3 colonies were rounder (i.e. less dispersed, less invasive) (H) and smaller (I).
Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test. The
proportion of circular colonies was analyzed using Fisher’s exact test. A value of p<0.05 was
considered statistically significant; *p<0.05, **p<0.01, ***p<0.001. Error bars indicate
Standard Deviation. Results are representative of at least 3 independent experiments.
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Up-regulation of TBX3 in 21NT (DCIS) cells results in alterations in
expression of key regulatory and EMT/invasion associated genes.
We assessed the mRNA expression patterns of TBX3iso1 and TBX3iso2 transfected 21NT
cells by RT2 PCR arrays, and found a number of alterations in expression of key regulatory
and EMT/invasion-associated genes. As 21NT cells transfected with either TBX3iso1 or
TBX3iso2 had shown a similar more aggressive phenotype, we focused our interest on genes
whose expression changed in common in both TBX3iso1 and TBX3iso2 transfected cells.
We identified altered expression of a number of genes involved in signal transduction, cell
cycle control, cell survival and EMT/invasiveness (Figure 2.3.6). In reference to pathways
potentially involved in control of cell cycle, proliferation, apoptosis and cell survival, we
observed significant down-regulation of CDKN2A (previously shown to be a key gene directly
regulated by TBX3 in blocking cell senescence (Rowley et al., 2004, Yarosh et al., 2008))
with up-regulation of marker of proliferation Ki67 (MKI67); Jun proto-oncogene (JUN);
nuclear receptor subfamily 3, group C, member 1 glucocorticoid receptor (NR3C1); epidermal
growth factor receptor (EGFR); androgen receptor (AR); interleukin-6 (IL6); SRC protooncogene (SRC); and V-Akt murine thymoma viral oncogene homolog 1 (AKT1). Although
the observed increase in retinoblastoma 1 (RB1), stratifin (SFN), breast cancer 1, early onset
(BRCA1) and breast cancer 2, early onset (BRCA2) may seem counter-intuitive when the
TBX3 up-regulated cells are found to be actively cycling and faster-growing, it is likely that
these are attempted adaptation responses to the more direct effect of CDKN2A downregulation by TBX3, the expected result of which would be release of cell-cycle checkpoint
control, inhibition of senescence and apoptosis and promotion of progression through the cell
cycle and cell proliferation.
Several genes potentially associated with EMT and cellular invasiveness were also
altered in TBX3 isoform transfectants. Transcriptional regulators twist family BHLH
transcription factor 1 (TWIST1) and snail family zinc finger 2 (SNAI2) were both up-regulated,
as was SRC, and there was also altered expression of several proteases and protease
inhibitors (including up-regulation of plasminogen activator, urokinase (PLAU), serpin
peptidase inhibitor, clade E, member 1 (SERPINE1), and matrix metallopeptidase 9 (MMP9);
and down-regulation of cystatin E/M (CST6)). Up-regulation of mesenchymal marker
vimentin, as well as EMT-markers Twist and Src were confirmed at the protein level as well
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(Figure 2.3.6 E). Whether directly or indirectly, up-regulation of either isoform of TBX3 in
21NT cells thus induced alterations in gene expression in pathways potentially involving cell
cycle, cell survival, cell growth control and EMT/invasiveness, with the resulting in vitro
phenotypes of more efficient and larger colony formation, increased proliferation/apoptosis
ratio and increased motility and invasiveness through Matrigel.
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Figure 2.3.6 – TBX3 overexpression in DCIS-like 21NT cells alters expression of key
regulatory and EMT/invasion-associated genes.
(A) Heat map (84 genes commonly dysregulated in breast cancer) showing absolute mRNA
expression of 84 breast-cancer related genes within the 21NT transfectant cells. (B) Fold
changes (mRNA) of genes significantly altered in expression in a similar fashion with
overexpression of both TBX3iso1 and TBX3iso2 in 21NT cells. Data analysis was conducted
by SA Biosciences PCR Array Data Analysis Web portal using the ΔΔCt method normalized
to acidic ribosomal phosphoprotein P0 (RPLP0) expression. Fold changes are compared to
21NT+EV control and are organized based on increasing fold change of TBX3iso1. The 24
genes shown had similar alterations in gene expression with statistically significant fold
changes for both isoforms (* p<0.05, ** p<0.01, ***p<0.001). Genes in green had reduced
expression, and genes in red had increased expression at the mRNA level with TBX3 isoform
overexpression. Results are representative of 3 RT2 PCR arrays per cell line. (C) Graphical
representation of fold changes in panel (A). Dotted line represents normalized expression of
transcript levels of empty vector control cells (fold change = 1). (D) Gene expression changes
with TBX3 isoform overexpression organized based on gene function groupings. Genes in
green had reduced expression, and genes in red had increased expression at the mRNA
level with TBX3 isoform overexpression. (e) Western blot showing increased expression of
Vimentin, Twist and Src protein levels with TBX3 overexpression.
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2.4 Discussion
By using the 21T cell line series to model the effects of putative drivers of the transition from
pre-invasive to invasive breast cancer progression, we are able to demonstrate that
overexpression of TBX3 can promote the transition of DCIS to IMC as assessed by in vitro
3D Matrigel growth assays. In particular, 21NT (DCIS-like) cells overexpressing TBX3iso1 or
TBX3iso2 showed increased colony-forming ability, with increased numbers of cells per
colony and a more dispersed (less “rounded”) colony morphology. Increased cell
invasiveness was also observed, both in terms of more dispersed colonies in 3D Matrigel
and increased invasion through Matrigel. In parallel, down-regulation of TBX3 in 21MT-1 cells
resulted in a less aggressive phenotype in 3D Matrigel, with smaller and less dispersed (less
invasive) colony morphology.
No significant difference in functional activity in any of these in vitro measures of
malignancy was observed between the TBX3 isoforms. Interestingly, RT2 PCR array analysis
did show several differences in gene expression profiles induced by TBX3iso1 and
TBX3iso2, as well as a number of commonalities (Figure 2.3.6 A). As we saw no difference
in functional effect, our analysis was focused on gene expression alterations occurring in
common between the two isoforms, which could potentially explain characteristics of the
more aggressive phenotype observed in both TBX3iso1 and TBX3iso2 transfectants.
Firstly, the increased colony-forming ability in 3D Matrigel, with larger colony size and
increased proliferation vs. apoptosis ratio observed with both TBX3iso1 and TBX3iso2 21NT
transfectants indicated an increased cell survival and predisposition for proliferation vs.
apoptosis (or senescence), effects that have been previously ascribed to TBX3 in other
systems (Brummelkamp et al., 2002, Carlson et al., 2002, Rowley et al., 2004, Yarosh et al.,
2008). Gene expression profiling of the TBX3 transfectants in our study showed altered
expression of several genes potentially involved in these processes in both TBX3iso1 and
TBX3iso2 transfected cells (i.e. down-regulation of CDKN2A (p14ARF, p16INK4A), with upregulation of MKI67, JUN, NR3C1, EGFR, AR, IL6, SRC and AKT1). Perhaps most
interesting of these is the down regulation of CDKN2A (p14ARF, p16INK4A) by both TBX3
isoforms, as previous studies have indicated p14ARF in particular to be a direct transcriptional
target of TBX3 in other systems (Yarosh et al., 2008), and that isolated down-regulation of
102

103

p14ARF can accomplish the same effect of increasing cell proliferation, decreasing cell
senescence and apoptosis (Rowley et al., 2004). Further work is required to determine
whether p14ARF or others of the candidate genes identified are responsible for the cell
survival/proliferation vs. apoptosis/senescence aspects of the TBX3 phenotype in these cells.
Another prominent aspect of the altered phenotype observed with both TBX3iso1 and
TBX3iso2 21NT transfectants was a more irregular/dispersed colony morphology in 3D
Matrigel, with increased cellular invasiveness in transwell assays, suggestive of an EMT
effect. In keeping with this, both TBX3iso1 and TBX3iso2 transfectants showed alteration in
expression of a number of EMT and invasion-related genes that are consistent with an EMT
phenomenon, including up-regulation of TWIST1, SRC, SNAI2, PLAU, SERPINE1, and
MMP9, with down-regulation of CST6. Western blot analysis showed up-regulation of Twist
and Src, along with mesenchymal marker Vimentin at the protein level as well.
Our work is in agreement with that of previous studies with other mammary epithelial
cells (MCF7, MDA-MB-435, HC11) (Platonova et al., 2007, Peres et al., 2010) in which TBX3
was shown to have functional effects including inhibition of senescence and promotion of cell
survival, proliferation and migration. We present the added novel finding, using a progression
series of mammary epithelial cells, that overexpression of TBX3 can trigger non-invasive
(DCIS-like, 21NT) cells to become invasive, possibly through an EMT-like process. In
addition, knockdown of TBX3 in invasive (21MT-1) cells can revert them to a less aggressive
phenotype, with less potential for 3D growth and a less infiltrative phenotype. Furthermore,
we have shown that these effects are not isoform specific, as both TBX3iso1 and TBX3iso2
were able to induce the same phenotypes in transfected 21NT cells. Finally, examination of
TBX3-induced changes in gene expression of 21NT cells has revealed specific cell
survival/anti-senescence/proliferation and EMT/invasiveness category alterations, which
may be involved in the functional changes observed. Future work will be necessary to
establish which of these changes may be key players in the TBX3-induced phenotypes.
We have demonstrated a role for both TBX3iso1 and TBX3iso2 in promoting the
transition from non-invasive to invasive breast cancer. We have shown that overexpression
of TBX3 can alter cell properties involved in cell survival/colony formation and invasiveness,
as well as regulate EMT/invasiveness-related genes. The identification of TBX3 as a potential
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regulator of early breast cancer progression from DCIS to IMC is of potential clinical utility
not only in identifying which DCIS lesions may be more likely to progress to invasion, but
along with a better understanding of the role of specific TBX3-induced gene expression
changes, in providing other potential molecular targets to block breast cancer progression at
this early, pre-invasive stage. The recent finding that TBX3 alterations may be key driver
mutations in breast cancer, and the suggestion that altered (probably increased) TBX3
function may be associated with at least some cases of familial breast cancer (Stephens et
al., 2012a), adds particular significance to the potential of TBX3 as an important regulator of
breast cancer progression, and added urgency to a better understanding of its role in the
malignancy of breast cancer.
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TBX3 promotes progression of pre-invasive breast cancer cells
by inducing EMT and directly up-regulating SLUG

SUMMARY OF FINDINGS
The acquisition of cellular invasiveness by breast epithelial cells and subsequent transition
from ductal carcinoma in situ (DCIS) to invasive breast cancer is a critical step in breast
cancer progression. Little is known about the molecular dynamics governing this transition.
We have previously shown that overexpression of the transcriptional regulator TBX3 in DCISlike cells increases survival, growth, and invasiveness. To explore this mechanism further
and assess direct transcriptional targets of TBX3 in a high-resolution, isoform-specific
context, we conducted genome-wide ChIP-arrays coupled with transcriptomic analysis. We
show that TBX3 regulates expression of several epithelial-mesenchymal transition (EMT)
related genes, including SLUG and TWIST1. Importantly, we demonstrate that TBX3 is a
direct regulator of SLUG, and SLUG expression is required for TBX3-induced migration and
invasion. Assessing TBX3 expression by immunohistochemistry in early stage (Stage 0 and
Stage I) breast cancers revealed high expression in low-grade lesions. Within a second
independent, early stage (Stage 0 and Stage I), non-high-grade cohort, we observed an
association between TBX3 expression in the DCIS and size of the invasive focus.
Additionally, there was a positive correlation between TBX3 and SLUG expression, and
TBX3 and TWIST1 expression in the invasive carcinoma. Pathway analysis revealed altered
expression of several proteases and their inhibitors, consistent with the ability to degrade
basement membrane in vivo. These findings strongly suggest the involvement of TBX3 in the
promotion of invasiveness and progression of early stage pre-invasive breast cancer to
invasive carcinoma through the low-grade molecular pathway.

Chapter 3 in this dissertation has been submitted, and is currently under peer-review.
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3.1 Introduction
Tumorigenesis within the breast is thought to involve advancement through distinct stages,
from benign ductal epithelial hyperplasia, to atypical ductal hyperplasia (ADH), ductal
carcinoma in situ (DCIS), and ultimately invasive and metastatic carcinoma (Burstein et al.,
2004). A very critical stage of this progression pathway is the acquisition of cellular
invasiveness. It is estimated that approximately 25-50% of DCIS will progress to invasive
carcinoma during the lifetime of the patient, a process generating potentially life-threatening
disease (Sagara et al., 2015). Clinical management of patients with DCIS usually consists of
surgical resection with additional radiation therapy for most patients (Fisher et al., 1999,
Mokbel and Cutuli, 2006). Several recent studies, however, have suggested that a subset of
patients with early-stage (non-high-grade) DCIS do not benefit from either surgery alone or
combined surgery and radiation, raising concern regarding over-treatment of this
subpopulation (Thorat et al., 2007, Formenti et al., 2011, Sagara et al., 2015). Paradoxically,
we are currently limited in our ability to identify patients with DCIS that have an intrinsically
higher risk of local and invasive recurrence, such that there is also a risk of under-treatment
if excision is incomplete or radiation therapy is omitted.
The 21T series cell lines have been proposed as a unique experimental model of
breast cancer progression (Band et al., 1990). Three cell lines were isolated from a single
patient and stably represent distinct stages of progression: 21PT cells mimic ADH (nontumorigenic), 21NT cells mimic DCIS (tumorigenic and non-metastatic), and 21MT-1 cells
depict characteristics of invasive mammary carcinoma (tumorigenic and metastatic) when
injected orthotopically into nude mice (Band et al., 1990, Souter et al., 2010). We have
previously conducted extensive characterization of these cell lines, including examination of
global gene-expression levels coupled with assessment of clinical literature on progression
(Souter et al., 2010). Importantly, we found that during the transition from the clonally-related
DCIS-like 21NT cells to invasive 21MT-1 cells, TBX3 was within the list of clinically-relevant
up-regulated transcripts (Souter et al., 2010).
TBX3 is a member of T-box family of transcription factors implicated in skeletal,
cardiac and mammary gland development (Willmer et al., 2017). TBX3 levels are upregulated in several cancers, with most of the literature focusing on breast cancer (Fan et al.,
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2004, Lomnytska et al., 2006, Yarosh et al., 2008, Souter et al., 2010) and melanoma
(Rodriguez et al., 2008, Peres and Prince, 2013). Due to alternative splicing, two TBX3
isoforms exist: TBX3iso1 and TBX3iso2. TBX3iso2 contains an additional 20-amino acid
sequence in the DNA binding domain attributed to the 2a exon, which TBX3iso1 lacks.
Differing expression levels of these isoforms has been reported in several breast cancer cell
lines (Fan et al., 2004). While the role of TBX3 in tumorigenesis is currently unclear,
accumulating evidence suggests that the TBX3-mediated transcriptional repression of p14ARF
(Lingbeek et al., 2002, Yarosh et al., 2008) and/or p21CIP1 (Hoogaars et al., 2008) plays a
role in bypassing cellular senescence and driving cancer progression. Recent work has
begun to identify a link between TBX3 expression levels and epithelial-mesenchymal
transition (EMT), with direct down-regulation of E-cadherin (Rodriguez et al., 2008). These
findings are important, as the switch from an epithelial to a mesenchymal phenotype has
been implicated in the acquisition of migratory and invasive properties, suppression of
senescence and apoptosis, as well as therapeutic resistance (De Craene and Berx, 2013).
SLUG (encoded by the SNAI2 gene) is a member of the SNAIL family of transcription factors
and a key mediator in the promotion of EMT (De Craene and Berx, 2013, Phillips and
Kuperwasser, 2014). Specifically, SLUG has been shown to trigger the initial phases of the
EMT process (Savagner et al., 1997).
In this study we explore the role of TBX3 in breast cancer progression pathways,
focusing specifically on its involvement in the induction of EMT and the transition from DCIS
to invasive mammary carcinoma. Immunohistochemical analysis has revealed that TBX3
levels are elevated in low-grade, pre-invasive DCIS lesions with an associated invasive
component, and significantly correlated with the size of the invasive focus. Using genomewide bioinformatic approaches in conjunction with more conventional in vitro studies, we
have identified SLUG and TWIST1 as downstream targets of TBX3 and have assessed their
expression by immunohistochemistry in two different patient cohorts. Our findings suggest
that TBX3 facilitates the process of early invasion in DCIS, by promoting the induction of
EMT and tumor progression through the low-grade pathway, as described by Bombonati and
Sgroi (Bombonati and Sgroi, 2011). Finally, we propose a progression model in which SLUG
is an important and necessary effector downstream of TBX3, leading to increased motility,
invasiveness, and induction of key invasiveness-associated genes.
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3.2

Methods

Cell lines and culture conditions
The 21T series cell lines (21NT and 21MT-1) were obtained as a gift from Dr. Vimla Band
(Dana Farber Cancer Institute) (Band et al., 1990). 21T series cell lines underwent
authentication testing by Idexx Radil (Case No. 20250-2013). Cells were maintained in
αMEM media supplemented with 2mM L-glutamine, 1µg/mL insulin, 12.5ng/mL EGF, 2.8µM
hydrocortisone, 10mM HEPES, 1mM sodium pyruvate, 0.1mM non-essential amino acids,
and 50µg/mL gentamycin sulfate and further supplemented with 10% FBS (αHE10F). All
reagents were obtained from Wisent Inc. Stable 21NT transfectants previously generated
(Krstic et al., 2016) were maintained in αHE10F medium supplemented with 500µg/mL G418
as a selection marker. Stable lentiviral transductants were maintained in αHE10F medium
supplemented with either 0.8µg/mL puromycin (TBX3 knockdown lines) or 500M
hygromycin (SLUG knockdown lines) as a selection marker.
Cell lines representing other molecular breast cancer subtypes were purchased from
ATCC. Cell lines were maintained in their respective media: T47D (RPMI), SKBR3 (McCoy’s
5A), and MDA-MB-468 (αMEM) supplemented with 10% FBS. All cell lines were regularly
tested and negative for Mycoplasma contamination using the Mycoplasma PCR Primer Set
(Agilent Technologies, 302008).

Stable Transfection
21NT parental cell lines were seeded into 6-well plates at 350,000 cells per well, and
transfected the following day at 3g of DNA plasmid per well using the Lipofectamine 3000
Transfection Kit (Invitrogen, L3000). Plasmid DNA constructs were previously described
(Krstic et al., 2016) and consist of an empty vector (EV), TBX3iso1, and TBX3iso2 construct
within a pcDNA3.1 (Invitrogen, V79020) vector. Selection was performed using αHE medium
supplemented with 500g/mL G418. Resistant clones were pooled, expanded, and frozen
for later use.

Transient Transfection
For assessment of E-cadherin expression and localization, 21NT parental cell lines were
seeded into 6-well plates at 350,000 cells per well, and transfected the following day with
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3g of DNA plasmid per well using the Lipofectamine 3000 Transfection Kit (Invitrogen,
L3000). Plasmid DNA constructs consisted of an empty vector (EV), TBX3iso1, and
TBX3iso2 construct within pZsGreen1-N1 vector containing the ZsGreen reporter gene. For
immunofluorescence studies, transfected cells were grown under normal conditions for 72
hours and then underwent immunofluorescent staining.
For invasion assay studies, cells (T-47D, SKBR3, MDA-MB-468) were incubated with
transfection reagent and the appropriate plasmid for 24 hours, then harvested and assays
were performed. Plasmid DNA constructs consist of an empty vector (EV), TBX3iso1, and
TBX3iso2 construct within pZsGreen1-N1 vector containing the ZsGreen reporter gene.

Lentiviral Transduction
The generation of shRNA-encoding lentivirus particles for TBX3 knockdown was conducted
as previously described (Krstic et al., 2016). The shRNA target sequence for TBX3 was
GCATACCAGAATGATAAGATA, which targeted the coding sequence of both TBX3iso1 and
TBX3iso2. The shRNA target sequence for Luciferase (representing an off-target control)
was ACGCTGAGTACTTCGAAATGT. The lentivirus particles were used to generate 21MT1 shLUC and 21MT-1 shTBX3 cell lines. Selection was performed using αHE medium
supplemented with 0.8g/mL puromycin. Resistant clones were pooled, expanded, and
frozen for later use.
Down-regulation of SLUG (SNAI2) was performed using lentivirus-mediated shRNA
transduction. 293T packaging cells were seeded at 80% confluence in 6-well plates with lowantibiotic growth media (DMEM with 10% FBS and 0.1x Penicillin/Streptomycin). The
following day the packaging cells were transfected with the packaging plasmid (Addgene,
pCMV-dR8.91, 900ng), envelope plasmid (Addgene, VSV-G/pDM2.G, 100ng), and psiLVRU6H vector encoding one of 4 shRNAs specific to SNAI2 (Genecopoeia, HSH017502LVRU6H, 1g) or an empty vector control (Genecopoeia, CSHCTR001-LVRU6H, 1g)
(quantities reported per well). The FuGENE transfection reagent (Promega, E2311) was
mixed with the 3-plasmid mix as per the manufacturer’s protocol. The transfection mix was
incubated for 30 minutes at room temperature, and 200L was added to the packaging cells.
Viral harvesting was done three times, spaced out by 12-24 hours by replacing media with
6mL of high-BSA growth media (20g BSA per 100mL DMEM). The three viral harvests were
pooled and the viral supernatant was frozen.
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21NT transfectants (21NT+EV, 21NT+TBX3iso1, 21NT+TBX3iso2) were seeded at
200,000 cells per well in 6-well plates. The following day 300L of the shRNA-encoding
lentiviral particles were added to the cells along with 2g polybrene (Sigma, TR-1003-G) per
2mL media. The cells were incubated at 37ºC overnight and transduced cells were selected
for by including 500M hygromycin (Invitrogen, 10687-010) in the media (aHE10F with
500M hygromycin, 500ug/mL G418). Media was replaced again the following day, and cells
were trypsinized and expanded into T25 flasks on the third day.

Preparation of 21T protein lysates
Protein lysates were prepared by adding 1mL of RIPA buffer (150mM NaCl, 1% Triton-X,
0.5% deoxycholic acid, 0.1% SDS, 50mM Tris-base; pH 8.0) with Halt Protease Inhibitor
Cocktail (Thermo Scientific, 78429) to confluent 10cm plates. Cells were scraped, collected
in a microcentrifuge tube, and incubated on ice for 10 minutes. Lysates were then centrifuged
at 13,000 RPM for 10 minutes at 4ºC. The supernatant was collected and protein
concentrations were determined using a Bradford Protein Assay kit (BioRad, 5000002) by
comparing to BSA standards.

Preparation of Conditioned Media and Western Blotting
For assessment of secreted protein expression (MMP9), conditioned media was prepared by
seeding 1.0x106 cells into T75 flasks, and cells were maintained in low serum media (αMEM
with 0.1% FBS) for 48 hours. Media was collected and concentrated 25X using centrifugal
filters (Amicon Ultra-4, UFC803024). Protein was resolved (40g) on a 10% SDS-PAGE gel.
Immediately after transferring proteins to a PVDF membrane, total protein was visualized by
Ponceau Stain using the BioRad ChemiDoc imaging system, and an image of the membrane
was acquired for subsequent normalization. The membrane was then de-stained and MMP9
protein levels were assessed by western blot (specifications can be found in ‘Electrophoresis
and Western Blotting’ section).

Electrophoresis and Western Blotting
Protein (10-50µg) was resolved on a 10% SDS-PAGE gel. The membrane was blocked with
5% milk for one hour (or 5% BSA where specified), then incubated with primary antibody
overnight at 4ºC; anti-TBX3 (Invitrogen, 424800; 1:1,000), anti-SLUG (Abcam, ab27568;
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1:1,000 in BSA), anti-Vimentin (Abcam, ab92547; 1:1,000), anti-Fibronectin (Abcam,
ab2413; 1:1,000), anti-uPa (Abcam, ab133563; 1:250), anti-MMP9 (Abcam, ab38898,
1:1,000), anti-MMP14 (Abcam, ab51074; 1:500), anti-Src (Cell Signaling, 2110; 1:1,000),
anti-pSrc (Y416) (Cell Signaling, 2101; 1:1,000 in BSA), anti-pSrc (Y527) (Cell Signaling,
2105; 1:1,000 in BSA), anti-TWIST1 (Abcam, ab50887; 1:100 in BSA), anti-CST6 (Sigma,
WH0001474M1; 1:1,000), anti-N-Cadherin (Abcam, 18203, 1:1,000), anti-Vinculin (Sigma,
V9264; 1:20,000). The membrane was incubated with secondary antibody conjugated to
HRP, either anti-rabbit (Sigma, A0545; 1:1,000) or anti-mouse (GE Healthcare, NXA931;
1:1,000) as appropriate, for 1 hour at room temperature. The western blots were visualized
using Luminata Crescendo (EDM Millipore, WBLUR0500) and images were taken using the
BioRad ChemiDoc imaging system. Densitometric quantification was performed using
ImageLab (BioRad), and quantities were normalized to vinculin expression. Where
quantifications of western blots is shown, data was acquired through densitometric
quantifications across three biological replicates.

Immunofluorescence
ZsGreen vector transiently transfected cells (described above) were fixed with 10% neutral
buffered formalin for 10 minutes, and permeabilized with 0.5% Triton X-100 in PBS for 10
minutes. Blocking was conducted with normal goat serum (Invitrogen, 50-0627) at room
temperature for 1 hour. Rabbit anti-E-cadherin antibody (BD Biosciences, 610181) was
added at a dilution of 1:150 in 10% normal goat serum and was incubated overnight at 4ºC.
The following day, cells were washed three times with PBS, and secondary antibody
Alexa647 Goat Anti-Rabbit IgG (Invitrogen, A21245) was added at a dilution of 1:1,000 in
10% normal goat serum and incubated for 1 hour at room temperature. Cells were washed
5 times with PBS. Hoechst 33342 (Invitrogen, H1399) diluted to 1:5,000 in PBS was
incubated for 30 minutes at room temperature. Cells were washed once with PBS. Coverslips
were mounted with ProLong Gold Antifade Reagent (Invitrogen, P36930). Images were
captured at 40X magnification using an Olympus Confocal Imaging System (FluoView
FV1000 coupled to the IX81 Motorized Inverted System Microscope). Images were converted
to 8-bit images by separating channels. Mean grey area was quantified within the red channel
across ZsGreen positive (transfected) cells. E-cadherin expression across the cell lines was
normalized to the empty vector control.
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Scratch Wound (Migration) Assay
Cells were cultured to near confluence in 6-well plates and starved in low serum media
(αMEM with 0.1% FBS) for 16 hours. A 2 mm wide scratch was then made in the confluent
monolayer. The cells were rinsed with PBS and fresh media (αMEM media with 10% FBS)
was added. Cell migration was visualized and phase contrast images were taken at 10X
using the Olympus IX70 inverted microscope after 6h, 12h and 24h. Cell migration was
calculated by comparing the wound area at the specified time points using ImageJ (Open
source, https://imagej.nih.gov/ij/). Means derived from four biological replicates were used
during analysis.

Transwell Invasion Assay
Transwell invasion assays were conducted to examine the invasive potential of the
transfected cell lines. Stably transfected 21NT cells (representing luminal B subtype) were
used for initial studies. For stable 21NT transfectant cells, 50,000 cells per 100L of media
were added to the upper chamber of a 8.0m pore transwell insert (Corning, 3422; 24-well
plate) coated with 10g of Matrigel (Corning, 354480). After incubation at 37ºC and 5% CO2
for 18 hours, the membranes were fixed with 1% glutaraldehyde for 20 min and stained with
full-strength Hematoxylin for 15 minutes. Cells which did not migrate and remained on the
upper surface of the membrane were removed using a cotton swab. Images of 5 nonoverlapping fields of view were acquired using an Olympus IX70 inverted microscope at 10X
objective. Cells were counted from the acquired images using ImageJ. Means derived from
4 replicates were used during analysis.
Invasiveness of transiently transfected cells was also assessed, including T-47D
(luminal A), SKBR3 (HER2-enriched), and MDA-MB-468 (basal-like) cells transfected with
either an empty vector (EV), TBX3iso1, or TBX3iso2 construct within the pZsGreen1-N1
vector containing a ZsGreen reporter gene. Twenty-four hours post-transfection, cells were
trypsinized, harvested, and suspended in their respective media in the absence of FBS and
addition of 0.1% BSA. Cells were then added to the upper layer of a 8.0M transwell insert
coated with 10g of Matrigel at 50,000 cells per 100L of media. After incubation at 37ºC
and 5% CO2 for 18 hours, the membranes were fixed with 1% glutaraldehyde for 20 min.
Cells which did not migrate and remained on the upper surface of the membrane were
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removed using a cotton swab. Green fluorescent images and brightfield images of 3 nonoverlapping fields of view were acquired and superimposed using an EVOS FL Auto
microscope at 10X objective. The number of green cells was determined using ImageJ
software. Means derived from four biological replicates were used during analysis.

Cell-Cell Adhesion Assay
The cell-cell adhesion assay was done as described (Rodriguez et al., 2008). Briefly, T75
plates were rinsed twice with PBS and cells were dissociated using 3mM EDTA. Cells were
resuspended in HE10F media and passed through a cell strainer to dissociate cell clusters.
Cells (200,000) were added to the appropriate media (HE10F with 3mM EDTA, or HE10F
with 1mM CaCl2) in a 6 cm petri dish. Plates were incubated at 37ºC on a shaking platform
for 30 minutes. After this incubation period, 10 non-overlapping fields of view per dish were
captured using the Olympus IX70 inverted microscope at 10X objective. Clusters containing
more than 4 cells were counted, and counts from 10 fields of view were added together for
each plate. Means derived from four biological replicates were used during analysis.

Gelatin Zymography
Cells (1.5x106) were seeded onto 10cm plates. The following day, media was replaced by
10mL of serum-free αHE media with 500µg/mL G418, and cells were serum-starved for 24
hours. Media was collected and concentrated 25X using centrifugal filters (Amicon Ultra-4,
UFC803024). Equal volumes (normalized to 1.5x106 cells) of the conditioned media was
loaded into a 10% Criterion Zymogram gel (BioRad, 3450080) without boiling/reducing and
resolved at 4ºC. To remove SDS from the gel, the gel was washed with renaturation buffer
(2.5% Triton X-100) twice for 30 minutes each, followed by two 20 minute washes with
distilled water. The gel was then incubated in development buffer (50mM Tris, 200mM NaCl,
5mM CaCl2 (anhydrous), 0.02% Brij-35, pH 7.5) at 37ºC for 16 hours. The gel was then
stained (40% methanol, 10% acetic acid, 0.5% Coomassie Blue R-250) for 1 hour at room
temperature with gentle agitation, followed by de-staining (40% methanol, 10% acetic acid)
until clear bands appeared. Images were taken using the BioRad ChemiDoc imaging system.
Reverse images were used for quantification. Means derived from three biological replicates
were used during analysis.
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Chick Chorioallantoic Membrane (CAM) Extravasation Assays
Cells were pre-labeled with 1µM CellTracker conjugated to Green CMFDA Dye (Thermo
Fischer Scientific, C7025) and washed once with PBS. Using the chorioallantoic membrane
(CAM) of the chicken embryo, embryonic day 12 embryos were intravenously (IV) injected
with 50,000 cells (50µL of 1×106 cells/mL cell suspension).
For the extravasation assays, rhodamine-labelled lectin (75µL of 0.1mg/mL, Vector
Laboratories Inc, RLK-2200) was intravenously injected 10 minutes after injection of
fluorescently-labelled cells in order to visualize the luminal surface of endothelial cells in the
CAM. Immediately following IV injection of lectin-rhodamine, a 1cm×1cm field of the CAM
marked by foil markers at the corners was made for each animal and the number of cells that
were intravascular, in the process of extravasation and extravasated into the CAM stroma
were counted at T=10 min and T=24 hours. A resonance scanner confocal microscope
(Olympus FluoView FV1000 coupled to the IX81 Motorized Inverted System Microscope)
was used to determine each cell's location within the CAM with respect to lectin-rhodamine
signal in real time. All quantifications were conducted blinded. Values reported represent the
percentage of cells that successfully extravasated in the 1cm×1cm field across 30 biological
replicates. All quantifications were conducted blinded.
For in vivo invadopodia assays, the chick embryos were returned to their incubators
after injection of labelled cells, and at the 6-hour time-point were intravenously injected with
rhodamine-labelled lectin (75µL of 0.1 mg/mL, Vector Laboratories Inc.) in order to visualize
the luminal surface of the endothelial cells in the CAM. A resonance scanner confocal
microscope was used to determine each cell's location within the CAM with respect to lectinrhodamine signal in real time. By scanning across the Z-axis, green fluorescently labeled
cells were assessed for the presence of functional invadopodia protruding between the
intravascular/extravascular boundary. Values reported represent the percentage of cells
displaying functional invadopodia in vivo across 6 biological replicates consisting of
approximately 30 scanned cells each. All quantifications were conducted blinded.

Invadopodia Formation Assay
The in vitro invadopodia formation assay was conducted as described (Artym et al., 2009).
Briefly, cover slips were coated with 1mL of cold poly-L–lysine (Sigma, P7405; 50µg/mL in
PBS) and aspirated after 20 minutes, followed by a 15 minute incubation with 0.5%
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glutaraldehyde. Coverslips were then inverted on an 80µl drop of 0.2% gelatin in PBS
labelled with Alexa594 (Thermo Fischer Scientific, G13187), and incubated for 10 minutes.
Coverslips were lifted, then incubated with 5mg/mL sodium borohydride for 15 minutes to
quench reactive groups in the gelatin matrix, followed by extensive washing with PBS. Cells
were trypsinized and plated on coverslips for 12-24 hours (as optimized) followed by fixation
with 4% paraformaldehyde and permeabilization with 0.1% Triton X-100 in PBS. Samples
were blocked with 5% skim milk powder, followed by staining with Alexa488-labelled
phalloidin (Thermo Fischer Scientific, A12379) to label F-actin. Cells were imaged using the
Nikon Fast A1R Upright Microscope. Cells with actin cores overlaying spots of degradation
were counted as invadopodia forming cells. Percentage of cells forming invadopodia was
quantified from 4 biological replicates, assessing invadopodia formation in 10-20 random,
non-overlapping fields.

RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)
RNA was isolated using the RNeasy Mini Kit (Qiagen, 74104). RNA (500ng) was transcribed
into cDNA using the qScript cDNA SuperMix (Quanta Biosciences, 84034). The RT 2 SYBR
Green ROX qPCR Mastermix (Qiagen, 330521) was utilized for quantitative PCR with the
primer sequences as listed in Table 3.1. The output Ct values were normalized to GAPDH
and RPLP0 expression for 21NT transfected and transduced cells, respectively, using the
∆∆Ct method. Means derived from a minimum of three biological replicates were used during
analysis.

118

119

Table 3.1 – Primer sequences utilized for qRT-PCR in mRNA studies.

mRNA Probe
Total TBX3

(F) Forward and (R) Reverse Primer Sequences, 5’ to 3’
F: CGCTGTGACTGCATACCAGA
R: GTGTCCCGGAAACCTTTTGC

TBX3iso1

F: AGTGGATGTCCAAAGTCGTCAC
R: CATGGAGTTCAATATAGTAAATCCATGTTTGTCTG

TBX3iso2

F: AGTGGATGTCCAAAGTCGTCAC
R: CACTTGGGAAGGCCAAAGTAAATCCATG

CDH2 (N-cadherin)
CST6
FN1 (Fibronectin)

F: GACGATCCCAATGCCCTCAA
R: ACATGTTGGGTGAAGGGGTG
F: TGAGGTCCTTGTGGTTCCCT
R: CCCTCGGGGACTTATCACATC
F: AGGAGAATGGACCTGCAAGC
R: GAAGTGCAAGTGATGCGTCC

GAPDH

F: AGGCTGGGGCTCATTTGAAG
R: CCATCCACAGTCTTCTGGGTG

MMP14

F: CCAGCAACTTTATGGGGGTG
R: GGCCCATAGGTGGGGTTTTT

MMP9

F: CTTTGAGTCCGGTGGACGAT
R: TCGCCAGTACTTCCCATCCT

TWIST1

F: GCAAGAAGTCGAGCGAAGAT
R: GCTCTGCAGCTCCTCGAA

RPLP0

F: CCTCATATCCGGGGGAATGTG
R: GCAGCAGCTGGCACCTTATTG

SLUG

F: GCCAAACTACAGCGAACTGG
R: GATGGGGCTGTATGCTCCTG

SRC

F: GCACAGGACAGACAGGCTAC
R: TCTGACTCCCGTCTGGTGAT

uPa

F: TCCAAAGGCAGCAATGAACT
R: GTGCTGCCCTCCGAATTTCT

VIM (Vimentin)

F: GGACCAGCTAACCAACGA
R: AAGGTCAAGACGTGCCAGAG

Chromatin Immunoprecipitation
Twenty million cells (per replicate) were grown to confluence for each cell line. The cells were
washed twice with cold PBS, and then cross-linked with 10mL of PBS with 1% formaldehyde
solution for 15 minutes at room temperature on a rocking platform. The reaction was
quenched with 1mL of 2.625M glycine. The cells were then scraped into the supernatant and
washed twice with cold PBS.
Pellets were resuspended in 1mL nuclei isolation buffer (50mM Tris pH 8.0, 60mM
KCl, 0.5% NP-40) with protease inhibitors (Thermo Scientific, 78429) and incubated on ice
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for 10 minutes, then spun at 3,000 RPM for 3 minutes at 4ºC for nuclei isolation. Nuclei were
resuspended in 1mL of Lysis Buffer (0.5% SDS, 10mM EDTA, 0.5mM EGTA, 50mM Tris
HCl, pH 8.0) with protease inhibitors. Chromatin was sonicated for 40 minutes at 2ºC (using
Diagenode Bioruptor Pico; 30 seconds on, 30 seconds off). The sonicated samples were
centrifuged at 13,000 RPM for 10 minutes at 4ºC to remove cell debris. Sonicated chromatin
was then pre-cleared with 200L Protein-A Dynabeads (Life Technologies, 10002D) for 1
hour at 4ºC on a rocking platform. Simultaneously, 50L of Protein-A Dynabeads were
washed with 0.5% BSA-PBS and incubated with 5g of normal rabbit IgG antibody
(Invitrogen, 10500C) or 5g of rabbit anti-TBX3 antibody (Invitrogen, 424800) in 100L of
dilution buffer (PBS with 0.2% Tween20 and 1% BSA) for 2 hours at room temperature on a
rocking platform (quantities listed per biological replicate). The bead-antibody complex was
then washed twice with 0.5% BSA-PBS, resuspended in dilution buffer and then added to
the sample. Immunoprecipitation was conducted overnight (16 hours) at 4ºC on a rocking
platform.
Bound chromatin was eluted the following day. Each wash step was performed at 4ºC
for 5 minutes on a rocking platform. Chromatin was washed with Wash Buffer I (20mM Tris
HCl, 150mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS) twice, Wash Buffer II (20mM
Tris HCl, 500mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS) once, and TE buffer (10mM
Tris HCl, 1mM EDTA, pH 8.0) twice. Bound chromatin was eluted using 200L of Elution
Buffer (100mM NaHCO3, 1% SDS) at 65ºC for 20 minutes. NaCl was added to a final
concentration of 200mM and incubated with the chromatin overnight at 65ºC for decrosslinking. Proteinase K (Thermo Scientific, AM2546) was added and incubated for 2 hours
at 50ºC, followed by RNase A (Thermo Scientific, 12091039) treatment for 60 minutes at
37ºC for protein and RNA degradation, respectively. The DNA was purified using the
QIAquick PCR Purification Kit (Qiagen, 28106) and eluted with 20L elution buffer.
For ChIP array purposes, the eluted DNA was amplified using the Whole Genome
Amplification Kit (Sigma, WGA2) as per the manufacturer’s protocol, with the omission of the
fragmentation step. In order to obtain sufficient DNA for ChIP-array hybridization, the
amplified DNA was re-amplified using the GenomePlex Complete Whole Genome
Reamplification kit (Sigma, WGA3) with the incorporation of dUTP (Jena Bioscience, NU1021S) at a final concentration of 2mM, and dTTP was reduced to 8mM. The DNA was once
again purified using the QIAquick PCR Purification Kit.
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For validation of select ChIP targets, 5uL of the eluate was used for qPCR. The %
input method was utilized for quantification of enrichment. An input of 5% was saved prior to
immunoprecipitation and was de-crosslinked and purified as described above. The Ct values
for the input was subtracted from the Ct values of the immunoprecipitated samples. A fold
change was then calculated consisting of TBX3 IP over IgG control (signal over noise) to
allow for easy comparison between primer sets. The primers used for ChIP-qPCR
experiments are listed in Table 3.2. The CDH1 transcription start site (TSS) and coding
region served as the positive and negative control, respectively. The CDH1 control primer
sequences were obtained from a previously published study reporting the TBX3 binding site
within E-cadherin in melanoma cell lines (Rodriguez et al., 2008).
Table 3.2 – Primer sequences utilized for ChIP-qPCR validation studies.
DNA Probe

(F) Forward and (R) Reverse Primer Sequences, 5’ to 3’

F: TCACAGGTGCTTTGCAGTTC
R: GTGAACCCTCAGCCAATCAG
F: AACAGCTGCTTGGTGACGTT
CDH1 coding region
R: CAAGCCTGGGAGTTAGGTG
F: AATGGGGCTTTCTGAGCCAC
SNAI2
R: TCCACGCCCAGCTACCCAA
CDH1 TSS

RNA-Seq
Cells were grown to 80% confluence and RNA was isolated using the RNeasy Mini Kit
(Qiagen, 74104) incorporating DNase I digestion (Qiagen, 79254). Samples were sent to the
Donnelly Sequencing Centre (Toronto, Canada) and assessed for RNA integrity using an
Agilent bioanalyzer. For each sample, stranded mRNA libraries were prepared and
sequenced on an Illumina HiSeq 2500 sequencer using V4 chemistry. Paired-end read
length

was

51

base

pairs. Raw

reads

were

then

uploaded

to

Basespace

(https://basespace.illumina.com/) and imported into Galaxy software (https://usegalaxy.org).
The FastqGroomer tool within Galaxy was used to prepare the files for alignment, and the
TopHat tool within Galaxy was used to align the FASTQ files to the reference genome (Hg19)
using the default parameters, except that the maximum number of alignments was capped
at 10. Aligned sequences were imported as .bam files into Partek Genomics Suite (PGS;
http://www.partek.com/pgs)

software

and

analyzed

using

the

RNA-Seq

analysis

workflow. Gene reads were normalized for transcript length using the RPKM normalization
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algorithm, and differentially expressed genes between TBX3iso1 or TBX3iso2 compared to
empty vector were determined using ANOVA statistical tests. For each comparison, final
gene lists were created using a minimum fold change cut-off of 1.5-fold, and a maximum
False Discovery Rate (FDR) of 0.05 (step-up FDR algorithm of Benjamini and Hochberg).

ChIP Promoter Arrays
Chromatin was immunoprecipitated as described above. The amplified product (7.5g) was
fragmented, labeled, and hybridized to the GeneChip Human Promoter 1.0R Array
(Affymetrix, 900776), and the hybridized array was scanned as per manufacturer’s
instructions. All microarray work was done at the London Regional Genomics Centre
(Robarts Research Institute, London, Canada). Resultant .cel files were then imported into
Partek Genomic Suites (PGS) and analyzed using the Chromatin Immunoprecipitation
workflow. Differential probe intensities between TBX3iso1 or TBX3iso2 vs. empty vector
were determined by ANOVA and enriched regions of significance were determined using the
MAT algorithm. To be further considered, an enriched region had to have a minimum MAT
score of 5 at p<0.05.

Bioinformatics Analysis
To compare RNA-Seq and ChIP-array datasets, gene lists were constructed using Venny 2.1
(Spanish National Biotechnology Centre; http://bioinfogp.cnb.csic.es/tools/venny/). Genes of
interest include those significantly altered with overexpression of both TBX3 isoforms by
RNA-Seq (fold change >1.5 relative to the empty vector, p<0.05), and genes which both
TBX3 isoforms directly bound in ChIP-array datasets (MAT score >5, p<0.05). Altered
biological functions with TBX3 isoform overexpression were examined using Ingenuity
Pathway Analysis (IPA) (Qiagen) by examining RNA-Seq data. Gene reads and ChIP binding
locations were visualized using Interactive Gene Viewer (IGV) software (Broad Institute).
Consensus binding motifs of highly conserved T-box proteins (TBX1, TBX2, TBX4, TBX5,
TBX15, TBX20, TBX21) within the JASPAR database (University of Copenhagen Centre for
Molecular Medicine and Therapeutics; http://jaspar.genereg.net) were assessed, and
coordinates that had overlap for all aforementioned related T-box transcription factors were
imported into IGV. DNase I hypersensitivity and RNA polymerase II ChIP tracks were also
imported into IGV. A cutoff threshold of >40 for each coordinate occurring in the RNA pol II
122

123

(POLR2A) ChIA-PET combined dataset in various cell lines was introduced to assess
consistent binding sites. The aforementioned ENCODE tracks are listed in Table 3.3.
The TCGA BRCA, Farmer Breast and Desmedt Breast datasets were interrogated
and data was exported using XenaBrowser (University of California, Santa Cruz;
https://xenabrowser.net/datapages/). The aforementioned datasets are listed in Table 3.3.
The PANTHER database (University of Southern California; http://pantherdb.org) was
used to conduct over-representation analysis using Fischer’s exact test with FDR multiple
test correction and focusing on protein class and Gene Ontology (GO) biological pathways.
Enrichr

pathway

analysis

(Icahn

School

of

Medicine,

Mount

Sinai;

http://amp.pharm.mssm.edu/Enrichr/) was conducted with the input list consisting of 194
genes significantly altered (fold change >1.5, p<0.05) for cells overexpressing either
TBX3iso1 or TBX3iso2 relative to the empty vector control from the normalized RNA-Seq
data. Results assessing Jensen TISSUES expression data are reported.

Table 3.3 – Publicly-available datasets utilized for analysis.
FILE

SOURCE

REFERENCE (or LINK)

POLR2A ChIAPET
DNase I
hypersensitivity
(master list)
TCGA Breast
Cancer (BRCA)

ENCODE:
ENCSR000CAA
ENCODE:
wgEncodeAwgDna
seMasterSites
GDC Project ID:
TCGA-BRCA
•
GEO:
GSE1561

http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encode
DCC/wgEncodeGisChiaPet/

Farmer Breast

Desmedt Breast

GEO:
GSE7390

http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encode
DCC/wgEncodeAwgDnaseMasterSites/
https://portal.gdc.cancer.gov/projects/TCGA-BRCA
Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M et
al. Identification of molecular apocrine breast tumours by
microarray analysis. Oncogene 2005 Jul 7;24(29):466071. PMID: 15897907
Desmedt C, Piette F, Loi S, Want Y et al. Strong time
dependence of the 76-gene prognostic signature for nodenegative breast cancer patients in the TRANSBIG
multicenter independent validation series. Clin Cancer
Res 2007 Jun 1;13(11)3207-14. PMID: 17545524
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Patient Characteristics in Immunohistochemistry Study
Patients with early-stage breast cancer were identified from the London Breast Cancer
Database on the basis of having either DCIS only (Stage 0), or DCIS with an associated
invasive component (Stage I; 2cm, and either pN0 or pN0mi). Cohort 1 consisted of 186
patients with low, intermediate, or high grade DCIS with the aforementioned characteristics
of no invasion or early invasion (Stage 0 or Stage I). Cohort 2 consisted of 118 patients with
non-high grade DCIS with the aforementioned characteristics, with either no invasion or early
invasion (Stage 0 or Stage I). Clinicopathological variables for cohort 1 and cohort 2 patients
entered into this study are listed in Table 3.4, left and right panel, respectively. There was no
overlap between patients in cohort 1 and cohort 2. The study was conducted under a protocol
approved by the Western University Health Sciences Research Ethics Board and the Clinical
Research Impact Committee of Lawson Health Research Institute.
Immunohistochemistry
Formalin-fixed, paraffin embedded tissues were sectioned at 4.0µm and added to a charged
glass slide. Sections were de-paraffinized, rehydrated, and incubated in TBS-Tween or TBSTriton (Tris buffered saline (TBS) + 0.5% Tween-20 for TBX3 and SLUG stains, and TBS +
0.1% Triton-X for TWIST1 stain) for 20 minutes for membrane permeabilization. Heat
induced antigen retrieval was conducted with citrate buffer (pH 6.0) for 20 minutes. The
UltraVision LP Detection System (Thermo Fischer Scientific, TL-015-HD) was used with
optimization of incubation length. Endogenous peroxidase activity was blocked for 10
minutes for all samples. For the TBX3 stain, slides were blocked for 5 minutes, incubated in
TBX3 primary antibody (Abcam, ab99302) at 1/200 dilution for 15 minutes at room
temperature, and 11 minutes in the HRP polymer. For the SLUG stain, slides were blocked
for 6 minutes using the UltraVision protein block and an additional 30 minutes using the Dako
protein block (Dako, CD310081) in order to reduce non-specific background staining. Slides
were incubated in SLUG primary antibody (Abcam, ab27568) at 1/750 dilution for 70 minutes
at room temperature, and 15 minutes in the HRP polymer. For the TWIST1 stain, slides were
blocked for 6 minutes, incubated in TWIST1 primary antibody (Abcam, ab50887) at 1/200
dilution for 1 hour at room temperature, 10 minutes in primary antibody enhancer, and 15
minutes in the HRP polymer. Signal for all markers was developed using DAB and slides
were counter-stained in Harris’s Hematoxylin.
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Quantification of Immunohistochemistry
Slides were stained and scanned using an Aperio AT2 slide scanner (Leica Biosystems). Full
scanned digital slides were analyzed by an anatomical pathologist (blinded as to the
diagnosis) and representative images were captured at 20x magnification using the Aperio
ImageScope slide viewing software. Each image represented one of four tissue
compartments including benign non-columnar cells, benign columnar cell lesions (CCLs;
includes columnar cell change, columnar cell hyperplasia or flat epithelial atypia), ductal
carcinoma in situ (DCIS), and invasive cancer. The expression of each molecular marker
was assessed using the ImmunoRatio plugin (University of Tampere, Finland) for ImageJ to
assess percentage of positive cells. For each image, the cell type of interest was solely
analyzed and the remaining cells (i.e. stromal cells) were cropped out. A control slide
representing serial sections was run for each batch of slides (with quantification and
statistical analysis) to ensure identical and reproducible staining for each run.
Statistical Analysis
Statistical analyses were conducted using GraphPad Prism 5. One-way ANOVAs were used
for experiments containing three or more groups, with either a Tukey or Dunnett’s post-hoc
test. T-tests were used for experiments containing two groups. Error bars represent standard
deviation. P-values less than 0.05 were considered statistically significant.
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3.3

Results
TBX3 overexpression is associated with an invasive and EMT
phenotype.

To examine the role of TBX3 in breast cancer, non-invasive 21NT cells (which endogenously
express low levels of TBX3) were stably transfected with either an empty vector, TBX3iso1
or TBX3iso2. Isoform specific up-regulation was confirmed at the mRNA level using isoform
specific primers, in addition to up-regulation of total TBX3 protein levels (Figures 3.3.1 A-B
and Appendix 1A). Functionally, up-regulation of either TBX3 isoform in DCIS-like 21NT cells
led to an increase in migration using the wound scratch assay (Appendix 2A). TBX3
overexpressing 21NT cells also exhibited reduced cell-to-cell adhesion in vitro (Appendix
2B). In the presence of calcium ions (+CaCl2), or after adding increasing doses of EDTA to
chelate free calcium, there were reduced levels of cell-to-cell adhesion, implying that several
cell-adhesion molecules may be involved (not solely Ca2+ dependent cadherins). As TBX3
has previously been shown to directly down-regulate E-cadherin (CDH1) in melanoma lines
(Rodriguez et al., 2008), and as loss of E-cadherin has been associated with the switch to
an EMT phenotype, we assessed E-cadherin expression by immunofluorescence. We
confirmed a down-regulation of E-cadherin protein levels as well as decreased membrane
localization with TBX3 overexpression (Appendix 2C).
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Figure 3.3.1 – TBX3 overexpression is associated with an invasive and EMT
phenotype.
(A) Total TBX3 protein levels were assessed by western blot in 21NT transfectant cells. (B)
Total TBX3, TBX3iso1, and TBX3iso2 transcript levels were assessed by qRT-PCR in 21NT
transfectant cells, normalized to GAPDH expression levels, and depicted as fold change
relative to the empty vector control. Means derived from three biological replicates were used
during analysis. (C-D) Assessment of cell extravasation and functional invadopodia formation
in vivo in the chick chorioallantoic membrane (CAM) model. Green (CMFDA) fluorescently
labeled cells were injected into the vasculature of the CAM (50,000 cells each), and the
vasculature was labeled red with lectin-rhodamine at T=0. For cell extravasation, cells were
counted 24 hours post injection in a 1cm2 area across 30 biological replicates. For functional
invadopodia formation, a binary quantification of in vivo invadopodia formation was
conducted 6 hours post cell injection. Cells were deemed positive for invadopodia formation
when they possessed protrusions from the vasculature into the stroma. Values reported
represent the percentage of cells displaying functional invadopodia in vivo across 6 biological
replicates consisting of approximately 30 scanned cells each. (E) In vitro invadopodia
formation assay for assessment of local cell invasion. Cells were added to red fluorescently
labeled gelatin and incubated for 12-24 hours (as optimized) to allow for substrate
degradation. Cells were visualized using labelled phalloidin for identification of cellular Factin cores at sites of local matrix degradation, signifying the presence of invadopodia.
Percentage of cells forming invadopodia was quantified from 4 biological replicates,
assessing invadopodia formation in 10-20 random, non-overlapping fields. (F-G) Protein
expression of EMT markers was assessed by western blot. Protein samples were separated
by 10% SDS-PAGE and quantified by densitometry. Protein levels were normalized to
Vinculin, which served as the loading control for all proteins aside from MMP9 (* secreted
protein); in the latter case, MMP9 levels in the conditioned media samples were normalized
to total protein per lane based on Ponceau staining of the membrane. Where quantification
of western blots are shown, data was acquired through densitometric quantifications across
three biological replicates.
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison
between three groups, and Student’s t-test for comparison between two groups. Error bars
represent standard deviation.
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In order to assess the aggressiveness of the cell lines in an in vivo system, we made
use of the chick embryo chorioallantoic membrane (CAM) model. Fluorescently labeled cells
were injected into the vasculature of chicks at embryonic day 12 and cell extravasation was
assessed as previously described (Kim et al., 2016) (Figure 3.3.1 C). Stable overexpression
of either isoform in 21NT cells resulted in an increase in extravasation within the CAM model.
Extravasation levels were reduced drastically with shRNA-mediated knockdown of TBX3 in
invasive 21MT-1 cells, which natively express TBX3 at high levels (protein levels shown in
Appendix 1B-C). In order to confirm that the cells are indeed better able to exit the
vasculature (and are not simply better able to survive at T=24h), we performed live functional
invadopodia assays within the CAM using confocal microscopy. Six hours after the injection
of fluorescently labeled cells into the vasculature of chick embryos, rhodamine-labelled lectin
was injected to visualize the vessel lumen and a binary quantification of invadopodia
formation was conducted (Figure 3.3.1 D). An increase in functional invadopodia was
observed with overexpression of either TBX3 isoform in 21NT cells. Furthermore, the
presence of functional invadopodia was reduced with TBX3 knockdown in 21MT-1 cells.
Changes to rates of invadopodia formation were also verified using a standard in vitro
invadopodia formation assay (Figure 1E), which mirrored the in vivo CAM data obtained.
More invasive phenotypes were also observed using transient transfections of
TBX3iso1 or TBX3iso2 into T47D (luminal A; ER+/PR+/HER2-), SKBR3 (HER2-enriched;
ER-/PR-/HER2+), and MDA-MB-468 (basal-like; ER-/PR-/HER2-) breast cancer cell lines,
representing different molecular subtypes (Appendix 3A-C). Collectively, this suggests that
these findings have broad applicability and are not cell-type specific.
The functional alterations associated with TBX3 isoform overexpression here suggest
a more invasive, epithelial-mesenchymal transition (EMT) phenotype. We examined the
expression of several EMT markers and observed alterations in multiple proteolytic enzymes
and their inhibitors (MMP9, MMP14, uPA up-regulated; CST6, down-regulated), as well as
EMT-associated

transcription

factors

(TWIST1,

SLUG

up-regulated)

with

stable

overexpression of either TBX3 isoform. These were confirmed at both the mRNA and protein
levels (Figure 3.3.1 F-G and Appendix 4A). We observed an increase in levels of active
MMP2, as assayed by gelatin zymography (Appendix 4B), indicating functional activation of
pathways involved in substrate degradation and invasiveness
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TBX3 overexpression leads to an alteration of mesenchymal transcript
levels and direct up-regulation of SLUG.
To examine transcriptional changes associated with TBX3 isoform overexpression and
elucidate mechanisms involved, RNA-Seq was conducted for TBX3iso1 and TBX3iso2
overexpressing cell lines. Ingenuity Pathway Analysis (IPA) indicated that the top predicted
functional changes associated with the unique transcriptional profiles obtained for the TBX3
transfectants include alterations in cellular movement, cellular growth and proliferation, cell
death, cell survival and cancer-associated processes (Figure 3.3.2 A). Enrichment analysis
(Enrichr) was conducted, with the input list consisting of genes significantly altered (>1.5 fold
up or down, FDR<0.05) for cells overexpressing either TBX3iso1 or TBX3iso2 relative to the
empty vector control. Comparison to the Jensen TISSUES expression database of largescale tissue expression profiles revealed mesenchymal genes as most enriched (Figure 3.3.2
B). The dbEMT database (Zhao et al., 2015) was used to compile a list of 377 EMT-related
genes for analysis of RNA-Seq data. Relative to the empty vector, alterations in abundance
of a large proportion of EMT-related genes were detected with TBX3 isoform overexpression
(Figure 3.3.2 C).
To determine whether the TBX3-dependent changes in gene expression are direct,
chromatin immunoprecipitation (ChIP) experiments were conducted using either an antiTBX3 antibody or rabbit IgG antibody as a non-specific control for background, and
immunoprecipitated DNA was hybridized to Affymetrix Promoter 1.0R arrays. Using this
approach we identified 5652 and 5512 specific binding sites for TBX3iso1 and TBX3iso2,
respectively. Further comparison of TBX3 binding sites with our expression analysis
identified 194 genes that were directly regulated by both TBX3 isoforms (>1.5 fold up or
down, FDR<0.05) (Figure 3.3.2 D). These 194 genes were analyzed using the PANTHER
database by conducting over-representation analysis and focusing on protein class
(Appendix 5). The lowest p-value and corrected FDR statistic corresponded to the protease
inhibitor protein class. Several other protein classes related to EMT were also altered,
including extracellular matrix proteins, metalloproteases, and serine protease inhibitors.
Importantly, within this list of 194 genes directly induced by TBX3 was SLUG (encoded by
the SNAI2 gene), a transcriptional regulator and potent inducer of EMT, that may provide a
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mechanism for the previously described EMT and invasion-associated functional changes in
the TBX3-transfected cells.
Both TBX3 isoforms were shown to bind near an intron/exon junction of the SNAI2
(SLUG) gene based on the ChIP-array data (Figure 3.3.2 E). TBX3 has previously been
shown to bind to the consensus T-box binding element (TBE) in several different contexts
(Coll et al., 2002b). Consensus TBEs were investigated using the JASPAR database of
transcription factor binding sites by assessing predicted binding coordinates of highly
conserved T-box proteins (Figure 3.3.2 E). A highly conserved TBE was found within the
SNAI2 (SLUG) gene region that coincides with binding of both TBX3 isoforms in the ChIParray dataset. We conducted ChIP qRT-PCR validation, using ChIP primers spanning this
identified TBE. Published primer sequences were used for the transcription start site (CDH1
TSS) and coding region (CDH1 coding) of E-cadherin (Rodriguez et al., 2008), representing
positive and negative controls, respectively (Figure 3.3.2 F). With TBX3 overexpression,
there was a 3-4-fold enrichment of TBX3 protein bound to the conserved TBE of the SNAI2
(SLUG) gene. Interestingly, this binding region overlaps with a DNase I hypersensitive region
and RNA polymerase II binding region, which is suggestive of open and transcriptionally
active chromatin (Figure 3.3.2 E).
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Figure 3.3.2 – TBX3 overexpression leads to an alteration of mesenchymal transcript
levels and direct up-regulation of SLUG.
Total mRNA was isolated from 21NT+EV, 21NT+TBX3iso1 and 21NT+TBX3iso2 cells in
duplicate and examined by RNA-Seq. (A) Pathway Analysis was conducted using all output
RNA-Seq data for TBX3iso1 and TBX3iso2 overexpressing cells and compared to the empty
vector control. (B) Enrichment analysis was conducted with the input list consisting of genes
significantly altered (fold change >1.5, FDR<0.05) for cells overexpressing either TBX3iso1
or TBX3iso2 relative to the empty vector control. Results comparing resultant RNA-Seq
profiles with the Jensen tissue dataset and lowest p-value tissue sites are shown. (C) Heat
map of EMT genes. The dbEMT database was used to compile a list of 377 EMT genes and
hierarchial clustering was conducted of RNA-Seq data. Duplicate samples are shown for
each cell line. (D) Chromatin Immunoprecipitation (ChIP) experiments were conducted with
either specific anti-TBX3 antibody or a nonspecific rabbit IgG control antibody.
Immunoprecipitated DNA was hybridized to an Affymetrix Promoter Array. Datasets from
RNA-Seq and ChIP-array experiments were integrated in order to examine the effects of
TBX3 isoform binding on gene transcript levels (all fold change >1.5, FDR<0.05). (E) RNASeq reads across the SNAI2 (SLUG) gene for 21NT+EV, 21NT+TBX3iso1 and
21NT+TBX3iso2 cell lines are shown in the top three lines, followed by the identified TBX3
ChIP array binding site. Binding sites for highly conserved T-box proteins within the SNAI2
(SLUG) gene were assessed using the Jaspar database of transcription factor binding sites.
Highly conserved T-box binding elements (TBEs) are shown. DNAse I hypersensitivity and
RNA polymerase II binding sites are shown in the bottom two lines. (F) TBX3 binds directly
to the SNAI2 (SLUG) gene. ChIP experiments were conducted with either a specific antiTBX3 antibody or a nonspecific rabbit IgG control antibody. Relative amounts of
immunoprecipitated DNA were assessed by qRT-PCR, using published sequences of the Ecadherin (CDH1) coding region and transcription start site (TSS) as negative and positive
controls, respectively. The SLUG primers used spanned both the predicted overlapping TBE
site identified in silico and the identified binding site from ChIP-array experiments. Values
shown represent input-adjusted, IgG control subtracted values for the specific TBX3 IP
normalized to the empty vector control. Means derived from four biological replicates were
used during analysis. *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey posthoc for comparison between three groups. Error bars represent standard deviation.
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SLUG up-regulation by TBX3 is essential for increased migration and
invasion.
We have shown that TBX3iso1 and TBX3iso2 directly bind to a consensus TBE within the
SNAI2 (SLUG) gene and leads to its transcriptional up-regulation. Given the strong evidence
within existing literature of SLUG involvement in the induction of EMT (De Craene and Berx,
2013, Phillips and Kuperwasser, 2014), we proceeded to investigate whether SLUG was
essential for the phenotypes observed with TBX3 overexpression. SLUG levels were
efficiently knocked down in 21NT control and TBX3 transfectant cell lines using stable
shRNA-mediated lentiviral transduction (Figure 3.3.3 A-B). In the scramble control (SCR),
cells overexpressing either TBX3iso1 or TBX3iso2 had higher rates of migration and invasion
relative to the empty vector control, similar to levels we previously reported in these cell lines
(Krstic et al., 2016). With SLUG knockdown, the rates of migration and invasion of TBX3
isoform transfectants were reduced to baseline levels, despite expressing high levels of
TBX3 (Figure 3.3.3 C-D).
A large proportion (7/10) of our previous list of EMT and invasion-associated genes
were still significantly altered with high TBX3 isoform expression in cells with SLUG
knockdown (Figure 3.3.3 E-F). However, the induction of several key invasivenessassociated genes up-regulated by TBX3 was significantly impaired in the absence of SLUG,
including MMP14, vimentin and fibronectin (Figure 3.3.3 E-F). Importantly, these findings
suggest that there are TBX3-induced changes in expression of EMT-related genes that are
both SLUG-dependent and SLUG-independent, and that the SLUG-dependent changes are
required (although not necessarily sufficient) for TBX3-induced migration and invasion.
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Figure 3.3.3 – SLUG up-regulation by TBX3 is essential for increased migration and
invasion.
(A) Western blot analysis showing knockdown of SLUG protein expression in shRNA
transductants. Protein levels were normalized to Vinculin, which served as the loading
control. (B) SLUG transcript levels were assessed by qRT-PCR, normalized to RPLP0
expression levels, and depicted as fold change relative to the empty vector control. (C-D)
Migration and invasion assays were conducted using 8.0µm pore transwells coated with
either gelatin (migration) or Matrigel (invasion). Cells were allowed to migrate or invade for
22 hours. The number of cells that migrated or invaded per high power field are shown.
Means derived from four biological replicates were used during analysis. (E) Protein
expression levels of EMT and invasion-associated genes were assessed by western blot.
Protein samples were separated by 10% SDS-PAGE and normalized to Vinculin, which
served as the loading control for all proteins. (F) The mRNA expression of several EMT and
invasion-associated genes was evaluated by qRT-PCR. Expression was normalized to
RPLP0 transcript levels and is depicted as fold change relative to the empty vector
shScramble control (+EV+SCR). Means derived from three biological replicates were used
during analysis. *p<0.05, **p<0.01, ***p<0.001 by either one-way ANOVA with Tukey posthoc or two-way ANOVA with Tukey post-hoc for comparison within and between sub-groups,
respectively. Error bars represent standard deviation.
135

136

TBX3 expression is elevated in low-grade, hormone-receptor positive
invasive breast cancers and associated precursor lesions.
Based on the association between TBX3 and an invasive and EMT phenotype in vitro and in
vivo in chick embryo assays, along with a direct link to SLUG signaling, we extended our
studies to human patient samples. To first assess the expression levels of TBX3, we focused
on nuclear TBX3 expression by immunohistochemistry in 186 pre-invasive (Stage 0, DCIS
only) and early invasive breast cancer (Stage I, invasion ≤2.0 cm) patient samples from the
London Breast Cancer Database. Clinicopathologic variables for cohort 1 patients entered
into this study are listed in Table 3.4 (left panel). We examined 4 sub-populations of cells
including 1) benign non-columnar, 2) benign columnar, 3) DCIS, and 4) invasive cancer, after
observing high expression of TBX3 in benign columnar cells (Figure 3.3.4 A). Earlier studies,
based on genome sequencing data and mutational association, suggest that columnar cell
lesions (CCL; includes columnar cell change, columnar cell hyperplasia, flat epithelial atypia
(FEA)) may be an early morphologic indicator of propensity for, or non-obligate precursor to
the development of breast cancer (Dabbs et al., 2006, Turashvili et al., 2008). We did not
see a significant association between level of TBX3 in the DCIS and the presence vs.
absence of invasion in cohort 1. We confirmed an association between TBX3 and estrogen
receptor (ER) and progesterone receptor (PR) expression in invasive breast cancers (Figure
3.3.4 B-C), which has been suggested by previous studies (Fillmore et al., 2010). TBX3
positivity was highest in low and intermediate grade DCIS and significantly lower in highgrade DCIS (Figure 3.3.4 D). We then examined a second independent patient cohort of 118
patients with non-high-grade (low and intermediate grade) DCIS, with or without associated
early invasive cancer (Stage 0 and Stage I) for increased power in evaluation of TBX3
association with invasiveness of low-grade breast cancers. Clinicopathologic variables for
cohort 2 patients entered into this study are listed in Table 3.4 (right panel). Based on results
from our second cohort assessing patient samples with early invasion, we found that nuclear
TBX3 expression by immunohistochemistry in the DCIS was associated with the size of the
invasive focus (p<0.001) (Figure 3.3.4 E).
Possible downstream effectors of TBX3 were identified in our ChIP-array and RNASeq studies. We conducted immunohistochemical staining for EMT transcription factors
SLUG and TWIST1 (which were shown to be directly and indirectly up-regulated by TBX3,
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respectively) in our second patient cohort (staining patterns shown in Figure 3.3.4 A).
Expression of each marker was assessed in all four cell populations in the same manner as
for TBX3. We identified a positive correlation between TBX3 expression and both SLUG
(p<0.05) and TWIST1 (p<0.001) expression in the invasive component (Figure 3.3.4 F-G).
Additionally, both SLUG and TWIST1 protein levels were up-regulated in CCLs, and SLUG
levels were significantly higher in low grade (Grade 1) DCIS lesions relative to both Grade
1+2 (mixed) and Grade 2 DCIS lesions (Figure 3.3.4 H), exhibiting staining patterns similar
to TBX3. Collectively, these results suggest that TBX3 may be facilitating the process of early
invasion even at the earliest stages of progression (i.e. CCLs, DCIS), and offer potential roles
for downstream EMT-related proteins such as SLUG and TWIST1 in invasiveness of early
stage breast cancer.
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Table 3.4 – Clinicopathologic variables for patients entered into this study.
Characteristic
Total
Age (yr)
≤50
>50
Associated invasion
No invasion
Micro-invasion
Invasion
Histological type of invasive cancer
Total cases with invasion
NST
NST with lobular features
NST with tubular features
NST with mucinous features
NST with micropapillary features
Invasive lobular carcinoma
Invasive tubular carcinoma
Invasive mucinous carcinoma
IMC histologic grade
Total cases with invasion
Low
Intermediate
High
DCIS nuclear grade
Total cases with DCIS
Low
Low + Intermediate
Intermediate
High
Hormone receptor status *
ER positive
PR positive
HER2 positive
Recurrence
No recurrence
Yes recurrence
Invasive recurrence
Non-invasive recurrence
Unknown
Micro-metastasis

COHORT 1
No. of patients (%)
186 (100)

COHORT 2
No. of patients (%)
118 (100)

17 (9.1)
169 (90.9)

14 (11.9)
104 (88.1)

100 (53.8)
12 (6.5)
74 (39.8)

84 (71.2)
2 (1.7)
32 (27.1)

74 (100)
55 (74.3)
9 (12.2)
3 (4.1)
3 (4.1)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)

34 (100)
26 (76.5)
3 (8.8)
3 (8.8)
0 (0.0)
0 (0.0)
0 (0.0)
1 (2.9)
1 (2.9)

74 (100)
26 (35.1)
36 (48.6)
12 (16.2)

34 (100)
16 (47.1)
18 (52.9)
0 (0.0)

100 (100)
10 (10.0)
0 (0.0)
41 (41.0)
49 (49.0)

118 (100)
16 (13.6)
44 (37.3)
58 (49.2)
0 (0.0)

66/82 (80.5)
52/71 (73.2)
16/57 (28.1)

33/34 (97.1)
29/34 (85.3)
3/34 (8.8)

162 (87.1)
13 (7.0)
10 (76.9)
3 (23.1)
11 (5.9)
8 (4.3)

0 (0.0)

0 (0.0)

Table 3.4. Clinicopathologic variables for patients entered into Cohort 1 and 2.
NST, no special type; IMC, invasive mammary carcinoma; DCIS, ductal carcinoma in situ;
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor
2; *only available for patients with IMC
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Figure 3.3.4 – TBX3 expression is elevated in low-grade, hormone-receptor positive
invasive breast cancers and associated precursor lesions.
Patient samples representing Cohort 1 were immunohistochemically stained and assessed
for nuclear TBX3 expression, and Cohort 2 samples were stained and assessed for nuclear
TBX3, SLUG and TWIST1 expression. (A) Representative expression and staining patterns
of Cohort 2 samples (TBX3 expression and staining patterns were similar in Cohort 1; not
shown). (B-D) Nuclear TBX3 expression was assessed by immunohistochemistry in Cohort
1, consisting of 186 patients with early-stage breast cancer (all nuclear grades) identified
from the London Breast Cancer Database on the basis of having either DCIS only (Stage 0),
or DCIS with an associated early invasive component (Stage I; 2cm, and either pN0 or
pN0mi). Nuclear TBX3 expression was compared across ductal epithelial cell types (benign
non-columnar, benign columnar, DCIS and invasive mammary carcinoma). The association
between TBX3 expression and (B) estrogen receptor (ER), (C) progesterone receptor (PR),
and (D) DCIS nuclear grade is shown. (E-H) Nuclear TBX3, SLUG and TWIST1 expression
was assessed by immunohistochemistry in Cohort 2, consisting of 118 patients with nonhigh-grade (nuclear grade 1 or 2) DCIS lesions, with or without associated early invasive
cancer (Stage 0 or Stage I). Expression levels were compared across ductal epithelial cell
types and clinical data. (E) Correlation analysis for nuclear TBX3 expression and size of the
invasive focus in patients with Stage I breast cancer. (F-G) Correlation analysis of
TBX3/SLUG expression and TBX3/TWIST1 expression in the invasive carcinoma. (H)
Association between nuclear SLUG expression and DCIS nuclear grade.
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison
between three groups, and Student’s t-test for comparison between two groups. Correlation
and p-values were calculated using the Pearson correlation statistic. Error bars represent
standard deviation.
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Elevated TBX3 levels are associated with poor prognosis of breast
cancer and are highly correlated with SLUG expression.
To assess the applicability of our findings in a broader breast cancer and pan-cancer context
we compared our findings with that of available transcriptomic datasets. Using the ICGC US
donor cohort, we found that TBX3 mRNA levels are elevated in tumor cells of several cancer
subtypes, including breast cancer (data not shown). By further profiling transcriptomic data
from the TCGA BRCA and the Farmer Breast study (Farmer et al., 2005), we identified an
association of higher TBX3 levels in luminal subtypes of breast cancer, and estrogen receptor
(ER) and progesterone receptor (PR) positive cancers (Figure 3.3.5 A-B). Survival analysis
of luminal A patients in the TCGA BRCA dataset showed a statistically significant difference
in survival (p<0.001) between patients with high and low TBX3 expression relative to the
median (Figure 3.3.5 C).
Our immunohistochemical biomarker analysis revealed a significant positive
correlation between TBX3, SLUG and TWIST1 expression within invasive breast cancer
lesions. To further examine the association between TBX3 and our identified downstream
targets SLUG and TWIST1 and relate it to histopathological grade, we interrogated
transcriptomics datasets with relevant grade information: TCGA BRCA (n=680 with grade
information) and Desmedt (n=196, node-negative breast cancers, all with grade information
(Desmedt et al., 2007)). TBX3 and SLUG mRNA levels were significantly lower in high-grade
breast cancers relative to low and intermediate-grade breast cancers (Figure 3.3.5 D)
(p<0.001), consistent with our immunohistochemical data. The Desmedt dataset also
showed reduced TWIST1 levels in high-grade breast cancers. There was a high degree of
overlap between TBX3 and SLUG in terms of patient characteristics and lesion types
identified in our immunohistochemical staining and within the transcriptomics datasets.
Additionally, upon examination of the TCGA TARGET GTEx dataset, we observed high coexpression of SLUG and TBX3 in 19,120 normal and tumor samples represented, and tight
association with MMP14 with high expression of both transcription factors (Figure 3.3.5 E).
Collectively, analysis of publicly available data further supports the association and likely
involvement of TBX3, along with downstream EMT transcription factors SLUG and TWIST1
in aggressiveness of low-grade breast cancers.
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Figure 3.3.5 – Elevated TBX3 levels are associated with poor prognosis of breast
cancer, and are highly correlated with SLUG expression.
(A-B) TBX3 expression was assessed across tumor characteristics in deposited
transcriptomics data consisting of the Farmer Breast and TCGA BRCA cohorts. TBX3 mRNA
expression by molecular subtype was further investigated in the TCGA BRCA dataset. (C)
Kaplan Meier survival curves for luminal A patients (ER+ PR+ HER2-) from the TCGA BRCA
dataset, separated into high (above median) vs. low (below median) TBX3 expression.
Number of events (breast cancer related deaths) are shown in the associated table. (D)
Expression of TBX3, SLUG and TWIST1 was assessed in the TCGA BRCA and Desmedt
datasets to compare expression levels across grades. Data shown represent mediancentered, z-score normalized values. (E) Correlation of SLUG, TBX3 and MMP14 expression
was assessed in the TCGA Target GTEx dataset, consisting of 19,120 normal and tumor
patient samples.
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison
between three groups. Survival analysis for Kaplan-Meier curve was calculated using the logrank test statistic. Correlation and p-values were calculated using the Pearson correlation
statistic. Error bars represent standard deviation.
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Figure 3.3.6 – TBX3 promotes progression of pre-invasive breast cancer cells by
inducing EMT and directly up-regulating SLUG.
Proposed model through which TBX3 promotes progression of pre-invasive ductal carcinoma
in situ (DCIS) lesions. TBX3 levels are low in benign non-columnar ductal breast epithelial
cells. In columnar cell lesions (CCLs), expression of TBX3 levels are up-regulated, with a
concomitant increase in SLUG and TWIST1 expression levels. This is predicted to promote
proliferation and plasticity of early, pre-invasive lesions. In a subset of low-grade DCIS, TBX3
expression is particularly high. Overexpression of TBX3 induces altered expression of
several proteases and protease inhibitors, leading to degradation of the basement membrane
and priming for early invasion of DCIS into adjacent stroma. These events are facilitated by
TBX3-induced and SLUG-dependent expression of pro-migratory molecules such as MMP14
(membrane-bound), fibronectin (extracellular matrix), and vimentin (intracellular).
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3.4

Discussion

The use of screening mammography over the past four decades has drastically increased
our ability to detect DCIS (Kerlikowske, 2010), but has been criticized as causing an overdiagnosis of breast cancer (Miller et al., 2014). Gene expression profiling has allowed for the
successful stratification of node-negative invasive breast cancer patients into low-risk and
high-risk groups, providing information useful in clinical decision-making for this population
(van 't Veer et al., 2002). These techniques have been extended to DCIS with some success
(Solin et al., 2013, Bartlett et al., 2014, Rakovitch et al., 2015). Additionally, panels of selected
markers, including p16, COX2 and Ki67 have shown some utility in their ability to predict
behaviour of DCIS in specific subsets of patients (Kerlikowske et al., 2010). Despite these
efforts, there are few validated diagnostic tests or biomarkers to aid in optimization of
treatment strategies for women with DCIS, and none that reliably predict risk for invasion,
leading to the possibility of both over-treatment and under-treatment of this subpopulation.
We have previously established a role for the transcriptional regulatory protein TBX3
in invasiveness of breast cancer (Krstic et al., 2016). In this current study we further explored
the mechanism of this activity, particularly as associated with the phenomenon of EMT. We
sought to take a high-resolution approach to identifying downstream targets of TBX3,
beginning with identification of transcriptomic changes with TBX3 overexpression and
assessment of direct TBX3 binding sites. From these initial genomic studies, we identified
SLUG and TWIST1 as potential downstream effectors up-regulated with TBX3
overexpression, and SLUG as a direct downstream mediator of TBX3-induced migration and
invasion. Importantly, we have discerned expression differences in these proteins between
benign non-columnar ductal epithelial cells, columnar cell lesions (CCLs), DCIS, and within
the invasive carcinoma. Our examination of TBX3 expression by immunohistochemistry in
two independent patient cohorts revealed that expression is highest in hormone receptor
positive, low-grade DCIS (and co-existing columnar cell lesions) and is associated with the
extent of invasion in early-stage breast cancers. These findings, coupled with our in vitro data
of an EMT-link, are consistent with a role for the TBX3 transcription factor in early invasion
events, likely working in conjunction with other EMT-related factors such as SLUG and
TWIST1, to facilitate a phenotype conducive to invasion.
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The prevailing breast cancer progression model supported by numerous genomic and
transcriptomic studies includes two divergent molecular pathways of progression – the lowgrade (ER+/PR+) and high-grade (ER-/PR-) pathway (Bombonati and Sgroi, 2011). Only a
subset of DCIS within each pathway will progress to invasive cancer. Interestingly,
sequencing and hierarchical clustering of DCIS and invasive samples has shown that
samples do not cluster by diagnosis, but rather by intrinsic molecular subtype (Muggerud et
al., 2010). This suggests that factors associated with invasiveness are distinct from histologic
grade and stage, and may indeed be present within the pre-invasive DCIS (Muggerud et al.,
2010).
Our proposed model of the stage-specific role of TBX3 in early breast cancer
progression is depicted in Figure 3.3.6. As observed in our immunohistochemical studies,
expression of EMT-related transcription factors (including TBX3) is low in benign noncolumnar breast epithelium. We have identified that TBX3 levels are significantly elevated in
CCLs. This is in accordance with existing studies examining patterns of gene expression
changes through breast cancer progression showing up-regulation of several malignancyassociated genes at the pre-invasive stage (Ma et al., 2003). This pro-EMT phenotype in
CCLs, with concomitant up-regulation of SLUG and TWIST1, is predicted to promote
proliferation and plasticity of the breast epithelial cells (De Craene and Berx, 2013). There is
accumulating evidence that CCLs, and in particular the CCL variant termed ‘flat epithelial
atypia’ (FEA), may be non-obligate precursors to the development of breast cancer (Dabbs
et al., 2006, Turashvili et al., 2008). Only some columnar cell lesions progress, even though
TBX3 and EMT transcription factors SLUG and TWIST1 are expressed in most (at least when
observed in association with DCIS). This suggests that there are likely other changes that
act in concert to allow for progression to occur.
In our present study, the significant level of enrichment of proteases, protease
inhibitors and enzyme modulators in RNA-Seq and ChIP-array datasets of DCIS-like 21NT
cells overexpressing TBX3 is consistent with the propensity to break down basement
membrane and invade. Previous studies have suggested that the gradual loss of basement
membrane, leading to changes in cell organization and polarity (rather than the acquisition
of additional mutations) is the main driver in the transition from an in situ to invasive
phenotype (Hu et al., 2008). We have confirmed up-regulation of MMP14 and urokinase-type
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plasminogen activator (uPA), and down-regulation of CST6 by qRT-PCR and western blot
analysis. Consistent with this, uPA and MMP14 overexpression have been shown to be
strong and independent predictors of breast cancer survival (Look et al., 2002, Têtu et al.,
2006). Furthermore, CST6 has been shown to be down-regulated in breast cancer
progression, with promoter hypermethylation documented at the DCIS stage (Ai et al., 2006).
We have shown that induction of MMP14 with TBX3 overexpression is a SLUG-dependent
process, and this signaling cascade may be important for TBX3-induced migration and
invasion. In keeping with this, it has been previously reported that MMP14 is among the main
regulators of the basement membrane transmigration process in vivo (Hotary et al., 2006),
likely due to MMP14 dependent activation of the main type IV collagenase MMP2 (Duffy et
al., 2000). Importantly, we have shown increased activity of MMP2 with TBX3
overexpression. Additionally, increased expression of several proteases has been shown to
indirectly enhance the activity of EMT transcription factors, leading to a positive feedback
loop (De Craene and Berx, 2013), potentially resulting in high expression levels of EMT
transcription factors and proteases as we have observed both in vitro and in our two patient
cohorts.
In conclusion, we propose a unique pathway in which TBX3 promotes progression
through advancement of low-grade DCIS to invasive carcinoma (Figure 3.3.6). Our proposed
model is particularly relevant in the non-high grade, ER-positive pathway of progression.
Overexpression of TBX3 at early pre-invasive stages (CCL, DCIS) of breast cancer
progression, inducing other molecular regulators of EMT (including SLUG and TWIST1), acts
as an enabler to set the stage for basement membrane breakdown and invasion into adjacent
stroma. Further validation of our findings in an independent cohort of Stage 0 and Stage I
breast cancer patients and comparison with follow-up data should be conducted in order to
assess whether TBX3 expression may provide reliable risk stratification for patients
diagnosed with DCIS, possibly in concert with multiple biomarkers such as Ki67, p16, COX2,
and/or multi-parameter gene expression assays (Kerlikowske et al., 2010, Bartlett et al.,
2014). As T-box proteins such as TBX3 have been shown to have detrimental effects with
respect to cancer progression and survival, a thorough understanding of the underlying
mechanisms involved is crucial.

147

148

3.5 References
Artym, V. V., Yamada, K. M. and Mueller, S. C. (2009) 'ECM degradation assays for analyzing local cell
invasion', Methods Mol Biol, 522, pp. 211-9.
Band, V., Zajchowski, D., Swisshelm, K., Trask, D., Kulesa, V., Cohen, C., Connolly, J. and Sager, R. (1990)
'Tumor progression in four mammary epithelial cell lines derived from the same patient', Cancer Res,
50(22), pp. 7351-7.
Bartlett, J. M., Nofech-Moses, S. and Rakovitch, E. (2014) 'Ductal carcinoma in situ of the breast: can
biomarkers improve current management?', Clin Chem, 60(1), pp. 60-7.
Bombonati, A. and Sgroi, D. C. (2011) 'The molecular pathology of breast cancer progression', J Pathol,
223(2), pp. 307-17.
Burgucu, D., Guney, K., Sahinturk, D., Ozbudak, I. H., Ozel, D., Ozbilim, G. and Yavuzer, U. (2012) 'Tbx3
represses PTEN and is over-expressed in head and neck squamous cell carcinoma', BMC Cancer,
12, pp. 481.
Burstein, H. J., Polyak, K., Wong, J. S., Lester, S. C. and Kaelin, C. M. (2004) 'Ductal carcinoma in situ of the
breast', N Engl J Med, 350(14), pp. 1430-41.
Coll, M., Seidman, J. G. and Müller, C. W. (2002) 'Structure of the DNA-bound T-box domain of human TBX3,
a transcription factor responsible for ulnar-mammary syndrome', Structure, 10(3), pp. 343-56.
Dabbs, D. J., Carter, G., Fudge, M., Peng, Y., Swalsky, P. and Finkelstein, S. (2006) 'Molecular alterations in
columnar cell lesions of the breast', Mod Pathol, 19(3), pp. 344-9.
De Craene, B. and Berx, G. (2013) 'Regulatory networks defining EMT during cancer initiation and
progression', Nat Rev Cancer, 13(2), pp. 97-110.
Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y.,
d'Assignies, M. S., Bergh, J., Lidereau, R., Ellis, P., Harris, A. L., Klijn, J. G., Foekens, J. A., Cardoso,
F., Piccart, M. J., Buyse, M., Sotiriou, C. and Consortium, T. (2007) 'Strong time dependence of the
76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter
independent validation series', Clin Cancer Res, 13(11), pp. 3207-14.
Diaz, L. K. and Sneige, N. (2005) 'Estrogen receptor analysis for breast cancer: current issues and keys to
increasing testing accuracy', Adv Anat Pathol, 12(1), pp. 10-9.
Duffy, M. J., Maguire, T. M., Hill, A., McDermott, E. and O'Higgins, N. (2000) 'Metalloproteinases: role in
breast carcinogenesis, invasion and metastasis', Breast Cancer Res, 2(4), pp. 252-7.
Fan, W., Huang, X., Chen, C., Gray, J. and Huang, T. (2004) 'TBX3 and its isoform TBX3+2a are functionally
distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines',
Cancer Res, 64(15), pp. 5132-9.
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., Macgrogan, G., Bergh,
J., Cameron, D., Goldstein, D., Duss, S., Nicoulaz, A. L., Brisken, C., Fiche, M., Delorenzi, M. and
Iggo, R. (2005) 'Identification of molecular apocrine breast tumours by microarray analysis',
Oncogene, 24(29), pp. 4660-71.

148

149

Fillmore, C. M., Gupta, P. B., Rudnick, J. A., Caballero, S., Keller, P. J., Lander, E. S. and Kuperwasser, C.
(2010) 'Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling', Proc
Natl Acad Sci U S A, 107(50), pp. 21737-42.
Fisher, E. R., Dignam, J., Tan-Chiu, E., Costantino, J., Fisher, B., Paik, S. and Wolmark, N. (1999) 'Pathologic
findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B17: intraductal carcinoma', Cancer, 86(3), pp. 429-38.
Formenti, S. C., Arslan, A. A. and Pike, M. C. (2011) 'Re: Long-term outcomes of invasive ipsilateral breast
tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS', J
Natl Cancer Inst, 103(22), pp. 1723.
Hoogaars, W. M., Barnett, P., Rodriguez, M., Clout, D. E., Moorman, A. F., Goding, C. R. and Christoffels, V.
M. (2008) 'TBX3 and its splice variant TBX3 + exon 2a are functionally similar', Pigment Cell
Melanoma Res, 21(3), pp. 379-87.
Hotary, K., Li, X. Y., Allen, E., Stevens, S. L. and Weiss, S. J. (2006) 'A cancer cell metalloprotease triad
regulates the basement membrane transmigration program', Genes Dev, 20(19), pp. 2673-86.
Hu, M., Yao, J., Carroll, D. K., Weremowicz, S., Chen, H., Carrasco, D., Richardson, A., Violette, S.,
Nikolskaya, T., Nikolsky, Y., Bauerlein, E. L., Hahn, W. C., Gelman, R. S., Allred, C., Bissell, M. J.,
Schnitt, S. and Polyak, K. (2008) 'Regulation of in situ to invasive breast carcinoma transition', Cancer
Cell, 13(5), pp. 394-406.
Kerlikowske, K. (2010) 'Epidemiology of ductal carcinoma in situ', J Natl Cancer Inst Monogr, 2010(41), pp.
139-41.
Kerlikowske, K., Molinaro, A. M., Gauthier, M. L., Berman, H. K., Waldman, F., Bennington, J., Sanchez, H.,
Jimenez, C., Stewart, K., Chew, K., Ljung, B. M. and Tlsty, T. D. (2010) 'Biomarker expression and
risk of subsequent tumors after initial ductal carcinoma in situ diagnosis', J Natl Cancer Inst, 102(9),
pp. 627-37.
Kim, Y., Williams, K. C., Gavin, C. T., Jardine, E., Chambers, A. F. and Leong, H. S. (2016) 'Quantification of
cancer cell extravasation in vivo', Nat Protoc, 11(5), pp. 937-48.
Krstic, M., Macmillan, C. D., Leong, H. S., Clifford, A. G., Souter, L. H., Dales, D. W., Postenka, C. O.,
Chambers, A. F. and Tuck, A. B. (2016) 'The transcriptional regulator TBX3 promotes progression
from non-invasive to invasive breast cancer', BMC Cancer, 16(1), pp. 671.
Lehr, H. A., Jacobs, T. W., Yaziji, H., Schnitt, S. J. and Gown, A. M. (2001) 'Quantitative evaluation of HER2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with
image analysis', Am J Clin Pathol, 115(6), pp. 814-22.
Lingbeek, M. E., Jacobs, J. J. and van Lohuizen, M. (2002) 'The T-box repressors TBX2 and TBX3
specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator', J Biol
Chem, 277(29), pp. 26120-7.
Lomnytska, M., Dubrovska, A., Hellman, U., Volodko, N. and Souchelnytskyi, S. (2006) 'Increased expression
of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients', Int J Cancer, 118(2),
pp. 412-21.
Ma, X. J., Salunga, R., Tuggle, J. T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker,
K., Zhang, B. M., Zhou, Y. X., Varnholt, H., Smith, B., Gadd, M., Chatfield, E., Kessler, J., Baer, T. M.,
Erlander, M. G. and Sgroi, D. C. (2003) 'Gene expression profiles of human breast cancer
progression', Proc Natl Acad Sci U S A, 100(10), pp. 5974-9.

149

150

Miller, A. B., Wall, C., Baines, C. J., Sun, P., To, T. and Narod, S. A. (2014) 'Twenty five year follow-up for
breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised
screening trial', BMJ, 348, pp. g366.
Mokbel, K. and Cutuli, B. (2006) 'Heterogeneity of ductal carcinoma in situ and its effects on management',
Lancet Oncol, 7(9), pp. 756-65.
Muggerud, A. A., Hallett, M., Johnsen, H., Kleivi, K., Zhou, W., Tahmasebpoor, S., Amini, R. M., Botling, J.,
Borresen-Dale, A. L., Sorlie, T. and Warnberg, F. (2010) 'Molecular diversity in ductal carcinoma in
situ (DCIS) and early invasive breast cancer', Mol Oncol, 4(4), pp. 357-68.
Peres, J. and Prince, S. (2013) 'The T-box transcription factor, TBX3, is sufficient to promote melanoma
formation and invasion', Mol Cancer, 12(1), pp. 117.
Phillips, S. and Kuperwasser, C. (2014) 'SLUG: Critical regulator of epithelial cell identity in breast
development and cancer', Cell Adh Migr, 8(6), pp. 578-87.
Rakovitch, E., Nofech-Mozes, S., Hanna, W., Baehner, F. L., Saskin, R., Butler, S. M., Tuck, A., Sengupta, S.,
Elavathil, L., Jani, P. A., Bonin, M., Chang, M. C., Robertson, S. J., Slodkowska, E., Fong, C.,
Anderson, J. M., Jamshidian, F., Miller, D. P., Cherbavaz, D. B., Shak, S. and Paszat, L. (2015) 'A
population-based validation study of the DCIS Score predicting recurrence risk in individuals treated
by breast-conserving surgery alone', Breast Cancer Res Treat, 152(2), pp. 389-98.
Rodriguez, M., Aladowicz, E., Lanfrancone, L. and Goding, C. R. (2008) 'Tbx3 represses E-cadherin
expression and enhances melanoma invasiveness', Cancer Res, 68(19), pp. 7872-81.
Sagara, Y., Mallory, M. A., Wong, S., Aydogan, F., DeSantis, S., Barry, W. T. and Golshan, M. (2015)
'Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based
Cohort Study', JAMA Surg, 150(8), pp. 739-45.
Savagner, P., Yamada, K. M. and Thiery, J. P. (1997) 'The zinc-finger protein slug causes desmosome
dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal
transition', J Cell Biol, 137(6), pp. 1403-19.
Shan, Z. Z., Yan, X. B., Yan, L. L., Tian, Y., Meng, Q. C., Qiu, W. W., Zhang, Z. and Jin, Z. M. (2015)
'Overexpression of Tbx3 is correlated with Epithelial-Mesenchymal Transition phenotype and predicts
poor prognosis of colorectal cancer', Am J Cancer Res, 5(1), pp. 344-53.
Solin, L. J., Gray, R., Baehner, F. L., Butler, S. M., Hughes, L. L., Yoshizawa, C., Cherbavaz, D. B., Shak, S.,
Page, D. L., Sledge, G. W., Jr., Davidson, N. E., Ingle, J. N., Perez, E. A., Wood, W. C., Sparano, J.
A. and Badve, S. (2013) 'A multigene expression assay to predict local recurrence risk for ductal
carcinoma in situ of the breast', J Natl Cancer Inst, 105(10), pp. 701-10.
Souter, L. H., Andrews, J. D., Zhang, G., Cook, A. C., Postenka, C. O., Al-Katib, W., Leong, H. S.,
Rodenhiser, D. I., Chambers, A. F. and Tuck, A. B. (2010) 'Human 21T breast epithelial cell lines
mimic breast cancer progression in vivo and in vitro and show stage-specific gene expression
patterns', Lab Invest, 90(8), pp. 1247-58.
Thorat, M. A., Parmar, V., Nadkarni, M. S. and Badwe, R. A. (2007) 'Radiation therapy for ductal carcinoma in
situ: is it really worth it?', J Clin Oncol, 25(4), pp. 461-2; author reply 462.
Turashvili, G., Hayes, M., Gilks, B., Watson, P. and Aparicio, S. (2008) 'Are columnar cell lesions the earliest
histologically detectable non-obligate precursor of breast cancer?', Virchows Arch, 452(6), pp. 58998.
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy,
K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S.,
150

151

Bernards, R. and Friend, S. H. (2002) 'Gene expression profiling predicts clinical outcome of breast
cancer', Nature, 415(6871), pp. 530-6.
Wang, H. C., Meng, Q. C., Shan, Z. Z., Yuan, Z. and Huang, X. Y. (2015) 'Overexpression of Tbx3 predicts
poor prognosis of patients with resectable pancreatic carcinoma', Asian Pac J Cancer Prev, 16(4), pp.
1397-401.
Willmer, T., Cooper, A., Peres, J., Omar, R. and Prince, S. (2017) 'The T-Box transcription factor 3 in
development and cancer', Biosci Trends, 11(3), pp. 254-266.
Yarosh, W., Barrientos, T., Esmailpour, T., Lin, L., Carpenter, P. M., Osann, K., Anton-Culver, H. and Huang,
T. (2008) 'TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone
deacetylases', Cancer Res, 68(3), pp. 693-9.
Zhao, M., Kong, L., Liu, Y. and Qu, H. (2015) 'dbEMT: an epithelial-mesenchymal transition associated gene
resource', Sci Rep, 5, pp. 11459.

151

Chapter 4

Isoform-specific promotion of
breast cancer tumorigenicity
by TBX3 involves induction
of angiogenesis

153

Isoform-specific promotion of breast cancer tumorigenicity by
TBX3 involves induction of angiogenesis

SUMMARY OF FINDINGS
TBX3 is a member of the highly conserved family of T-box transcription factors involved in
embryogenesis, organogenesis and tumor progression. While the functional role of TBX3 in
tumorigenesis has been widely studied, less is known about the specific functions of the
different TBX3 isoforms. Through alternative splicing and exon skipping events, TBX3
encodes two isoforms – TBX3iso1 and TBX3iso2. TBX3iso2 contains an additional 20 amino
acid sequence inserted into the DNA binding domain which TBX3iso1 lacks. We report, for
the first time, that TBX3 isoforms have differential tumorigenic potential in nude mouse
xenograft experiments when transfected into non-tumorigenic DCIS-like 21NT cells, with
overexpression of TBX3iso1 more commonly associated with invasive carcinoma. Histologic
examination showed high vascularity of tumors that arise from TBX3iso1 overexpressing
cells. Through transcriptomic analysis of signaling pathways altered with TBX3iso1 and
TBX3iso2 overexpression, we reveal that there are significant differences in angiogenesisrelated

genes.

Importantly,

osteopontin

(OPN),

a

cancer-associated

secreted

phosphoprotein, was shown to be significantly up-regulated with TBX3iso1 overexpression.
This pattern was observed across three non/weakly-tumorigenic breast cancer cell lines
(21PT, 21NT, MCF7). Up-regulation of OPN in TBX3iso1 overexpressing cells resulted in
induction of hyaluronan synthase 2 (HAS2) expression and increased retention of hyaluronan
in pericellular matrices. The described changes involving TBX3iso1-dependent promotion of
angiogenesis may explain the differences in tumor formation rates between TBX3 isoforms
in vivo. Within the TCGA breast cancer cohort, there was an 8.1-fold higher
TBX3iso1/TBX3iso2 ratio in tumors relative to control, and this ratio was positively associated
with tumor grade. This shift of an increased TBX3iso1/TBX3iso2 ratio in tumors relative to
control tissue is observed across several TCGA tumor subtypes that overexpress TBX3.
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4.1 Introduction
TBX3 is a member of the highly conserved family of T-box transcription factors involved in
embryogenesis and organogenesis. Germline mutations or haploinsufficiency of TBX3
results in ulnar-mammary syndrome (UMS, OMIM 181450), characterized by mammary
gland hypoplasia, apocrine gland, dental, and genital defects, emphasizing its broad
expression profile (Bamshad et al., 1999, Bamshad et al., 1997). TBX3 levels are upregulated in several cancer types, including breast (Fan et al., 2004, Lomnytska et al., 2006,
Yarosh et al., 2008, Souter et al., 2010), melanoma (Rodriguez et al., 2008), colorectal (Shan
et al., 2015), pancreatic (Cavard et al., 2009), cervical (Lyng et al., 2006), ovarian (Lomnytska
et al., 2006), gastric (Miao et al., 2016), and prostate cancers (Gudmundsson et al., 2010),
suggesting its potential role as an oncogenic driver in multiple cancer types.
TBX3 is alternatively spliced, leading to two predominant isoforms: TBX3iso1 and
TBX3iso2. TBX3iso2 contains a unique 20 amino acid sequence inserted into the DNA
binding domain attributed to the 2a exon. Addition of the 2a exon within TBX3iso2 shifts
residues critical for TBX3 interaction with DNA (particularly Ser224 and Met225) (Coll et al.,
2002), however, the effect on transcriptional regulation and its functional relevance remains
unclear.
TBX3 isoform ratios have been found to be tissue and species specific (Fan et al.,
2004), with differing relative levels of TBX3iso1/TBX3iso2 reported in several breast cancer
cell lines (Bamshad et al., 1999, Fan et al., 2004). Additionally, the T-box binding domain
which differs between the two TBX3 isoforms has been shown to be important for proteinprotein interactions, facilitating interactions with core histones and chromatin-interacting
proteins such as methyltransferases (Demay et al., 2007, DeBenedittis and Jiao, 2011, Miller
et al., 2008).
Conflicting results have been published regarding functionality of the TBX3 isoforms.
Fan et al. reported that the 20-amino acid addition in TBX3iso2 hinders its binding to a
previously identified T-box element (TBE) through in vitro oligonucleotide binding assays,
suggesting that the protein’s DNA binding is altered (Fan et al., 2004). In a study by Hoogaars
et al., both TBX3 isoforms were able to bind to the TBE in the Nppa and p21 CIP1 promoters,
suggesting that they have similar functions in vitro (Hoogaars et al., 2008). Due to the growing
amount of literature implicating TBX3 in the promotion of tumorigenesis in several cancer
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types (Fan et al., 2004, Lomnytska et al., 2006, Yarosh et al., 2008, Souter et al., 2010,
Rodriguez et al., 2008, Cavard et al., 2009, Lyng et al., 2006, Gudmundsson et al., 2010,
Krstic et al., 2016), it is essential to address the functional relevance of TBX3 isoforms and
their altered expression in cancer.
In this study, we provide evidence for differential tumorigenicity of TBX3 isoforms
through in vivo nude mouse xenograft experiments. Importantly, by conducting high
throughput RNA sequencing, we have shown that TBX3iso1-induced tumorigenicity is
associated with selective up-regulation of angiogenesis-promoting genes, including
osteopontin (OPN), and subsequent induction of hyaluronan synthase 2 (HAS2) expression.
This is accompanied by induction of endothelial cell tubule formation by conditioned media
from TBX3iso1 overexpressing cells in vitro. Increased expression of OPN has been
associated with advanced tumor stage and poor prognosis of breast cancer (Rudland et al.,
2002, Tuck et al., 1998), and both OPN and hyaluronan promote the process of angiogenesis
(Chakraborty et al., 2008, Chakraborty et al., 2006, Takahashi et al., 2002, Cook et al., 2005,
Hirama et al., 2003, Takano et al., 2000, Shijubo et al., 1999, Asou et al., 2001, Pröls et al.,
1998, Koyama et al., 2007, Rooney et al., 1995). Lastly, we utilized the TCGA breast cancer
dataset to determine differential expression of TBX3 isoforms. We found an 8.1-fold higher
TBX3iso1/TBX3iso2 ratio in tumor tissues relative to control. This pattern of an increased
TBX3iso1/TBX3iso2 ratio for tumor tissues relative to control was observed across several
different tumor types which overexpress TBX3. This study is the first of its kind to report
significant functional differences between the two TBX3 isoforms, both in vivo and in vitro.
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4.2 Methods
Cell lines and culture conditions
The 21T series cell lines (21PT, 21NT) were obtained as a gift from Dr. Vimla Band (Dana
Farber Cancer Institute) (Band et al., 1990). The 21PT and 21NT cell lines and transfectants
underwent cell line authentication by Idexx Radil (Case No. 20250-2013). The 21PT and
21NT cell lines were maintained in αMEM media supplemented with 2mM L-glutamine,
1µg/mL insulin, 12.5ng/mL EGF, 2.8µM hydrocortisone, 10mM HEPES, 1mM sodium
pyruvate, 0.1mM non-essential amino acids, 50µg/mL gentamycin sulfate, and 10% FBS.
MCF7 cells were maintained in DMEM media supplemented with 10% FBS. Stable 21PT,
21NT and MCF7 transfectants were maintained in their respective media supplemented with
500µg/mL G418 as a selection marker. All reagents for culture of breast cancer cell lines
were obtained from Wisent Inc. Human neonatal dermal microvascular endothelial cells
(HDMECs) were obtained from Lonza (CC2516; Walkersville, MD). Cells were expanded in
Endothelial Basal Media-2 (EBM-2; Lonza, 00190860) supplemented with 20% FBS and
SingleQuots (Lonza, CC-4176) growth factors. The minimum density for sub-culturing was
maintained at 2500 cells/cm2. Only HDMECs under passage 10 were used for experiments.

Generation of stable transfectant cell lines
Stable transfectants were generated using plasmid constructs previously described (Krstic et
al., 2016), consisting of either an empty vector (EV), TBX3iso1, or TBX3iso2 construct within
a pcDNA3.1 vector (Invitrogen, V79020). Briefly, cells (21PT, 21NT, MCF7) were seeded into
6-well plates at 350,000 cells per well. The following day, cells were transfected using the
Lipofectamine 3000 Transfection Kit (Invitrogen, L3000; 3g of plasmid DNA per well) as per
the manufacturer’s protocol. Selection was performed using the aforementioned media for
each cell line, further supplemented with 500µg/mL G418. Resistant clones were pooled,
expanded, and frozen for later use.

RNA isolation and qRT-PCR
RNA was isolated using the RNeasy Mini Kit (Qiagen, 74104) and converted into cDNA using
the qScript cDNA SuperMix (Quanta Biosciences, 84034). The RT 2 SYBR Green ROX qPCR
Mastermix (Qiagen, 330521) was utilized for quantitative PCR with the primer sequences
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listed in Table 4.1. The output values were normalized to GAPDH expression and are shown
as fold changes relative to the empty vector control.

Table 4.1 – Primer sequences utilized for qRT-PCR in mRNA studies.
mRNA Probe Primer Sequences (Forward and Reverse, 5’ to 3’)
Total TBX3

F: CGCTGTGACTGCATACCAGA
R: GTGTCCCGGAAACCTTTTGC

TBX3iso1

F: AGTGGATGTCCAAAGTCGTCAC
R: CATGGAGTTCAATATAGTAAATCCATGTTTGTCTG

TBX3iso2

F: AGTGGATGTCCAAAGTCGTCAC
R: CACTTGGGAAGGCCAAAGTAAATCCATG

GAPDH

F: AGGCTGGGGCTCATTTGAAG
R: CCATCCACAGTCTTCTGGGTG

COX1

F: CGCCAGTGAATCCCTGTTGT
R: GTCACACTGGTAGCGGTCAA

HAS2

F: GTTGGGGGAGATGTCCAGATTT
R: CGGTTCGTGAGATGCCTGT

IL1RN

F: AGCAAGATGCAAGCCTTCAG
R: CCTTGCAAGTATCCAGCAACTA

OPN

F: TTGCAGTGATTTGCTTTTGC
R: TCAATGGAGTCCTGGCTGTC

VEGFR2

F: CCCAGATGACAACCAGACGG
R: GCCTTCAGATGCCACAGACT

Nude mouse xenografts
Cells were grown to confluence on 150mm tissue culture dishes. Cells were harvested,
washed twice with ice cold PBS, and resuspended in serum-free αHE media. The cell
suspension (100µL containing 1.0x107 cells) was injected into the second thoracic mammary
fat pad of 8 to 9 week old female nude mice at 10 mice per group. Mice were monitored
regularly for tumor growth up to 1 year post-injection and euthanized either when tumors
reached a volume of 2,500mm3 or one year post-injection, whichever occurred first. The
primary tumor and/or mammary fat pad, brain, liver, spleen, kidneys, lungs, along with left
and right axillary, brachial, and inguinal lymph nodes were collected. All tissues were
formalin-fixed, paraffin-embedded, sectioned and H&E stained. Tissues were examined by
an anatomic pathologist, and where indicated, sections were stained using anti-human
mitochondrial antibody to confirm metastasis of xenograft cells. Animal care and surgical
157

158

procedures were conducted in accordance with the recommendations of the Canadian
Council on Animal Care, under a protocol approved by Western University’s Council on
Animal Care.

Immunohistochemistry of mouse xenograft tissues
Formalin-fixed, paraffin embedded tissues were sectioned at 4.0µm thickness onto charged
glass slides. Sections were de-paraffinized and rehydrated. Antigen retrieval was conducted
with 10mM citrate buffer (pH 6.0) for 20 minutes, maintaining sub-boiling conditions. The
UltraVision LP Detection System (Thermo Fischer Scientific, TL-015-HD) was used as per
the manufacturer’s protocol. Suspect tissues and lymph nodes were stained using an antihuman mitochondrial antibody (Thermo Fischer Scientific, MS-1372-P0; 1/100 for 20 minutes
at room temperature) to confirm metastases. The degree of angiogenesis was assessed
across primary tumors using an anti-mouse CD31 antibody (BD Pharmingen, 550274; 1/50
at 4ºC overnight). OPN expression was assessed across primary tumors using an antihuman OPN antibody (AssayDesigns mAb53, 905-629; 1/750 for 90 minutes at room
temperature). Signal for all stains was developed using DAB, and slides were counter-stained
in Harris’s Hematoxylin. Expression of human mitochondria was classified as either positive
or negative. For quantification of CD31 expression by immunohistochemistry, images of 10
non-overlapping areas exhibiting high vessel density were acquired using the Olympus IX70
inverted microscope at 10X objective, and the number of vessels per high power field was
assessed using ImageJ. For quantification of OPN expression by immunohistochemistry,
images of 10 random, non-overlapping areas were acquired using the Olympus IX70 inverted
microscope at 10X objective across. Images were imported to ImageJ, and colour
deconvolution using the H DAB setting was conducted. DAB images representing positive
OPN signal were kept, thresholded, and the percentage of positive signal within the image
area was quantified.

In vitro endothelial tubule formation assay
In vitro endothelial tubule formation assays were conducted as previously described
(Arnaoutova and Kleinman, 2010). Briefly, human neonatal dermal microvascular endothelial
cells (HDMECs) were grown to 80% confluency. Growth factor reduced Matrigel (Thermo
Fischer Scientific, CB356239) was added to 96 well plates (50µL/well). HDMECs were
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trypsinized, washed twice with PBS, and re-suspended at 200,000 cells/mL in media (1:1
mixture of conditioned media and basal EBM-2 media with 20% FBS and no SingleQuots
growth factors). Conditioned media was prepared by seeding 1.0x10 6 cells into T75 flasks,
and cells were maintained in low serum media (αMEM with 0.1% FBS) for 48 hours. The
endothelial cells suspended in conditioned media were added to the 96 well plate on top of
the Matrigel (100µL, 20,000 cells per well) and incubated at 37ºC for 16 hours. For all studies,
tubule formation was observed after 16 hours and phase contrast images were taken of 3
non-overlapping fields of view per well using the Olympus IX70 inverted microscope at 10X
objective. The number of endothelial cell tubules formed per well were counted using ImageJ
(represented as branch points per 3 high power fields). All experiments were done with
HDMECs under 10 passages.

Analysis of secreted OPN by ELISA
Cells were seeded at a density of 1.0x106 into T75 flasks (with 10mL media) and grown in
serum-free αMEM media (with the aforementioned supplements) for 48 hours. Conditioned
media (100µL) were subject to ELISA using a Dual Mono ELISA kit (Enzo Life Sciences, ADI900-142) following the manufacturer’s instructions. Human recombinant OPN provided within
the kit was used to create a standard curve. OPN levels were normalized to equal amounts
of cells.

Particle exclusion assay
Particle exclusion assays were conducted to visualize pericellular matrices, as previously
described (Cook et al., 2006). Briefly, 1.5x104 cells were plated in 6-well plates in triplicate
and allowed to adhere overnight. The following day, cells were pre-treated in the presence
or absence of hyaluronidase (Sigma, H1136) (16 units/mL in αHE media with 0.1% BSA) for
20 minutes at 37ºC. The media was then removed, and fixed sheep erythrocytes (Innovative
Research, IC100-0210) were added in PBS with 0.1% BSA and allowed to settle for 10
minutes. Plates were imaged using the phase contrast setting on an Olympus IX70 inverted
microscope at 10X objective. Pericellular matrices appeared as halos surrounding cell
surfaces from which fixed red blood cells were excluded. In order to quantify matrix
production, a ratio of the pericellular matrix area over the cell area was calculated by tracing

159

160

around the cell coats (matrices) and cell areas of 30 randomly selected cells using ImageJ.
A ratio of 1.0 indicated the absence of a pericellular matrix for a particular cell.

Bioinformatics analyses
RNA-Seq data from 21NT+EV, 21NT+TBX3iso1 and 21NT+TBX3iso2 cell lines was
analyzed in order to examine differences in resultant transcriptional profiles with
overexpression of TBX3iso1 and TBX3iso2. Enrichment analysis (Enrichr; Icahn School of
Medicine, Mount Sinai) was conducted for cells overexpressing either TBX3iso1 or TBX3iso2
relative to the empty vector control, focusing on genes altered >1.5 fold up or down for only
one isoform, or >1.5 fold in opposite directions for both isoforms, and all with corrected
FDR<0.05 (http://amp.pharm.mssm.edu/Enrichr/). Results from WikiPathways analysis are
reported.
An angiogenesis gene signature consisting of 222 genes was compiled by integration
of genes with the Ingenuity Pathway Analysis (IPA; Qiagen) gene ontology term
‘angiogenesis of tumor’, along with the angiogenesis gene lists from the databases in Table
2 (top datasets, white).
The ICGC (US donors) data was exported using XenaBrowser (University of
California, Santa Cruz; https://xenabrowser.net/datapages/), and TBX3 mRNA expression
was assessed across all cancer subtypes. Transcript levels of TBX3 isoforms were acquired
from the TCGA portal, and examined in the breast cancer (BRCA) dataset. A ratio of total
transcript reads for TBX3iso1 (uc001tvu) over total transcript reads for TBX3iso2 (uc001tvt)
was compared against clinical data and tumor characteristics. Grade information for patients
within the TCGA BRCA was obtained from Budczies et al. (Budczies et al., 2015). The TCGA
and GTEx datasets were compared simultaneously through the use of the ‘transcripts’
function in XenaBrowser. The aforementioned datasets are listed in Table 4.2 (bottom
datasets, black).
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Table 4.2 – Publicly-available datasets utilized for analysis.
Project

Dataset

REFERENCE (or LINK)

MsigDB (Broad Institute)

http://software.broadinstitute.org/gsea/index.jsp

PubAngioGen
(East China Normal University)

http://www.megabionet.org/aspd
Li et al, 2015 (Li et al., 2015)

AngioDB
(Pusan National University)
dbANGIO
(Memorial University of
Newfoundland)

Sohn et al, 2002 (Sohn et al., 2002)
http://www.med.mun.ca/angio/
Savas et al, 2012 (Savas, 2012)

ICGC (US Donors)

https://xenabrowser.net/datapages/

TCGA breast cancer (BRCA)

https://portal.gdc.cancer.gov/projects/TCGA-BRCA

TCGA BRCA grade information

Budczies et al, 2015 (Budczies et al., 2015)

GTEx (Genotype Tissue
Expression)

https://xenabrowser.net/transcripts/

Statistical Analysis
Statistical analyses were conducted using GraphPad Prism 5. One-way ANOVA with Tukey
post-hoc tests were conducted for the majority of analyses unless otherwise specified. Error
bars are representative of standard deviation measurements. P-values less than 0.05 were
considered statistically significant.
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4.3

Results
TBX3iso1 possesses enhanced tumorigenic potential in nude mice.

In order to examine tumorigenicity of TBX3 isoforms, we overexpressed either TBX3iso1 or
TBX3iso2 in non-tumorigenic, DCIS-like 21NT breast cancer cell lines (Figure 4.3.1 A). Cells
were injected into the mammary fat pad of nude mice. Mice were monitored for up to a year,
or until primary tumors reached a volume of 2,500 mm 3, whichever occurred first. A majority
(6/10) of mice injected with cells overexpressing TBX3iso1 developed invasive carcinoma
and reached the end-point tumor volume, a significantly higher rate than mice injected with
cells overexpressing TBX3iso2 (1/9; p<0.05 relative to TBX3iso1) or the empty vector control
(0/10; p<0.01 relative to TBX3iso1) (Figure 4.3.1 B-D). Additionally, the TBX3iso1 tumors
exhibited a shorter lag period of in vivo growth, all forming before the TBX3iso2 tumor (Figure
4.3.1 C). All primary tumors (or mammary fat pad injection site) were assessed histologically
by an anatomical pathologist, and the presence of precursor lesions (atypical ductal
hyperplasia, ADH; ductal carcinoma in situ, DCIS) was documented (Figure 4.3.1 D).
Representative images of histological lesions observed are shown in Figure 1E, representing
DCIS, invasive mammary carcinoma (IMC) invading into skeletal muscle, and a metastatic
lesion within the brachial lymph node (Figure 4.3.1 E). All collected organs were assessed
for metastases, and suspect tissues were stained using anti-human mitochondrial antibody
for confirmation (Figure 4.3.1 E, bottom right panel). One of the mice in the TBX3iso2 group
developed lymphoma and was removed from the study.

162

163

163

164

Figure 4.3.1 – TBX3iso1 possess enhanced tumorigenic potential in nude mice.
(A) Total TBX3, TBX3iso1 and TBX3iso2 expression was assessed by qRT-PCR, normalized
to GAPDH expression levels, and depicted as fold change relative to the empty vector
control. (B) Cells (1x107) were injected into the mammary fat pad of nude mice. Mice were
sacrificed when the tumor volume reached 2,500mm 3, or one-year post injection, whichever
occurred first. The Kaplan-Meier plot shows disease-free survival over 365 days postinjection. An event was defined as tumor volume reaching the 2,500mm 3 end-point. (C)
Tumor volume showing growth kinetics over time. TBX3iso1 tumors are shown in different
colours, while the TBX3iso2 tumor is shown in black. (D) Histological analysis of H&E stained
slides was conducted by an anatomical pathologist for all mammary fat pads and primary
tumors. Cases with atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS),
invasive mammary carcinoma (IMC) and metastasis were documented. All tissues and lymph
nodes collected were examined for metastases in mice with IMC. Metastases were confirmed
through

positive

immunohistochemical

staining

for

anti-human

mitochondria.

(E)

Representative images of cases of DCIS, IMC showing invasion into skeletal muscle, and
metastasis into right brachial lymph node. Suspect metastases from H&E slides were
confirmed through immunohistochemistry with anti-human mitochondrial antibody.
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison
between three groups. Survival analysis for Kaplan-Meier curve was calculated using the logrank test statistic. Error bars represent standard deviation.
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TBX3iso1 promotes angiogenesis in vivo and in vitro.
Differential tumorigenicity between TBX3 isoform transfectants was a striking and novel
finding. We re-examined our previous RNA-Seq dataset of 21NT transfectant cell lines
(21NT+EV, 21NT+TBX3iso1, 21NT+TBX3iso2) to specifically assess for differences in
expression profiles between the two TBX3 isoform transfectants. Interestingly, all of the cell
lines had distinct expression signatures and clustering patterns (Figure 4.3.2 A), suggesting
differential transcriptional function of the TBX3 isoforms. We observed 470 differentially
expressed genes between TBX3iso1 and TBX3iso2. Pathway analysis of up-regulated genes
with TBX3iso1 overexpression identified its potential role in osteopontin signaling,
glycolysis/gluconeogenesis, and angiogenesis (Figure 4.3.2 B). Alternatively, pathway
analysis of the up-regulated genes with TBX3iso2 overexpression identified alterations in the
cytokines and inflammatory responses (Figure 4.3.2 C). Notably, TBX3iso2 overexpression
resulted in down-regulation of genes involved in glycolysis/gluconeogenesis, showing
inverse patterns from TBX3iso1 overexpressing cells.
Gross examinations of xenograft tumors revealed high vascularity of tumors formed
by TBX3iso1 overexpressing cells. Given this observation, and our finding of an enrichment
of angiogenesis-related genes upon TBX3iso1 overexpression, we examined tumor
vascularity through CD31 immunohistochemistry and quantification of microvascular density
(Figure 4.3.2 D). Microvascular density within the TBX3iso1 tumors was significantly higher
than the TBX3iso2 tumor for the majority (4/6) of tumors tested. In order to functionally
examine for angiogenic properties, we isolated conditioned media from 21NT transfectant
cells and incubated them with human dermal microvascular endothelial cells (HDMECs) on
Matrigel for 16 hours to allow for endothelial cell migration and formation of tubule structures,
mimicking angiogenesis in vitro (Figure 4.3.2 E). We observed marked differences in the
promotion of angiogenesis in vitro between conditioned media from cells overexpressing
TBX3iso1, which resulted in significantly higher rates of tubule formation by endothelial cells,
relative to conditioned media from TBX3iso2 overexpressing cells or the empty vector
control.
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Figure 4.3.2 – TBX3iso1 promotes angiogenesis in vitro and in vivo.
(A) Heat map showing large-scale transcriptional changes by RNA-Seq across 21NT+EV,
21NT+TBX3iso1, and 21NT+TBX3iso2 cell lines. Principle component analysis (PCA) was
conducted to assess the similarity in global transcriptional profiles between transfectant cell
lines. (B) Enrichment analysis highlights pathways associated with transcripts up-regulated
(red) and down-regulated (green) with TBX3iso1 overexpression relative to the empty vector
control. (C) Enrichment analysis highlights pathways associated with transcripts up-regulated
(red) and down-regulated (green) with TBX3iso2 overexpression relative to the empty vector
control. (D) Assessment of blood vessel density within primary tumors by CD31
immunohistochemistry. Primary tumors were stained for CD31 by immunohistochemistry and
the number of vessels per non-overlapping high power field were quantified across 10 tumor
hotspots. Averages across 10 hotspots for each mouse is shown. (E) Tubule formation assay
to asses in vitro angiogenesis. Conditioned media was collected after 48h incubation with
1x106 cells of each cell type. Conditioned media was incubated with human dermal
microvascular endothelial cells (HDMEC) on growth factor reduced Matrigel for 16 hours at
37ºC. Tubule branch points per 3 high power fields (one well) was quantified at the 16h mark.
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison
between three groups. Error bars represent standard deviation.
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Osteopontin is specifically up-regulated by TBX3iso1.
In order to explore differences in transcriptional profiles between the two TBX3 isoforms on
angiogenesis-related gene expression, we generated an angiogenesis gene signature
consisting of 222 genes using publicly-available databases (as described in Bioinformatics
Methods, Table 4.2) and conducted hierarchical clustering of RNA-Seq expression data for
all cell lines (Figure 4.3.3 A). Investigation of the depicted cluster at a higher resolution
revealed up-regulation of a subset of pro-angiogenic transcripts in TBX3iso1 overexpressing
cells and down-regulation in TBX3iso2 overexpressing cells relative to the empty vector
(Figure 4.3.3 B). Genes showing the most pronounced differences between TBX3iso1 and
TBX3iso2 transfectants (OPN, COX1, IL1RN) were validated by qRT-PCR (Figure 4.3.3 C).
The VEGF family is commonly referred to as the main pro-angiogenic factors across cancer
subtypes (Oltean and Bates, 2014, Ladomery et al., 2007), with VEGFR2 acting as the key
receptor responsible for mediating VEGF-induced angiogenic activity (Takahashi et al.,
2002). For this reason, expression of VEGFR2 was also validated by qRT-PCR and found to
be down-regulated in TBX3iso2 overexpressing cells (as observed in RNA-Seq data)
(Appendix 10).
We focused our further studies on OPN since its mRNA levels displayed the greatest
difference between TBX3iso1 and TBX3iso2 overexpressing cells, and OPN is known to be
pro-angiogenic (Takahashi et al., 2002, Asou et al., 2001, Pröls et al., 1998, Takano et al.,
2000, Cook et al., 2005). OPN expression was then assessed in additional stable TBX3
transfectant cell lines (TBX3 expression levels for 21PT and MCF7 transfectant cell lines are
shown in Appendix 11 A-B). Overexpression of TBX3iso1 resulted in significant up-regulation
of OPN mRNA levels in all three transfectant cell lines (Figure 4.3.3 C-D). Additionally, OPN
mRNA levels were significantly down-regulated in all three cell lines overexpressing
TBX3iso2. We then proceeded to evaluate the levels of OPN protein released into the
conditioned media previously used for in vitro tubule formation assays. OPN protein levels
were quantified by ELISA by comparing to recombinant human osteopontin standards
(Figure 4.3.3 E). Relative to the empty vector control, there was a 49.0-fold and 3.9-fold
increase in secreted OPN levels for TBX3iso1 and TBX3iso2 overexpressing cells,
respectively. As another mode of confirmation, we conducted immunohistochemical staining
for OPN in the xenograft primary tumors and observed a significantly higher proportion of
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OPN positive tumor cells in TBX3iso1 tumors relative to the TBX3iso2 tumor (Figure 4.3.3
F).
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Figure 4.3.3 – Osteopontin is specifically up-regulated by TBX3iso1.
(A) Heat map showing expression of 222 angiogenesis-related genes by RNA-Seq across
21NT+EV, 21NT+TBX3iso1, and 21NT+TBX3iso2 cell lines. (B) Cluster showing upregulation of pro-angiogenic transcript with TBX3iso1 overexpression and down-regulation
with TBX3iso2 overexpression. Osteopontin (OPN) mRNA expression is shown in red. (C)
Expression of OPN mRNA levels in 21PT, 21NT and MCF7 transfectant cell lines was
assessed by qRT-PCR, normalized to GAPDH expression levels, and depicted as fold
change relative to the empty vector control. (D) OPN protein levels from conditioned media
was assessed by ELISA and normalized to cell numbers. Human recombinant OPN (hrOPN)
was used to generate a standard curve for determination of OPN protein concentration. (E)
Primary tumors were stained for OPN by immunohistochemistry. Color deconvolution was
conducted using ImageJ, followed by thresholding of brown signal to assess percentage of
high power field positive for OPN expression across ten non-overlapping areas. Percentage
of the high power field (HPF) positive for OPN is shown across 10 fields of view per tumor.
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison
between three groups, and Student’s t-test for comparison between two groups. Error bars
represent standard deviation.
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TBX3iso1 overexpression leads to increased HAS2 levels and
pericellular hyaluronan retention.
We have previously shown that OPN induction of hyaluronan synthase 2 (HAS2) and hence
hyaluronan (HA) production is associated with aggressiveness of 21NT cells (Cook et al.,
2006). Given that all three of the cell lines we tested (21PT, 21NT, MCF7) showed upregulation of OPN only with TBX3iso1 overexpression, we examined HAS2 mRNA levels.
For all three cell line transfectants, overexpression of TBX3iso1 was associated with a
significant up-regulation of HAS2 expression (Figure 4.3.4 A). Alternatively, overexpression
of TBX3iso2 resulted in down-regulation of HAS2 mRNA expression in 21PT and MCF7
transfectant cell lines, with no change in HAS2 expression in the 21NT transfectant cell line.
Hyaluronan (HA) is produced by hyaluronan synthase enzymes (HAS1-3) at the intracellular
face of the plasma membrane, and then extruded from the cell and either released into the
microenvironment, or retained in pericellular coats (Weigel and DeAngelis, 2007, Tammi et
al., 1998, Evanko et al., 2007). High levels of synthesis and retention of HA in pericellular
coats has been shown to have an important role in malignant progression (Cook et al., 2006)
and is an indicator of poor prognosis in epithelial cancers (Auvinen et al., 2014, Tammi et al.,
2008, Auvinen et al., 2000). In order to examine the phenomenon of HA retention, particle
exclusion experiments were conducted using fixed sheep erythrocytes in order to visualize
matrix production and retention (Figure 4.3.4 B-C). Due to the unique biochemical properties
of HA, including its highly polar structure and large size, addition of partially negatively
charged erythrocytes allows for visualization of matrices due to erythrocyte exclusion. Cells
overexpressing TBX3iso1 had significantly larger pericellular coats relative to TBX3iso2
overexpressing cells and the empty vector control, suggesting higher levels of hyaluronan
production. Administration of hyaluronidase (HAse) completely abolished matrix assembly in
TBX3iso1 overexpressing cells, confirming the presence of HA in the pericellular coats.
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Figure 4.3.4 – TBX3iso1 overexpression leads to increased HAS2 levels and
pericellular hyaluronan retention.
(A) Expression of HAS2 mRNA levels in 21PT, 21NT and MCF7 transfectant cell lines was
assessed by qRT-PCR, normalized to GAPDH expression levels, and depicted as fold
change relative to the empty vector control. (B-C) Particle exclusion experiment for
visualization of pericellular matrices. Cells were pre-treated in the presence or absence of
hyaluronidase for 20 minutes, followed by removal of media and addition of fixed sheep
erythrocytes. Pericellular matrix area was calculated by tracing around cell coats (matrices)
and cell areas across 30 randomly selected cells. A ratio of 1.0 indicated the absence of a
pericellular matrix for a particular cell.
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison
between three or more groups. Error bars represent standard deviation.
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Cancer progression involves transcriptional changes resulting in an
increase in the TBX3iso1/TBX3iso2 ratio.
TBX3 is overexpressed in several different cancer types (Fan et al., 2004, Lomnytska et al.,
2006, Yarosh et al., 2008, Souter et al., 2010, Rodriguez et al., 2008, Cavard et al., 2009,
Lyng et al., 2006b, Gudmundsson et al., 2010, Miao et al., 2016). Examination of ICGC data
(US Donor-centric) revealed breast cancer as amongst the cancers with the highest
expression of all tumor tissue sites (Figure 4.3.5 A). We then interrogated TBX3 isoform
expression in the TCGA breast cancer cohort, assessing the ratio of transcript reads for
TBX3iso1 over TBX3iso2 for each breast cancer patient and comparing to clinical
characteristics (Summarized in Figure 4.3.5 B). The TBX3iso1/TBX3iso2 expression ratio
was 8.1-fold higher in tumor samples relative to normal controls (Figure 4.3.5 C). Additionally,
this ratio was positively associated with higher tumor grade (Figure 4.3.5 D) along with more
aggressive breast cancer subtypes (Figure 4.3.5 E). Upon examination of isoform-specific
expression in tumor types where TBX3 overexpression has been documented (breast
cancer, melanoma, colon, and pancreatic cancer), we observed an upwards shift in
TBX3iso1 expression and downwards shift in TBX3iso2 expression within tumor tissues
(TCGA cohorts) relative to an expanded cohort of normal tissue controls (GTEx normal tissue
dataset) (Appendix 12).
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Figure 4.3.5 – Cancer progression involves transcriptional changes resulting in an
increase in TBX3iso1 to TBX3iso2 ratio.
(A) Assessment of ICGC data (US Donor-centric) data shows total TBX3 levels across tumor
subtypes. Total TBX3 transcript expression in breast cancer is shown in orange. (B) TBX3
isoform ratios were interrogated in the TCGA breast cancer cohort by calculating the total
transcript reads for TBX3iso1 over the total transcript reads for TBX3iso2 for each patient.
Ratios were compared between normal and tumor tissues. (C) The TBX3iso1/TBX3iso2
across breast cancer grades.
*p<0.05, **p<0.01, ***p<0.001 by the non-parametric Kruskal-Wallis statistic with Dunn’s
multiple comparison post-hoc test due to non-Gaussian distribution of ratios. Error bars
represent standard deviation.
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4.4 Discussion
Alternative splicing is a post-transcriptional mechanism that adds an enhanced layer of
complexity and diversification to genes encoded in the genome. Cancer cells are able to
exploit the process of alternative splicing to produce isoform switches, resulting in enhanced
survival, proliferation and invasiveness (Oltean and Bates, 2014, Shen et al., 2016).
Interestingly, transcriptional analysis of alternative-splicing and assessment of exon inclusion
events have been shown to outperform gene expression-based survival predictors across 6
different cancer types, including breast cancer (Shen et al., 2016).
Existing literature examining TBX3-induced tumorigenicity through the use of
xenograft models (Rodriguez et al., 2008, Peres and Prince, 2013, Willmer et al., 2016),
along with the single published transgenic TBX3-inducible mouse model (Liu et al., 2011),
have focused on only one isoform of TBX3 in different parental cell lines which makes
comparison of results difficult. Liu et al. showed that inducible overexpression of TBX3iso2
in murine mammary glands results in mild focal hyperplasia and importantly no tumor
formation (Liu et al., 2011). For several other studies, which isoform was cloned and
overexpressed is not stated (Peres and Prince, 2013, Perkhofer et al., 2016). Additionally,
studies

which

employed

knockdown

of

total

TBX3

expression

followed

by

xenotransplantation of cells into mice has revealed that TBX3 is associated with tumor
formation, but not whether differences exist between isoforms (Peres et al., 2010).
We therefore sought to investigate the functional consequence of this highly
conserved splice event as it relates to TBX3-induced tumorigenesis. We have conducted
nude mouse xenograft experiments utilizing non-tumorigenic, DCIS-like 21NT cell lines, and
have reported significant differences between TBX3 isoforms in the promotion of
tumorigenesis, with TBX3iso1 overexpression more commonly associated with invasive
carcinoma in vivo. This difference is likely associated with differing ability to induce
angiogenesis, and is related to differential expression of a number of angiogenesisassociated genes.
While angiogenesis has a limited role in normal physiology, it is a fundamental
requirement in malignant progression (Hanahan and Weinberg, 2000). This requirement of
angiogenesis is due to the inability of avascular tumors to access oxygen and nutrients
through diffusion alone (Rooney et al., 1995, Hanahan and Weinberg, 2000, Ladomery et al.,
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2007). After cytokines are released from cells, they are able to diffuse into the extracellular
milieu and act on nearby quiescent endothelial cells to induce proliferation and migration
towards the tumor (Ladomery et al., 2007). As observed by in vitro tubule formation assays,
pro-angiogenic factors are released from cells overexpressing TBX3iso1 that are functional
in activating endothelial cells. We report that one key pro-angiogenic factor up-regulated by
TBX3iso1 is OPN. OPN has previously been described to act as a cytokine in various
contexts (Ashkar et al., 2000, Denhardt et al., 2001, Takahashi et al., 2002), with several
studies ascribing it a pro-angiogenic function (Pröls et al., 1998, Takano et al., 2000, Asou
et al., 2001, Takahashi et al., 2002). Importantly, elevated OPN expression is associated with
several breast cancer-related prognostic factors, including early metastasis and poor
outcome (Bellahcène and Castronovo, 1995, Rudland et al., 2002, El-Tanani et al., 2004,
Bramwell et al., 2006, El-Tanani et al., 2006). A great deal of overlap has been reported on
the cellular functions affected by OPN and HA (Kim et al., 2005). The two markers have both
been correlated with cancer survival (Bellahcène and Castronovo, 1995, Auvinen et al., 2000,
Rudland et al., 2002, El-Tanani et al., 2004, Bramwell et al., 2006, El-Tanani et al., 2006,
Tammi et al., 2008, Veiseh et al., 2014) and are frequently co-expressed (Kim et al., 2005,
Lee et al., 2007). We have previously reported OPN-induced up-regulation of HAS2 in 21NT
breast cancer cell lines is necessary for both anchorage-independent growth and adhesion
of tumor cells to bone marrow endothelial cells (Cook et al., 2006). Moreover, both HA and
OPN are ligands for CD44 (in this case on endothelial cells) (Weber et al., 1996), and their
binding promotes angiogenesis through stimulation of endothelial cell migration, survival and
lumen formation (Brooks et al., 1994, Senger et al., 1996, Trochon et al., 1996, Griffioen et
al., 1997, Arap et al., 1998, Scatena et al., 1998, Bayless et al., 2000, Cao et al., 2006).
Our novel in vivo findings relating to differential tumorigenicity of TBX3 isoforms and
downstream confirmation of associated pathways suggest that the assessment of relative
levels of splice variants may be more important than the assessment of total transcript levels
per gene (Blencowe, 2006, Li et al., 2006, Zhang et al., 2006). This focus on isoform ratios
has been suggested by several studies (Venables, 2004, Blencowe, 2006, Ladomery et al.,
2007, Pajares et al., 2007). There are additional examples of alternatively spliced transcripts
having diverse and even antagonistic functions (Pajares et al., 2007). A prominent example
includes alternative splicing of VEGF; most splice variants are actively pro-angiogenic, while
the VEGFb splice variant is only six amino acids different relative to its most similar isoform
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but is actively anti-angiogenic (Ladomery et al., 2007). A splicing switch from the antiangiogenic to pro-angiogenic variant is observed both in cancer progression (Venables,
2004, Pajares et al., 2007, Oltean and Bates, 2014), along with diseases such as proliferative
diabetic retinopathy (Blencowe, 2006, Ladomery et al., 2007).
It is unknown whether this increase of TBX3iso1 over TBX3iso2 expression is a cause
or effect of the tumorigenic process; a splice shift phenomenon may be due to several factors,
including potential epigenetic changes within the TBX3 gene, or due to changes in upstream
splicing machinery (Cui et al., 2004, Ladomery et al., 2007). It is becoming quite clear that
splice changes and isoform shifts in cancer are non-random and play a key role in cancer
progression (Venables, 2004, Ladomery et al., 2007, Pajares et al., 2007). Various strategies
are being employed in an attempt to exploit alternative splicing in diagnosis, prognosis and
treatment of cancer (Yamaguchi et al., 1998, Venables, 2004, Ladomery et al., 2007). On
this note, Venables et al. examined expression of breast cancer-associated genes and their
alternatively spliced transcripts through assessment of isoform ratios (Venables et al., 2008).
They reported cancer-specific exon loss for several transcripts as well as a significant overlap
with previously identified ovarian cancer-specific splice changes (Klinck et al., 2008,
Venables et al., 2008). This suggests that a subset of the alternative splicing events identified
by high throughput transcriptomic analysis may be common across cancer subtypes.
It is well established that TBX3 is aberrantly overexpressed in several cancer types
(Fan et al., 2004, Lomnytska et al., 2006, Lyng et al., 2006, Rodriguez et al., 2008, Yarosh
et al., 2008, Cavard et al., 2009, Souter et al., 2010, Shan et al., 2015, Miao et al., 2016,
Gudmundsson et al., 2010). We have added to the existing literature and reported that in
particular,

an

increased

TBX3iso1/TBX3iso2

ratio

is

associated

with

several

clinicopathological parameters in the TCGA breast cancer cohort. Additionally, TBX3iso1
promotes a pro-angiogenic gene signature associated with elevated OPN and HAS2
expression, as well as increased pericellular HA retention. These pro-angiogenic changes
associated with elevated TBX3iso1 expression promote vascular channel formation by
endothelial cells in vitro, and likely explain the high tumor formation rates and high vascularity
of primary tumors formed in mouse xenograft assays. A thorough understanding of
transcriptional control by TBX3, in an isoform-specific context, is therefore vital in order to
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understand the effect of TBX3 in promotion of tumorigenicity in breast cancer as well as other
cancer types.
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General Discussion
Through the use of the 21T series breast cancer cell lines representing distinct stages of
progression (ADH, DCIS, IDC) in the 3D Matrigel system, our lab employed array-based
transcriptional profiling to identify clinically-relevant genes which may be implicated in the
DCIS to IDC transition (Souter et al., 2010). TBX3 was identified as 2.8-fold up-regulated in
this transition (Souter et al., 2010). Based on these preliminary findings, as well as
accumulating literature implicating TBX3 in the promotion of malignancy, I focused on
elucidating the role of TBX3 isoforms in breast cancer progression.
I hypothesized that the transcriptional regulatory proteins TBX3iso1 and TBX3iso2
have distinct roles in breast cancer progression, which is likely mediated by their
downstream transcriptional targets. The follow-up work to address my hypothesis was
organized into three main chapters, dealing with (1) functionality of TBX3 isoforms in vitro,
(2) mechanism by which TBX3 isoforms promote EMT, and (3) in vivo differences between
TBX3iso1 and TBX3iso2.
(1) CHAPTER 2 – Examination of functional and phenotypic changes associated with
modulation of TBX3 levels at various stages of breast cancer progression
I have shown that overexpression of TBX3iso1 and TBX3iso2 promotes progression in an
in vitro model of early stage breast cancer. This occurs through alteration of several
cellular properties including growth, survival, invasiveness, and the acquisition of an EMT
phenotype. Prominent functional and phenotypic changes initially identified with
overexpression of TBX3iso1 and TBX3iso2 were identical. I therefore focused on the
molecular mechanism by which TBX3 isoforms promote invasiveness and induction of
EMT in the next chapter, since the acquisition of an EMT phenotype is associated with
several clinical parameters including reduced survival and chemo-resistance (Polyak and
Weinberg, 2009, De Craene and Berx, 2013, Nieto et al., 2016).
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(2) CHAPTER 3 – TBX3 promotes progression of pre-invasive breast cancer cells by
inducing EMT and directly up-regulating SLUG
In order to assess the downstream mechanisms responsible for TBX3-induced EMT, I
conducted ChIP-arrays and RNA-Seq to assess the direct transcriptional targets of
TBX3iso1 and TBX3iso2, focusing on genes/pathways similarly regulated by both
isoforms. I found that both TBX3 isoforms regulate expression of several EMT-related
genes, including SLUG (directly) and TWIST1 (indirectly). Translating these in vitro
molecular findings to clinical samples of early-stage breast cancers, I showed that TBX3
levels are up-regulated in CCLs, with a concomitant increase in SLUG and TWIST1
expression. This is predicted to promote proliferation and plasticity of early, pre-invasive
lesions. TBX3 expression is maintained in a subset of low-grade DCIS, and was
associated with the degree of invasiveness of Stage I breast cancers. Pathway analysis
revealed that overexpression of both TBX3 isoforms induces altered expression of several
proteases and protease inhibitors, which is consistent with the ability to degrade basement
membrane and prime for early invasion. These events are facilitated by TBX3-induced
and SLUG-dependent expression of pro-migratory molecules such as MMP14, fibronectin,
and vimentin. My proposed model of TBX3-dependent advancement of low-grade DCIS
to IDC is particularly relevant in the non-high grade, ER-positive pathway of progression.
(3) CHAPTER 4 – Isoform-specific promotion of breast cancer tumorigenicity by TBX3
involves induction of angiogenesis
My last chapter deals with elucidation of relevant mechanisms responsible for increased
tumorigenicity of TBX3iso1 in vivo in nude mouse xenograft assays. Tumors generated
from non-tumorigenic cells overexpressing TBX3iso1 were invasive and highly vascular.
Mining of transcriptional differences in RNA-Seq data revealed up-regulation of proangiogenic transcripts with overexpression of TBX3iso1; this was not observed with
overexpression of TBX3iso2. Importantly, overexpression of TBX3iso1 consistently
resulted in up-regulation of OPN and HAS2 across three non-tumorigenic breast cancer
cell lines, and increased hyaluronan retention in 21NT transfectants. Lastly, examination
of the TCGA breast cancer cohort revealed a transcriptional shift during cancer
progression, with an 8.1-fold higher TBX3iso1/TBX3iso2 ratio in tumors relative to control.
This ratio was also associated with tumor grade and aggressive breast cancer subtypes.
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5.1 Promotion of invasiveness by TBX3
Transcriptional profiling of isogenic DCIS-like and IDC-like cells grown in 3D Matrigel was
previously conducted by our laboratory, in which TBX3 was identified as significantly upregulated in the DCIS to IDC transition (Souter et al., 2010). At that time, the focus of TBX3related studies within the literature was characterization of functional and phenotypic
changes associated with TBX3 (irrespective of isoform), along with identification of
transcriptional targets and validation across cancer subtypes. Additionally, much of the
existing literature focused on TBX3 in embryogenesis and development of organ systems.
TBX3 transcriptional targets are likely context dependent, as studies have shown that
conclusions regarding effects mediated by TBX3 are often not consistent across cancer
subtypes, let alone in the process of embryogenesis vs. tumorigenesis (Willmer et al., 2016a,
Zhu et al., 2016).
My initial studies required characterization of TBX3-mediated effects in breast cancer,
with validation across cell lines representing different molecular subtypes. I characterized the
phenotypic and functional changes associated with overexpression of TBX3iso1 and
TBX3iso2 in breast cancer cell lines. Changes associated with overexpression of TBX3
isoforms included increased cell survival, proliferation and colony-forming ability, decreased
apoptosis, and increased invasiveness. In contrast, shRNA-mediated knockdown of total
TBX3 levels in invasive 21MT-1 cells resulted in decreased colony formation rates, along
with decreased invasiveness. Throughout my studies, overexpression of either TBX3iso1 or
TBX3iso2 resulted in increased invasiveness, as shown by transwell invasion assays, along
with in vitro invadopodia formation, and in vivo extravasation and invadopodia formation
assays within the CAM model. Use of the CAM model further aided in demonstrating changes
in invasiveness between 21MT-1 transductant cells (shTBX3 21MT-1 and shLUC 21MT-1),
as we were unable to use them in traditional in vitro migration and invasion assays due to
the larger size of the cells. The inclusion of several layers of validation regarding in vivo
invasiveness as well as several methods of detecting invadopodia formation are novel
findings, further supporting the existing literature regarding TBX3-induced invasiveness
across several cancer types (Rodriguez et al., 2008, Peres et al., 2010, Willmer et al., 2016a).
Initiation of invadopodia formation commences through the binding of growth factor
ligands to their cognate receptor, leading to activation of Src kinase required for induction of
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invadopodia-specific proteins (Murphy and Courtneidge, 2011, Burger et al., 2014). Several
growth factors (i.e. TGF-ß, FGF, Wnts) are able to induce expression of TBX3 (Renard et al.,
2007, Fillmore et al., 2010, Li et al., 2013). I have shown that overexpression of either
TBX3iso1 or TBX3iso2 leads to up-regulation of Src at the mRNA and protein level. The
activity of Src is modulated through phosphorylation at residues Y527 (inhibitory) and Y416
(activating) (Irtegun et al., 2013). Overexpression of TBX3iso1 and TBX3iso2 resulted in
reduced phosphorylation at the inhibitory Y527 site suggesting increased functionality
(Irtegun et al., 2013), with no change in phosphorylation at Y416. Several proteases are also
enriched within invadopodia structures, including MMP2, MMP9 and MMP14 (Weaver,
2006). Importantly, both TBX3iso1 and TBX3iso2 up-regulate MMP9 and MMP14
expression, and an increase in the active MMP2 was observed by gelatin zymography,
further aiding in focal ECM degradation. I have also shown that the induction of the
membrane-bound protease MMP14 by TBX3 is dependent on SLUG expression. My work
has therefore added to the literature in terms of characterization of functionality of TBX3
isoforms, including promotion of invadopodia formation and focal substrate degradation.
TBX3 may be an important regulator of invasiveness through enhancing invadopodia
formation, as TBX3 is induced by several upstream growth factors, and modulates
expression of downstream effectors important for the proper functionality of invadopodia.

5.2 Transcriptional targets of TBX3 – Cell Cycle Control
While transcriptional regulation by TBX3 is not well understood and continues to focus on its
repressive effects on transcription (with much of the literature focusing on direct repression
of p14ARF by TBX3), there are a few studies in which TBX3 was shown to directly up-regulate
gene transcription. This includes direct up-regulation and binding to the TBE in the promoter
of jun dimerization protein 2 (JDP2), a histone chaperone with an important role in
differentiation and senescence, along with Connexin 43 (GJA1) and GATA6, which are
important regulators of heart development (Jin et al., 2002, Nakade et al., 2009, Boogerd et
al., 2011, Lu et al., 2011, Yao et al., 2014).
Through integrated analysis of coupled ChIP-array and RNA-Seq data for TBX3iso1
and TBX3iso2 overexpressing cells, I observed that approximately 2/3 of TBX3iso1 and
TBX3iso2-bound genes were down-regulated, and 1/3 of TBX3iso1 and TBX3iso2-bound
genes were up-regulated at the mRNA level. Noteworthy genes which were bound in ChIP188
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arrays and transcriptionally up-regulated by both TBX3 isoforms include cyclin D (CCND1),
cyclin E (CCNE1) and cell division cycle 25 homolog A (CDC25A), all of which are important
cell cycle regulators, as well as SLUG (SNAI2), an EMT-inducing transcription factor.
Importantly, the aforementioned cell cycle regulators are all involved in mediating the
transition from G1 to S phase. The CDC25A phosphatase removes the inhibitory phosphate
groups on the cyclin D-CDK4/6 and cyclin E-CDK2 complexes (Robert, 2015). Once
activated, the major role of the cyclin D-CDK4/6 and cyclin E-CDK2 complexes is
phosphorylation of the Rb protein (Robert, 2015). Rb is first phosphorylated by the cyclin DCDK4/6 complex, resulting in reduced affinity of Rb for E2F (Robert, 2015). The cyclin ECDK2 complex further phosphorylates Rb, ensuring maximal release of E2F (Robert, 2015).
Upon release from Rb, E2F activates transcription of genes involved in DNA replication
(Robert, 2015).
The processes associated with G1/S phase transition are negatively regulated by
inhibitors of CDKs previously described: p16INK4A (inhibitor of kinases; inhibits cyclin DCDK4/6 complex) and p21CIP1 (cyclin inhibitory protein; inhibits cyclin D-CDK4/6, cyclin ECDK2, cyclin A-CDK2 complexes). The well-described anti-senescence effect mediated by
TBX3 through direct down-regulation of p14ARF (Brummelkamp et al., 2002, Lingbeek et al.,
2002, Yarosh et al., 2008), p16INK4A (Kumar P et al., 2014), and p21CIP1 (Hoogaars et al.,
2008, Willmer et al., 2016b) are therefore amplified through direct up-regulation of cyclin D1,
cyclin E1, and CDC25A, all of which are required for progression from G1 to S phase.
Interestingly, cyclin D is often up-regulated in breast cancer and is strongly expressed
in ER+ breast cancers resistant to hormone therapy (Kenny et al., 1999, Hui et al., 2002,
Hodges et al., 2003), displaying similar expression patterns with TBX3 (Fillmore et al., 2010).
Additionally, up-regulation of cyclin E and CDC25A is associated with reduced survival in
breast cancer (Cangi et al., 2000, Keyomarsi et al., 2002).
The various direct mechanisms whereby TBX3 controls expression of important
mediators of cell cycle progression is summarized in Figure 5.2.1. As highlighted above, upregulation of CDC25A is suggestive of increased activation of G1-phase cyclin-CDK
complexes which are required for G1/S phase transition (Sandhu et al., 2000). Downregulation of p14ARF, p16INK4A, and p21CIP1 results in reduced inhibitory effects on G1-phase
cyclin-CDK complexes. This increased expression and potentially increased activity of cyclin
189

190

D-CDK4/6 and cyclin E-CDK2 is expected to result in accelerated cell cycle progression and
increased rates of proliferation (Masamha and Benbrook, 2009). TBX3 is also required for
S/G2 phase transition, as depletion of TBX3 results in accumulation in S phase; the authors
suggested that this may be mediated through TBX3-dependent down-regulation of p21CIP1
(Willmer et al., 2015). TBX3 is therefore able to promote progression through both G1/S and
S/G2 phase transitions, which is associated with increased proliferation rates. Indeed, these
findings are in accordance with the widely-documented pro-proliferative effect associated
with up-regulation of TBX3, as well as my findings of increased proliferation and growth rates
in 3D Matrigel with overexpression of TBX3iso1 and TBX3iso2 reported in Chapter 1 (Lee et
al., 2007a, Platonova et al., 2007, Miao et al., 2016, Willmer et al., 2016b, Wu et al., 2017).
While binding events for CCND1, CCNE1 and CDC25A contain significant FDRcorrected statistical values, and are transcriptionally up-regulated with overexpression of
both TBX3 isoforms, further validation studies are needed to assess whether these binding
events are direct and occur in breast cancer cell lines and various other cancer cell lines.
Further elucidation of direct transcriptional targets of TBX3 is important in order to understand
the functionality of TBX3 with regards to transcriptional regulation. This should be assessed
in an isoform-specific context.

Figure 5.2.1 – Proposed model of control of cell cycle progression by TBX3.
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5.3 Transcriptional targets of TBX3 – EMT Regulation
Through assessment of gene expression changes associated with overexpression of
TBX3iso1 or TBX3iso2 relative to the control, there were prominent alterations in expression
of EMT and invasion-associated genes. This was observed in the high-throughput RNA-Seq
data, and recapitulated in the qRT-PCR arrays and through various functional assays. While
the association between TBX3 and an EMT phenotype has been previously suggested
through profiling of epithelial and mesenchymal markers (Humtsoe et al., 2012, Shan et al.,
2015, Miao et al., 2016) along with direct down-regulation of E-cadherin (Rodriguez et al.,
2008, Dong et al., 2018), direct modulation of transcription factors and inducers of EMT by
TBX3 has not been reported and is therefore a novel finding.
Although several genes involved in the cell cycle were both bound by and up-regulated
by both TBX3 isoforms (according to ChIP-array and RNA-Seq data, respectively), I focused
on TBX3-induced up-regulation of SLUG transcript levels due to its well-documented role in
EMT (Barrallo-Gimeno and Nieto, 2005, Humtsoe et al., 2012, Phillips and Kuperwasser,
2014). ChIP-array analysis showed that TBX3iso1 and TBX3iso2 bind near an intron-exon
junction of the SLUG (SNAI2) gene. Through merging of ChIP-array data with Encyclopedia
of DNA Elements (ENCODE) files, this binding site was revealed to possess a highly
conserved TBE, located within the 5’ end of exon 2. This identified TBE overlaps with an
RNA polymerase II (Pol II) binding site and a DNase I hypersensitivity (DHS) region. This
binding has been validated by ChIP qRT-PCR, showing that overexpression of TBX3iso1 or
TBX3iso2 leads to their enrichment at this genomic location. Since this binding is not located
in an upstream promoter region and rather is located near an intron/exon boundary, my
interpretation is that TBX3 promotes transcriptional elongation of the SLUG transcript and
prevents stalling of Pol II transcriptional machinery. The effect of these proposed molecular
events would lead to elevated SLUG transcript levels, as shown by RNA-Seq, and validated
by qRT-PCR and western blot.
High throughput experiments utilizing Pol II ChIP-Seq (Guenther et al., 2007, Muse et
al., 2007, Zeitlinger et al., 2007) and global run-on sequencing (GRO)-Seq to assess sites of
active transcription (Core et al., 2008, Larschan et al., 2011, Min et al., 2011) have revealed
that Pol II pausing is a widespread and critical rate-limiting step governing gene transcription
(Kwak and Lis, 2013). The prolonged binding of transcription factors, along with Pol II stalling
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contributes to maintenance of an open chromatin structure, and is therefore a feature of
active, highly-regulated genes (Fuda et al., 2009, Gilchrist et al., 2010, Jonkers and Lis,
2015). Assessment of TBX3 binding sites across the genome has identified a significant
overlap with Pol II binding sites from the ENCODE database; this may be inherent due to
close associations with transcription factors and Pol II, and/or a byproduct of promoter array
usage and enrichment of promoter binding sites which are also occupied by Pol II.
This identified TBX3 binding site in the SNAI2 gene contains a DHS region, which is
associated with open and transcriptionally active chromatin. DHS is often used as markers
of cis-regulatory elements including promotors, enhancers, and silencers (Lewin et al., 2011).
The ENCODE DNase-Seq datasets revealed a high degree of overlap of DHS regions for
the TBX3 binding site across a panel of 125 diverse cell and tissue types (identified in 41/125
cell lines) (Thurman et al., 2012). This region may therefore act as an enhancer and regulate
transcription of the SNAI2 gene through binding of various co-activators and/or transcription
factors such as TBX3. Enhancers are cis-regulatory elements that promote transcription of
nearby gene(s) through binding of trans-activating transcription factors, and by interacting
with proximal regulatory factors through chromatin looping mechanisms (Lewin et al., 2011).
While enhancers play a modest role on transcriptional initiation, they are able to increase
elongation efficiency (Krumm et al., 1993, Yankulov et al., 1994, Krumm et al., 1995). The
process of enhanced transcriptional elongation may be mediated through 3D chromatin
looping, which brings promoters and enhancers into close proximity, attracting transcription
factors and promoting continuation of transcriptional elongation (Ghavi-Helm et al., 2014,
Heinz et al., 2015, Jonkers and Lis, 2015). Some transcription factors (such as MYC and
NFKB) are also able to increase Pol II efficiency through recruiting elongation factors
(Yankulov et al., 1994, Rahl et al., 2010, Danko et al., 2013, Diamant and Dikstein, 2013,
Kwak and Lis, 2013). TBX3 may therefore regulate expression of SLUG through the
promotion of transcriptional elongation of SLUG transcripts, and prevention of Pol II stalling.
Further studies are needed in order to substantiate this hypothesis, as association with
enhancers and non-promoter binding of TBX3 have not been reported.
TBX3 may also promote SLUG expression through indirect mechanisms as well. As
degradation of SLUG is induced through binding of p53 and p21CIP1 (Kim et al., 2014), direct
down-regulation of p21CIP1 by TBX3 may also result in reduced degradation of SLUG.
192

193

5.4 TBX3 in precursor lesions – CCLs and DCIS
My findings from Chapter 3 represent the first study to assess TBX3 expression by
immunohistochemistry separately in various cell compartments, and the first in-depth TBX3
IHC study in breast cancer. Elevated expression of EMT-transcription factors, including
TBX3, SLUG and TWIST1 in CCLs was an interesting and unexpected finding. CCLs, and
particularly the FEA variant, are on a histological continuum with ADH, DCIS and IDC,
representing the earliest morphological precursor in the LG breast cancer progression
pathway (Wellings and Jensen, 1973, Wellings et al., 1975, Lee et al., 2006, Abdel-Fatah et
al., 2008, Feeley and Quinn, 2008, Turashvili et al., 2008). As such, CCLs possess increased
levels of genomic aberrations including low rates of allelic imbalances relative to
morphologically normal breast epithelial cells (Simpson et al., 2005, Dabbs et al., 2006,
Turashvili et al., 2008, Bürger et al., 2013, Bombonati and Sgroi, 2011), often coexist with
both precursor lesions (ADH, DCIS) and IDC (Go et al., 2012), and are frequently detected
as abnormalities on mammographically screening (Lerwill, 2008). It has been demonstrated
that loss of 16q, an early mutational event associated with progression along the LG breast
cancer pathway, occurs in similar rates across FEA, ADH and DCIS; the degree of genomic
instability, however, increases with further progression (O'Connell et al., 1998, Moinfar et al.,
2000, Simpson et al., 2005, Larson et al., 2006, Gao et al., 2009).
CCLs are typically ER+, PR+, HER2-, and prominently express increased levels of
Ki67, Bcl2 and cyclin D, thereby promoting a proliferative and anti-apoptotic profile
(Polosukhin, 1999, Vincent-Salomon, 2003, Tremblay et al., 2005, Simpson et al., 2005,
Dabbs et al., 2006, Lee et al., 2006, Noel et al., 2006, Bombonati and Sgroi, 2011).
Interestingly, previous studies have reported increased ER expression in CCLs relative to
adjacent morphologically normal breast epithelial cells (Tremblay et al., 2005, Lee et al.,
2006, Lee et al., 2007b, Abdel-Fatah et al., 2008). Downstream targets of ER include several
genes involved in proliferation and apoptosis (Gompel et al., 2000, Anderson and Clarke,
2004), and it has therefore been suggested that the pro-proliferative and anti-apoptotic profile
in CCLs may be stimulated by estrogen and mediated through ER (Wellings et al., 1975, Lee
et al., 2007b). Overexpression of ER-α in breast epithelial cells of transgenic mice results in
rapid development of hyperplasia and DCIS, with occasional progression to invasive
carcinoma (Frech et al., 2005). These studies suggest that the effects mediated by estrogen
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through ER may be partially responsible for the development of CCLs, as well as subsequent
progression to more advanced lesions (Frech et al., 2005).
Our group, and others, have shown that TBX3 expression is tightly correlated with ER
expression (Fan et al., 2004, Fillmore et al., 2010). It is intriguing to speculate whether ER
and TBX3 are coordinately expressed to similar degrees in precursor lesions of the breast.
Indeed, the TBX3 promoter possesses multiple half-estrogen response elements (Fan et al.,
2004), and administration of endogenous estradiol induces expression of TBX3 (Fillmore et
al., 2010). Additionally, TBX3 is required for the formation of ER+ mammary epithelial cells
(Kunasegaran et al., 2014), showing reciprocal induction of gene expression between TBX3
and ER. The reported benefits of anti-estrogen therapies such as tamoxifen for patients with
precursor lesions (Fisher et al., 1999, Esteva and Hortobagyi, 2004, Allred et al., 2012,
Coopey et al., 2012) may work, in part, through inhibition of TBX3 expression at this early,
critical stage of tumorigenesis. While this is only speculative, more work is needed in order
to fully establish this link, including examination of TBX3 expression in epithelial cell
compartments (FEA, ADH and DCIS) in patients who have undergone treatment with
tamoxifen.
Aside from up-regulation of ER expression, there is currently limited knowledge
regarding transcriptional profiles of CCLs. Through micro-dissection of histologically normal
epithelial cells and CCLs, Lee et al. conducted microarray analysis in order to examine
changes in gene expression profiles and associated molecular pathways altered in CCLs
(Lee et al., 2007b). They reported that CCLs frequently reactivate pathways involved in
embryonic development and suppress pathways involved in terminal differentiation (Lee et
al., 2007b). My finding of elevated expression of EMT transcription factors, particularly the
estrogen responsive transcription factor TBX3 with critical roles in development, is in
agreement with the aforementioned studies. In addition to the high throughput transcriptional
studies, my IHC studies have shed light on the elevated expression of EMT transcription
factors in CCLs, including TBX3, SLUG and TWIST1. It is possible that TBX3 is inducing
expression of SLUG and TWIST1 at this early stage of progression, as expressions of all
aforementioned markers is coordinately elevated. Although associations in expression has
been shown in vitro, this may not necessarily hold true in vivo. Sophisticated experiments
involving temporal induction of TBX3 in mouse mammary glands, and assessment of induced
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genes at various stages may be the best way to answer this experimental question. While
one may obtain correlational data through assessment of expression of particular markers
through IHC, one cannot conclude that direct transcriptional up-regulation of particular genes
is occurring in a particular lesion in vivo.
The prevailing view is that activation of a single oncogene is insufficient to drive cancer
progression; cooperation with other oncogenes and/or mutational events is frequently
employed by EMT transcription factors in the process of malignant transformation (Ansieau
et al., 2008, Smit and Peeper, 2010, Morel et al., 2012, Tran et al., 2012, Puisieux et al.,
2014). For example, while TBX3 expression on its own is usually not enough to impart
malignant properties to genomically stable cells, overexpression of MYC or oncogenic HRasVal17 with TBX3 (but not by themselves), protects cells from apoptosis through inhibition
of p14ARF (Carlson et al., 2002). Additionally, up-regulation of EMT transcription factor
reduces the number of genetic events required for malignant transformation of breast
epithelial cells, allowing cells to overcome onco-suppressive mechanisms (Morel et al., 2012,
De Craene and Berx, 2013, Puisieux et al., 2014). Increased ER expression and downstream
signaling is also permissive for the accumulation of genetic alterations (Lee et al., 2007b).
The aforementioned processes, acting together and regulated by TBX3, may lead to
promotion of an EMT phenotype at early stages, and allow for full progression to IDC.
Expression of TBX3, SLUG and TWIST1 is up-regulated in CCLs and maintained in
some DCIS lesions, and may impart additional properties associated with induction of
invasiveness. In my evaluation of DCIS lesions with and without associated invasion, there
was no difference in TBX3 expression between Stage 0 and Stage I samples. I did, however,
observe a strong positive correlation between TBX3 expression in the DCIS lesion and size
of the invasive focus. Importantly, I showed that elevated TBX3 expression within LG DCIS
was associated with larger invasive carcinomas across Stage I cancers. While TBX3 itself
was not useful in predicting invasion, it may have an association with the degree of
invasiveness, as observed in my IHC, functional and molecular studies. These findings
suggests that there are potentially other co-factors that may be acting in concert with TBX3
in the promotion of invasiveness.
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Interestingly, pathway analysis of transcripts altered by both TBX3iso1 and TBX3iso2
revealed significant enrichment of proteases and protease inhibitors. This transcriptional
event is particularly important at the pre-invasive stage, as focal disruption of the basement
membrane has been shown to coincide with the dissolution of the myoepithelial cell layer and
progression of DCIS to IDC (Man et al., 2003, Hu et al., 2008). Proteases secreted by tumor
cells are able to progressively destroy the basement membrane, which leads to dissolution
of the myoepithelial cell layer (Hu et al., 2008). This is important, as additional mutations
within tumor cells of DCIS are not required for progression; the loss of basement membrane,
myoepithelial cell dissolution, and loss of epithelial cell organization and polarity is sufficient
to promote this transition (Hu et al., 2008). Previous studies have reported that MMP14 is
amongst the main regulators of the basement membrane transmigration process in vivo
(Hotary et al., 2006), likely through activation of MMP2 (Duffy et al., 2000). Through my
studies I have shown that overexpression of TBX3 isoforms results in increased MMP14
expression, and induction of MMP14 is dependent on SLUG. Additionally, I have shown that
overexpression of both TBX3 isoforms is associated with increased activity of MMP2.
In conclusion, I have proposed a unique pathway in which TBX3 promotes progression
through advancement of low-grade DCIS to invasive carcinoma, as depicted in Figure 3.3.6
of Chapter 3. This model is particularly relevant in patients with ER+, non-high grade
precursor lesions (CCL, DCIS), in which overexpression of TBX3 induces other molecular
regulators of EMT (including SLUG and TWIST1). Additionally, TBX3 up-regulates
expression of several proteases (i.e. MMP9, MMP14, uPa), and down-regulates expression
of several protease inhibitors (i.e. CST6). These transcriptional changes mediated by TBX3
set the stage for basement membrane breakdown and invasion into adjacent stroma. Further
studies are needed in order to assess whether TBX3 expression may provide reliable risk
stratification for patients diagnosed with DCIS. This may potentially be conducted in concert
with multiple biomarkers and/or multi-parameter gene expression assays in order to increase
predictive and/or prognostic value.
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5.5 TBX3 in IDC
I have demonstrated significant differences in tumorigenicity between the TBX3
isoforms through nude mouse xenograft experiments, which was a surprising and novel
finding. Although existing literature has focused solely only one isoform of TBX3 (often the
clone used is not specified), a few existing studies have suggested that the two TBX3
isoforms have differential functionality (Stennard et al., 1999, Fan et al., 2004, Lee et al.,
2007a, DeBenedittis and Jiao, 2011, Zhao et al., 2014). Through mining of differences in
transcriptional profiles between TBX3iso1 and TBX3iso2 overexpressing cells and
conducting pathway analysis, I have reported that overexpression of TBX3iso1 is associated
with a pro-angiogenic gene signature.
The effects mediated by TBX3 isoforms with regard to EMT and promotion of
invasiveness were identical throughout my findings in Chapter 2 and Chapter 3. Due to these
similarities, along with an absence of commercially available isoform-specific antibodies for
TBX3, I focused on total TBX3 protein expression in my IHC study. While I have shown that
expression of total TBX3 levels are up-regulated in early stages of breast cancer progression,
the relative abundance of each isoform is unknown. As TBX3iso1 is associated with the

promotion of angiogenesis, it may therefore be helpful at later stages of tumor development.
The process of angiogenesis is vital for tumor growth, since solid cancers must form
a blood supply if they are to grow beyond 1-2 mm in size; tumor vascularization thus allows
for acquisition of nutrients, oxygen perfusion, and systemic spread (Hanahan and Weinberg,
2000, Knowles and Selby, 2005). Indeed, the xenograft tumors formed by TBX3iso1
overexpressing cells were highly vascular, as gauged by microvascular density counts. As
observed by in vitro tubule formation assays, pro-angiogenic soluble factors are released
from cells overexpressing TBX3iso1 that are functional in activating endothelial cells. On the
contrary, conditioned media from cells overexpressing TBX3iso2 had similar effects on
endothelial cells as the empty vector control. Importantly, TBX3iso1 (but not TBX3iso2) is
able to up-regulate expression of OPN and HAS2, and lead to increased pericellular HA
retention. The aforementioned transcriptional changes were robust and observed across
three cell lines, with expression of OPN and HAS2 often down-regulated with overexpression
of TBX3iso2. It is well documented that elevated levels of OPN and HA within the
microenvironment are able to promote angiogenesis in vivo through binding of OPN (via
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integrins, CD44) and HA (via CD44) on endothelial cells, thereby promoting their migration,
proliferation, and vascular channel formation (Brooks et al., 1994, Senger et al., 1996,
Trochon et al., 1996, Griffioen et al., 1997, Arap et al., 1998, Scatena et al., 1998, Bayless
et al., 2000, Savani et al., 2001). These binding and downstream signaling events leading to
vascularization are permissive to tumor growth, and likely allowed for the observed
exponential growth of tumors. Based on the kinetics of tumor growth which I reported in
Chapter 4, as well as well as my findings of the pro-angiogenic function of TBX3iso1, the
enhanced growth and tumorigenicity is likely due to the process of angiogenesis. This is in
agreement with the findings of Shirinifard et al., who conducted 3D simulations of tumor
growth, reporting that exponential growth of tumor cells at late stages of tumor development
occurs only in vascularized tumors, whereas tumor growth in avascular tumors did not
exceed linear growth values (Shirinifard et al., 2009). Further studies are required for
elucidation of differential targets of TBX3iso1 and TBX3iso2, and assessment and validation
of which direct targets downstream of TBX3iso1 may be responsible for up-regulation of proangiogenic factors and thus vascular channel formation by endothelial cells.
My mining of the TCGA breast cancer dataset has revealed a transcriptional shift in breast
cancer progression, with increased TBX3iso1/TBX3iso2 expression in cancer tissues relative to
normal breast tissue. This shift of increased TBX3iso1 expression was associated with several
clinicopathological parameters, including high grade and more aggressive breast cancer
subtypes. Interestingly, these are the opposite characteristics identified for TBX3 expression in
breast cancer. I believe that this splice shift is due to changes in upstream splicing machinery,
as several splice regulatory proteins are up-regulated in breast cancers (Watermann et al., 2006,
Huang et al., 2007, Skotheim and Nees, 2007, Venables et al., 2008). Differences in breast
cancer specific alternative splicing events have been observed between grade 1 and grade 3
breast tumors as well, with a distinct trend towards exon loss of several transcripts in ER- tumors
(Venables et al., 2008). These splicing changes were not associated with differences in combined
expression of alternatively spliced transcripts (and as such TBX3 expression is low in ER- tumors)
(Venables et al., 2008). It has been strongly suggested that functional selection for oncogenic
splice variants occurs within tumors (Venables et al., 2008), and enhanced expression of
TBX3iso1 may be an adaptive oncogenic mechanism. While the splice factors which are
associated with an elevated TBX3iso1/TBX3iso2 ratio are unknown, they appear to be
associated with aggressive breast tumors.
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5.6 Future Studies
To summarize, I have identified that the transcriptional regulator TBX3 is highly expressed in
precursor lesions of the breast including CCLs and DCIS, in a manner similarly implicated in
the context of other cancer types (Fan et al., 2004, Hansel et al., 2004, Lomnytska et al.,
2006, Lyng et al., 2006, Rodriguez et al., 2008, Yarosh et al., 2008, Cavard et al., 2009,
Gudmundsson et al., 2010, Souter et al., 2010, Witte, 2010, Begum and Papaioannou, 2011,
Miao et al., 2016). TBX3 expression is elevated in ER+, PR+, low-grade breast cancers, and
is significantly associated with the degree of invasiveness in Stage I breast tumors. These
studies have provided critical information regarding the stages in which expression of
nuclear-localized TBX3 is up-regulated in cancer cells, and may be transcriptionally active in
the promotion of tumorigenesis within the breast. Based on my IHC studies, TBX3 appears
to be promoting progression of precursor lesions (CCLs, DCIS) through the low-grade
molecular pathway.
Further exploration of possible target genes that are regulated by and downstream of
TBX3 isoforms should be conducted in order to identify and validate direct targets which are
critical to cellular invasion. These gene products may themselves be potential targets for
breast cancer therapy. This may include validation of identified cell-cycle proteins and/or
mediators of EMT (such as SLUG) in other breast cancer cell lines, and further validation in
cell lines representing other cancer subtypes. Initial validation in a breast cancer context is
important, as functional effects mediated by TBX3, as well as direct transcriptional targets,
are often described as context-dependent and may vary across cancer subtypes (Willmer et
al., 2016a, Zhu et al., 2016, Willmer et al., 2017).
An important follow-up experiment to my findings would be micro-dissection of the
DCIS cross-sections (Stage 0 and Stage I) which express high vs. low TBX3 to assess for
enrichment of transcripts associated with elevated TBX3 expression and invasiveness.
Importantly, elevated TBX3 expression in DCIS of Stage I breast cancer samples is
associated with the degree of invasiveness. Critical information may therefore be obtained
through these transcriptional profiling experiments, which may link elevated and co-ordinate
expression of TBX3 and another potential co-factor with invasiveness of breast cancers.
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As I have reported significant differences between TBX3 isoforms in the promotion of
angiogenesis and in vivo tumorigenesis, high-resolution analysis of differential transcriptional
targets of TBX3iso1 and TBX3iso2 is required to elucidate which genes may be responsible
for mediating this phenotype, with emphasis on genes involved in facilitating up-regulation of
OPN (as TBX3iso1 does not directly bind the SPP1 gene). Additionally, as the T-box domain
facilitates several protein-protein interactions (Hoogaars et al., 2008, Lu et al., 2010), there
are likely differences in which proteins TBX3iso1 and TBX3iso2 interact with. This has been
suggested by limited studies (Zhao et al., 2014), but would be interesting to explore further.
While these studies likely do not possess immediate translatable findings, they would be
important in fully understanding the functional differences between TBX3 isoforms.
In conclusion, my thesis research has established that TBX3 is an important mediator
of invasiveness in early-stage breast cancers. My proposed model is particularly relevant for
luminal A breast cancers, which represents approximately 70% of all breast cancer
diagnoses (Howlader et al., 2014). My findings will permit further understanding of expression
profiles of precursor lesions, including CCLs and DCIS. An understanding of such molecular
alterations and associated transcriptional profiles is essential in order to provide prognostic
and predictive information regarding the propensity to progress to IDC, thereby avoiding
progression to stages associated with reduced survival. Decisions regarding clinical
management should be done on a per-patient basis based on the intrinsic characteristics of
the tumor. Assessment of TBX3 expression, isoform ratios, and/or downstream signaling
pathways in patients with low-grade DCIS may aid in this endeavor, although validation and
follow-up studies are required. The validation cohort would be very important, as the single
study which assessed the natural progression of LG DCIS across a median of 31 years
highlighted that the risk of invasive recurrence is greatest within the first fifteen years after
diagnosis (Sanders et al., 2005). Critical information may therefore be obtained through these
profiling experiments, which may link elevated and co-ordinate expression of TBX3 and
another potential co-factor with invasiveness of breast cancers.
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Appendices
6.1 Chapter 3 – Supplementary Data

Appendix 1 – TBX3 protein expression in 21NT transfectant and 21MT-1 transductant
cell lines.
(A-C) Western blot analysis showing total TBX3 protein levels in generated stable cell lines. 21NT
cells were transfected to overexpress TBX3iso1 or TBX3iso2, or transfected with an empty vector
(EV) control. 21MT-1 cells were transduced with either shLUC (luciferase; off-target control) or
shTBX3. Protein samples were separated by 10% SDS-PAGE and quantified by densitometry.
Protein levels were normalized to Vinculin, which served as the loading control.
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison between
three groups, and Student’s t-test for comparison between two groups.
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Appendix 2 – Phenotypic assessment of TBX3 overexpressing cell lines.
(A) Assessment of migration in 2D in 21NT transfectant cell lines. A scratch was produced in a
confluent monolayer of cells, and migration of cells into the scratch area was monitored at 0, 12 and
24 hours post-scratch. Migration was quantified as ratio of wound area filled at 0 and 12 hours, and
normalized to the empty vector control. (B) Cell-cell adhesion assay. Cells were harvested and resuspended in media containing either 3mM EDTA or 1mM CaCl2 and incubated in a petri dish at 37ºC
for 30 minutes with gentle agitation. Clusters containing over 4 cells were counted across 10 fields of
view. (C) 21NT cells were transiently transfected with either a TBX3iso1 or TBX3iso2 plasmid
containing a ZsGreen reporter, or empty vector control expressing ZsGreen. CDH1 was visualized
using a red-fluorescently labeled antibody. CDH1 signal was quantified by counting pixels within the
red channel of ZsGreen positive transfected cells.
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison between
three groups.
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Appendix 3 - Effect of TBX3 overexpression on invasiveness in cell lines representing
other breast cancer molecular subtypes.
The invasive ability of TBX3 transfectant lines was assessed using Matrigel-coated transwell inserts.
(A-C) T-47D (luminal A), SKBR3 (HER2-enriched), and MDA-MB-468 (basal-like) cells were
transfected with either an empty vector (EV), or TBX3iso1, or TBX3iso2 construct within the
pZsGreen1-N1 vector containing a ZsGreen reporter. Twenty-four hours post-transfection, 50,000
cells were added to the upper chamber of an 8.0µm pore transwell insert coated with Matrigel and
allowed to invade for 18 hours. The number of green cells per field of view was used in the analysis.
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison between
three groups.
213

214

Appendix 4 – Assessment of EMT markers in TBX3 overexpressing cell lines.
(A) The mRNA expression of several EMT markers was evaluated by qRT-PCR. Expression
was normalized to GAPDH expression levels, and depicted as fold change relative to the
empty vector control. (B) Conditioned media was concentrated and resolved on a 10%
zymogram gelatin gel. The gel was renatured and developed, and size of the proteolyzed
bands was quantified by densitometry using the reverse image (as shown). Active (82 kDa)
vs. inactive (pro-) MMP9 (92 kDa), and active (63 kDa) vs. inactive (pro-) MMP2 (72 kDa)
were identified by molecular weight.
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison
between three groups.
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Appendix 5 – Protein class analysis of direct transcriptional targets of TBX3.
The 194 genes directly bound by both TBX3 isoforms in ChIP-array data and whose transcript
levels were significantly altered in expression by RNA-Seq (>1.5 fold up or down, FDR<0.05)
were analyzed using the PANTHER database, conducting over-representation analysis and
focusing on protein class. Protein classes with the lowest p-values are shown. P-values were
calculated by comparing expected numbers compared to input numbers in the gene list.
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6.2 Chapter 3 – Immunohistochemistry Quality Control
As shown in Appendix 6-9, stringent quality control measures were used for all IHC-based
quantifications. For TBX3 expression specifically, I conducted cell fractionation experiments
through isolation of cytoplasmic and nuclear fractions by ultracentrifugation, followed by
immunoblotting cellular fractions of 21PT and 21NT transfectants, and 21MT-1 transductants
(Appendix 6). Although these examples represent isogenic cell lines and cellular fractionation
was not conducted on other cell lines representing different molecular subtypes from different
patients, we observed exclusive nuclear localization of TBX3 in cell fractionation experiments
as well as in IHC. While TBX3 is a transcription factor and is expected to be located to the
nucleus, a few studies have reported cytoplasmic expression of TBX3 by IHC in colorectal
cancer, pancreatic cancer, and HNSCC (Burgucu et al., 2012, Shan et al., 2015, Wang et
al., 2015). Lomnytska et al. reported elevated levels of truncated TBX3 protein in the plasma
of breast cancer and ovarian cancer patients, in which they suggested that TBX3 is mislocalized in cancer tissues and leaks out of cells and into plasma (Lomnytska et al., 2006).
One of the most important aspects of reliable IHC staining is antibody selection,
requiring new optimization depending on each new batch or clone, and selecting conditions
that offers the highest contrast of true positive signal over background (Yaziji and Barry,
2006, Matos et al., 2010). We have conducted thorough optimization of TBX3 IHC protocols,
utilizing several commercially-available antibodies (Abcam, ab99302, rabbit polyclonal (used
for study); Abcam, 154828, rabbit monoclonal; Invitrogen, 42-4800, rabbit polyclonal; Sigma,
HPA005799, rabbit polyclonal). Several parameters have been considered, including antigen
retrieval time and buffer components, antibody and concentration, blocking steps, etc. until a
clean staining pattern with minimal background was achieved. Unfortunately, IHC staining
patterns observed are a direct result of the staining optimization process, and improper
localization can be observed without thorough optimization and proper positive and negative
controls (Matos et al., 2010). Several of the aforementioned conditions (and remaining
antibodies) gave high levels of background staining along with a consistent brown ‘blush’ in
carcinoma cells, the extent which I believe is artifactual. It is a common rule that when the
subcellular and micro-anatomical location of the protein of interest is known, the
immunoreactivity pattern obtained for IHC studies should follow this distribution (Seidal et al.,
2001). While I cannot exclude that cytoplasmic TBX3 expression is not associated with any
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clinicopathological parameters, we focused exclusively on nuclear-localized TBX3 for
quantification purposes, as this is where TBX3 is active in regulating transcription. SLUG and
TWIST1 IHC optimization and quantification of expression was conducted in the same
manner as TBX3.
Expression of TBX3, SLUG and TWIST1 was assessed in the same area across serial
sections in a control slide (Appendix 7, Appendix 8), and expression was assessed for each
run to ensure reproducible results and therefore eliminate potential confounding variables
(Appendix 9). For each of the markers, I quantified expression in benign non-columnar
epithelial cells, CCLs, DCIS, and in the invasive carcinoma. This mode of assessment is
particularly strong and enhances our understanding of distribution of markers in a cellspecific context. Additionally, the use of full slides allows for observation of expression
patterns along a larger area and therefore minimizes sampling bias associated with tumor
heterogeneity which is inherent in the use of tissue microarrays (Rubin et al., 2002,
Besusparis et al., 2016). Lastly, I used semi-automated computer-assisted image analysis
for my quantification of biomarker expression due to the ease and efficiency of use, as well
as its documented association with increased accuracy and reproducibility when compared
to manual quantification methods (Cross, 2001, Lehr et al., 2001, Umemura et al., 2004, Diaz
and Sneige, 2005, Matos et al., 2010).
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Appendix 6 – TBX3 expression in nuclear and cytoplasmic fractions of 21T cells.
Cellular fractionation and analysis of TBX3 expression in nuclear and cytoplasmic
compartments of (A) 21PT, (B) 21NT, and (C) MT-1 cell lines. The 21PT and 21NT cell lines
were stably transfected with either an empty vector (EV), TBX3iso1 or TBX3iso2
overexpressing plasmid. Total TBX3 expression was knocked down in 21MT-1
transductants; the shTBX3 clone with highest knockdown is shown. Nuclear fractions are
shown by histone H4 expression, and cytoplasmic fractions are shown by vinculin.
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Appendix 7 – ImmunoRatio analysis of TBX3 expression in benign and columnar
breast epithelium.
Scanned digital slides of TBX3, SLUG and TWIST1 immunohistochemically stained slides
were quantified for nuclear expression of each marker using ImmunoRatio. TBX3 expression
by IHC in benign and columnar breast epithelial cells, and the associated quantification
process is shown. The process consisted of four major steps: (1) Images of tissue
compartments were acquired, and included benign non-columnar cells, benign columnar cell
lesions (CCLs; includes columnar cell change, columnar cell hyperplasia or flat epithelial
atypia), DCIS and invasive cancer. (2) Stromal cells, necrotic areas, and cells outside of the
compartment in question were cropped out using ImageJ in order to solely analyze
expression of markers in the cell type of interest. (3) The faint background signal was
removed using ImageJ in order to bring out blue hematoxylin stain of negative nuclei. (4) The
ImmunoRatio plugin for ImageJ was used to quantify percentage of nuclei positive for each
marker. A control slide representing serial sections was included for each run (with
quantification and statistical analysis) to ensure identical and reproducible staining for each
run.
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Appendix 8 – ImmunoRatio analysis of TBX3 expression in DCIS and IDC.
Scanned digital slides of TBX3, SLUG and TWIST1 immunohistochemically stained slides
were quantified for nuclear expression of each marker using ImmunoRatio. TBX3 expression
by IHC in DCIS and IDC, and the associated quantification process is shown. The process
consisted of four major steps: (1) Images of tissue compartments were acquired, and
included benign non-columnar cells, benign columnar cell lesions (CCLs; includes columnar
cell change, columnar cell hyperplasia or flat epithelial atypia), DCIS and invasive cancer.
(2) Stromal cells, necrotic areas, and cells outside of the compartment in question were
cropped out using ImageJ in order to solely analyze expression of markers in the cell type of
interest. (3) Faint background signal was removed using ImageJ in order to bring out blue
hematoxylin stain of negative nuclei. (4) The ImmunoRatio plugin for ImageJ was used to
quantify percentage of nuclei positive for each marker. A control slide representing serial
sections was included for each run (with quantification and statistical analysis) to ensure
identical and reproducible staining for each run.
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Appendix 9 – Quality control of TBX3 staining by immunohistochemistry.
A control slide representing serial sections was included for each IHC run. Images were
acquired of the same DCIS across serial section, and quantification was conducted as
described in Materials and Methods (Chapter 3) and shown in Appendix 8. Expression of
markers was graphed, and statistical analysis were conducted in order to ensure identical
and reproducible staining for each run. If expression of markers was statistically different in
the control slide, quantification was not conducted, and the batch of slides was re-stained
until a similar staining pattern was observed.
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6.3 Chapter 4 – Supplementary Data

Appendix 10 – Expression of VEGFR2 by qRT-PCR.
The mRNA expression of VEGFR2 was assessed across 21NT transfectant cell lines by
qRT-PCR, normalized to GAPDH expression levels, and depicted as fold change relative to
the empty vector control.
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison
between three groups. Error bars represent standard deviation.
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Appendix 11 – TBX3 expression in stable transfectant cell lines.
(A) Total TBX3, TBX3iso1 and TBX3iso2 expression was assessed by qRT-PCR in 21PT
stable transfectant cell lines, normalized to GAPDH expression levels, and depicted as fold
change relative to the empty vector control. (B) Total TBX3, TBX3iso1 and TBX3iso2
expression was assessed by qRT-PCR in MCF7 stable transfectant cell lines, normalized to
GAPDH expression levels, and depicted as fold change relative to the empty vector control.
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison
between three groups. Error bars represent standard deviation.
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Appendix 12 – Assessment of TBX3 isoform expression in TCGA and GTEx datasets.
TBX3iso1 and TBX3iso2 expression levels were assessed across tumor types in which TBX3
overexpression has been documented (breast cancer, melanoma, colon, and pancreatic
cancer). Isoform percentage is shown along the top axis, with TBX3 isoform expression
shown in tumors (The Cancer Genome Atlas, TCGA; purple hills) and normal tissues
(Genotype Tissue Expression Project, GTEx; blue hills). Data was assessed using
XenaBrowser (www.xenabrowser.net).
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